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Abstract
Background -  Ischaemia/reperfusion accounts for a large proportion of fatalities in the 
developed world. Even if death is avoided, the patient suffers a deterioration in their 
quality of life. Erythropoietin (EPO) has been examined in clinical studies investigating 
its effect in anaemic chronic heart failure patients with any positive effect attributed to 
the correction of anaemia. Given the recent discovery of the EPO receptor on the 
myocyte surface, this thesis examined whether EPO could have a direct effect on the 
myocardium and limit ischaemia/reperfusion injury and the mechanism by which any 
protection occurs.
Methods and results -  Using an isolated perfused rat model of ischaemia/reperfusion, 
we demonstrated that EPO could mimic preconditioning in a PI-3-Kinase (PI3K)- 
dependent manner. Administration of EPO at reperfusion limited infarct size by 
activation eNOS and could be abolished by inhibitors of NOS, PI3K and ERK 1/2. This 
thesis also showed that EPO could delay mitochondrial permeability transition pore 
opening (mPTP) in an oxidative stress myocyte model of mPTP opening, an effect that 
was suppressed by inhibitors of NOS and PBK. A 3 week treatment of EPO reduced 
injury in a NOS-dependent manner that was independent of haematocrit. Finally this 
thesis demonstrated that administration of EPO as late as 30 minutes after 
commencement of reperfusion could still reduce infarct size.
Conclusion -  This thesis demonstrated that EPO can be used in a variety of settings to 
elicit a protective effect against ischaemia/reperfusion injury. This variety of effective 
time points promises an important future role for EPO in the treatment of ischaemic heart 
disease.
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Chapter 1
Chapter 1 - Introduction
Despite the increasing prevalence of such diseases as AIDS and cancer, cardiovascular 
diseases remain by far the largest causes of mortality and morbidity. They cause one third 
of all deaths globally1 with about half of these deaths attributed to coronary heart 
disease2, making them one o f the world’s biggest killers. Within Europe, they are 
estimated to cost the European Union economy €169 billion per year, with coronary heart 
disease costing around €45 billion2. Clearly, coronary heart disease remains a huge 
problem in terms of deaths, debilitating conditions and economic burden on society. 
Therefore more research is required in order to try to limit death and improve the quality 
of life of those suffering from these diseases and, as such, thorough research resulting in 
effective treatment remains an imperative.
1.1 Ischaemic Heart Disease
Ischaemic heart disease is a major contributor o f coronary heart disease and despite 
receiving much attention is still not understood completely. It is characterised as a disease 
that involves periods of no or low blood flow supply to the myocardium resulting in an 
inadequate oxygen delivery to meet demand. In individuals at rest, this lack of oxygen 
will usually be due to atherosclerotic lesions that obstruct or reduce blood flow in cardiac 
arteries preventing oxygenated blood reaching their intended tissue target. This limitation 
of oxygen supply has other implications, such as oedema, reduction in nutrient
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availability and raised levels of potassium and sodium. Moreover an adenosine 5’- 
triphosphate (ATP) depletion and reduction in the pool of available adenylate will not 
only affect the ATP dependent channels initially, but will also eventually lead to cell 
death in the case of continued paucity of ATP. An additional implication of reduced 
levels of oxygen is the occurrence of acidosis. Acidosis results on the one hand from 
lactate accumulation produced as a by-product of anaerobic glycolysis and and on the 
other from accumulation of CO2 due to impaired blood flow. The level of lactate, initially 
increased in response to reduced levels of ATP4, will eventually cause an inhibition of 
glycolysis. This metabolic wind-down is also manifest in the reduction in fatty acid 
oxidation5 and oxidative phosphorylation, leading to diminished levels of NADH6 as 
pyruvate is converted to lactate.
Irreversible cell death caused by ischaemia is thought to occur as a result of 
necrosis brought on by calcium overloading of the cell7, which is discussed in greater 
detail in section 1.2.
All these elements may seem distinctly secondary in comparison with the problem 
of the oxygen debt caused by reduced blood flow. However, they all compound the 
difficulties faced when trying to prevent cell death.
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Cellular Elements Action as a result of Ischaemia
Oxygen Tension 1
ATP i
Glucose 4 .
Glycolysis Initially rate increased, inhibited long-term
Fatty Acid Oxidation Inhibited
pH 1
Table 1.1, The cellular events associated with ischaemia in the myocardium.
1.2 Cell Death
Although there have been several articles suggesting novel forms of cell death, there 
remain only 2 distinct recognised processes by which cells die, namely apoptosis and 
necrosis. Necrosis is an un-programmed method of cell death that has long been 
considered the method responsible for injury within the myocardium as a result of an 
ischaemic insult. During ischaemia it is thought that the reduction in oxygen brings about 
a switch to anaerobic respiration which has the effect of reducing stored levels of 
glycogen and the production of ATP. This lack of glycogen and ATP is thought to be the 
cause of ischaemia-induced necrosis within the cell8. The reduction in pH and 
accumulation of CO2 associated with ischaemia tends to cause a sodium overload as the 
Na+/H+ pump attempts to discharge protons from the cell in exchange for sodium ions. 
This sodium overloading can itself lead to mitochondrial damage9 but it can also lead to a 
catastrophic calcium overloading within the cell as a result of the exchange of this extra
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sodium for calcium by the Na+/Ca2+ transporter. This calcium has difficulty in being 
cleared from the cell as a consequence of dysfunction of the calcium ATPase transporter 
due to ATP depletion, thus exacerbating the problem of calcium accumulation.
Necrosis itself is characterised histologically by membrane disruption, such as to the 
cristae of the mitochondria and to the outer membrane, as well as by general 
mitochondrial swelling10.
A study by Kajstura and colleagues examined the relative roles of apoptosis and necrosis 
within ischaemia/reperfusion-induced infarction in rats, and determined that apoptosis 
accounted for the greater part of the infarct size compared to necrosis11. This research 
was backed up in a study by Dumont and colleagues in which they examined die
initiation of apoptosis subsequent to ischaemia/reperfusion by the use of the marker
10annexin v, suggesting that apoptosis was a major contributor to infarction . However, a 
study by Ohno et al. found that the use of supposed end-stage markers of apoptosis (DNA 
laddering and TUNEL positivity), to measure apoptosis in a model of 
ischaemia/reperfusion in rabbits, demonstrated that a characteristic of necrosis, i.e. 
plasma cell disintegration, is also present13. Thus many studies that have used TUNEL or 
DNA ladder positivity as conclusive proof that apoptosis was the cause of cell death may 
actually have witnessed a hybrid form of cell death with both apoptotic and necrotic 
markers present. However, Yellon’s group showed that inhibition of the caspase family, 
central to the apoptotic process, in particular caspases 3, 8 and 9, given at the point of 
reperfusion, substantially reduced infarct size14. Therefore, while it is difficult to 
distinguish precisely the manner of cell death responsible for much of the infarction
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caused by ischaemia/reperfusion, according to classical definitions, the beneficial effect 
of inhibiting the apoptotic machinery suggests that prevention of apoptosis is a valid area 
of research in trying to limit injury in this setting.
From these studies it can be hypothesised that necrosis alone does not account for the 
totality of injury suffered as a result of ischaemia/reperfusion, but that apoptosis has a 
significant impact on cell death within the myocardium.
1.2 .1  A p o p to sis
Apoptosis is an energy-dependent process and therefore it is thought to be predominant 
once reperfusion has commenced15,16 due to the rapid restoration of ATP levels. 
Apoptosis can be initiated externally by cytokines, such as TNFa and Fas, or triggered 
internally by the release of cytochrome c from the mitochondria. Both of these pathways 
have the outcome o f activating the caspase cascade which is central to the execution of 
apoptosis. These caspases are a series of enzymes that exist in an un-cleaved pro-form 
and are activated by cleavage at specific aspartate residues. As caspases are enzymes that 
can cleave at aspartate sites, once one caspase is activated it can initiate a proteolytic 
caspase cascade. Each caspase cleaves the pro-form of the next, subsequently activating
17 7ftit. The phenotypic endpoints of apoptosis reflect the cleavage targets of the caspases ' .:
1. Focal adhesion kinase -  causing loss of adhesion,
2. Lamins -  resulting in disassembly of nuclear lamina,
3. Structural proteins such as actin and gelsolin initiating blebbing
Anthony J. Bullard 21
Chapter 1
4. The activation of CAD endonuclease and inactivation of DNA repair enzymes, 
leading to DNA condensation and fragmentation.
The end result of apoptosis is the rounding of the cells into easily phagocytosed vesicles, 
which means that there is a reduced risk of inflammation.
It has been suggested that there are more ways for cells to die than merely 
apoptosis and necrosis; however none of the suggested additional methods have 
phenomena that are distinctively different from apoptosis and necrosis so it is difficult to 
class them as discrete processes. Instead, what seems likely is that a stimulus that triggers 
the initiation of the apoptotic pathway may become subverted into necrosis, possibly due 
to a depletion of ATP during ischaemia, for example21. A theory which tries to explain 
the switch between apoptosis and necrosis takes into account the relative rate of 
‘metabolic catastrophe’ versus the speed of caspases and endonucleases activation. If the 
caspases and endonucleases are activated before metabolic dysfunction causes disruption 
of the cellular plasma membrane, apoptosis will occur, otherwise the phenotypic feature 
of cell death will be necrotic22. This apparent apoptotic initiation with seemingly necrotic 
end-points, as described earlier in the study by Ohno and colleagues13, gives the 
appearance of an alternative process, but in actual fact cell death can be viewed as a 
spectrum with necrosis at one end of the scale and apoptosis on the other.
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Figure 1.1, A simplified schematic of apoptosis indicating initiation from external 
influences via TNF receptor and Fas, or internally by causing cytochrome c release from 
the mitochondria.
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1 .3  P rec o n d itio n in g
One method that has become well established in limiting ischaemic injury is ischaemic 
preconditioning (IPC). The preconditioning protocol of brief periods of ischaemia leading 
to a limitation in ischaemia/reperfusion-induced infarction was discovered in 1986 by 
Murry et al who, in a now landmark paper, were the first to describe the phenomenon in
23dogs . Subsequent research confirmed these findings and demonstrated that the duration 
of protection extends to about 4 hours. Since then, extended investigations have aimed to 
elucidate the cellular mechanisms responsible for this protection. Research implicated 
several possible triggers of EPC and attempted to utilise these triggers individually. For a 
review see Yellon and Downey24.
Several key protein kinases have been implicated in mediating preconditioning’s 
protection, including phosphatidylinositol-3’-OH kinase (PBK), Akt and PKC, although 
the role of some, such as p38 MAPK, ERK 1/2 and JNK, is more ambiguous.
Protein Kinase C (PKC) has many isoforms that seem to perform different functions. In 
IPC the 5-isoform is known to migrate to the mitochondria where it potentially can alter 
the flow of electrons in oxidative phosphorylation or affect the mPTP inhibiting its 
opening25, whereas the e-isoform moves to the intercalated disk 26 and so possibly plays a 
role in intercellular communication . A recent series of studies by Mochley-Rosen’s 
group suggest that the 5-isoform is pro-apoptotic as selective inhibition of this isoform 
prior to ischaemia afforded protection in neonatal myocytes, adult primary myocytes and 
isolated organ perfusion models . In contrast, the same group found that the s-isoform 
was activated during IPC and that an e-isoform knockout could not be preconditioned.
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It has been suggested that PKC is downstream of PDK in a signalling cascade 
which provides an additional method by which PI3K can implement its protective effect.
1.3.1 PI3K
PI3K was first implicated as a mediator of nerve growth factor’s protection 10 years ago 
29. Since then much research has focused upon the mechanism by which PBK imparts its 
protective effects. One crucial finding in this search was the discovery that PBK causes 
the activation of Akt via the protein kinase PDK-1 which directly phosphorylates Akt30"
32. Akt is a key component in imparting protection as it seems to have multiple targets 
that inhibit the apoptotic processes. For instance, it phosphorylates and, as a consequence, 
inhibits the pro-apoptotic factor Bad, preventing it from migrating to the mitochondria 
and causing cytochrome c release33. Akt also phosphorylates Caspase 9s4, forkhead 
transcription factors35 and GSK 3(336. On the other hand Akt can phosphorylate, and thus 
activate, anti-apoptotic factors such as eNOS37 and PKC38. All these actions individually 
and in conjunction have the overall result of preventing apoptosis and, importantly, Akt 
activation has been shown to be essential for the protection seen in preconditioning39.
In implementing the protective outcome of preconditioning, finding the end effector has 
long been an ongoing target of research in this field. However, recently it has been 
demonstrated that the prevention of the opening of the mitochondrial permeability 
transition pore (mPTP) is a potentially important candidate as an effector of 
preconditioning40.
This inhibition of pore opening has the effect of preventing cytochrome c release, 
calcium overload of the mitochondria and large-scale release of ROS, as well as the
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collapse of the mitochondrial electrochemical gradient which results in ATP depletion. It 
is a matter of ongoing research, however, as to precisely how the ‘survival’ kinase 
pathway feeds into and/or influences the opening of the mPTP.
Ischaemia, Adenosine, Bradykinin, Opioid
Receptor
Caspase 9
GSK3B
AKTeNOS Forkhead Transcription Factors
14-3-3 7  (BAD
Mitochondrion
Transition 
Pore
Figure 1. 2, The basic mechanisms involved in preconditioning
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As a result, pharmacological interventions using adenosine receptor agonists41, 
bradykinin42, m ito-K ATP channel openers43 and many others have shown that such 
interventions can mimic IPC’s effects, i.e. that they appear to confer a “memory effect” 
even after they have been eliminated from the system.
Despite the general assumption that ischaemic preconditioning limits injury caused by 
ischaemia, IPC has also been demonstrated to activate kinases associated with the 
limitation of reperfiision injury44. The inhibition of these kinases at reperfusion abrogates 
the protective effects of ischaemic preconditioning and strongly suggests that the 
beneficial effects of preconditioning are due to a limitation of the reperfusion injury 
rather than of the damage induced by ischaemia.
1.4 Reperfiision
The best treatment for ischaemia is the restoration of blood flow, or reperfusion. This has 
the effect of immediately providing oxygen and glucose and allowing removal of 
excretory products from the tissues. However, it has become increasingly evident that 
reperfiision, paradoxically, can itself induce injury over and above that caused by the 
preceding period of ischaemia. This additional damage has come to be termed 
‘reperfiision injury’45 and consists of increased infarct size, loss of function, oedema, 
damaged micro vasculature and arrhythmias. The precise reason as to why this additional 
injury occurs is a matter of ongoing research with much attention being focused upon the 
role of reactive oxygen species (ROS) in causing, or triggering, this injury.
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Experimentation suggested that free-radical scavengers could limit injury in a 
surgical model of ischaemia reperfusion46. Indeed, given that ROS release has been 
associated with the triggering of apoptosis47, and that reperfusion injury has been 
associated with apoptosis as distinct from the necrosis attributed to cell death caused by 
ischaemia48, it is entirely feasible that ROS is a major cause of apoptotic cell death 
resulting from reperfusion. It also seems that increased extra-mitochondrial calcium 
concentration enhances the cytochrome c-releasing potency of ROS49. This burst of ROS, 
in addition to an increase in mitochondrial calcium overload and correction of acidosis, 
are factors which favour the likelihood of mPTP opening with the consequence of 
mitochondrial membrane collapse, leading to ATP depletion, and necrosis. This is 
followed by cytochrome c release, resulting in initiation of mitochondria-dependent 
apoptosis50. Pharmacological inhibition of mPTP opening, by cyclosporine-A and by 
sanglifehrin-A administered at the point of reperfusion in an isolated rat model, confirms 
the role mPTP opening in initiation and mediation of cellular death51'55. Thus, as has 
occurred in the study o f preconditioning, inhibition of mPTP opening has become a focus 
in limiting reperfusion-induced injury.
The difference in the mechanisms of cell death in ischaemia versus reperfusion seems 
potentially possible due to restored levels of ATP which are necessary for the apoptotic 
process, with an absence of ATP likely leading to a necrotic form of cell death. However, 
necrosis is not exclusive to ischaemia any more than apoptosis is to reperfusion.
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Figure 1.3 Windows of therapy
Since injury can be caused by both ischaemia and reperfusion, it is possible that 
interventions can limit injury in both of these settings in a clinical scenario.
1.7 Kinase involvement in limitation o f Reperfiision Injury
While it is important to re-introduce blood flow as rapidly as possible, too abmpt a 
reperfusion can cause an increase in severity of injury. It has been shown that a ‘gradual 
reperfusion’, i.e. where the flow initially was low but gradually increased, showed a
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reduced infarct size compared to a group that had full flow restored from the 
commencement of reperfusion56.
Recently, the concept of postconditioning has been introduced. This occurs when 
reperfiision is interspersed with very brief periods of ischaemia, leading to a significant 
reduction in injury caused both in animals57 and, latterly, humans58. There are a number 
of hypotheses associated with the mechanism of action of postconditioning. One such 
hypothesis is that post-conditioning is just another modified form of gradual reflow. 
However, differences between observed features of postconditioning and gradual 
reflow56, such as a reduction in accumulation of neutrophils and preservation of 
endothelial function in animals subject to postconditioning57,59, suggest that 
postconditioning is more than just an altered form of the gradual reflow phenomenon. 
More recent work has centred around the activation of protein kinase pathways that have 
been associated with anti-apoptotic actions, such as PBK and Akt60 (discussed in detail in 
sections 1.3.1 and 1.4.1). It is considered that both kinases act in a similar way to prevent 
cell death at reperfusion as they do as mediators of preconditioning. In addition to the 
PBK-Akt pathway, certain other protein kinases have long been associated with infarct 
limitation, preservation of myocardial function and suppression of inflammation. These 
protein kinases form a mechanism recently termed the ‘Reperfiision Injury Salvage 
Kinase’ or RISK pathway61. This pathway can be utilised by pharmacological agents or 
other interventions, such as postconditioning, to successfully limit the extent of 
reperfusion-induced injury.
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Figure 1.4, The Reperfusion Injury Salvage Kinase (RISK) pathway components.
Adapted from Hausenloy et al61
As can be seen from figure 1.4, the 2 major components of the RISK pathway are Akt 
and ERK 1/2.
1.4.1 ERK 1/2
ERK 1/2, also known as p42/44, belong to a family o f Ser-/Thr- kinases also referred to 
as the Mitogen Activated Protein Kinases or MAPKs. Other members of this family 
include p38 and p46/54 or SAPK/JNK as they are also known. Whilst the other family 
members seem to be activated in response to some forms o f stress, the activation of ERK
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has been considered to be involved in growth and differentiation. Indeed, activation of 
ERK is usually necessary to bring about hypertrophy62. The MAPKs are activated by dual 
phosphorylation of a Thr-X-Tyr motif63 in response to certain growth factors binding to 
their G-protein-linked receptors and activating the Ras-Raf pathway. ERK itself is 
activated by dual phosphorylation at Thr202/Tyr204 for ERK1 and Thrl85/Tyrl87 for 
ERK2, both of which can be phosphorylated individually. Although both sites must be 
phosphorylated to activate the kinase64, there is not much information about whether 
there is any difference between p42 and p44 in the cell’s response. Upon activation ERK 
translocates to the nucleus where it activates transcription factors, such as myc, elk and 
brf 1, known to be involved in differentiation and growth65 by phosphorylating proline 
residues that reside next to serine or threonine residues66.
Of more direct interest, with respect to the acute scenario of ischaemia/reperfusion, is the 
finding of Allen et al that ERK inhibits caspase 9 by phosphorylating Thrl2567. 
Pharmacological inhibition of caspase 9 has been shown to limit reperfusion injury14, 
thus providing a feasible mechanism of protection for ERK 1/2. In addition, ERK causes 
phosphorylation of the Ser 112 residue of BAD and thus inactivates it via p90rsk68.
1.4.2 Protection against Reperfiision Injury using Pharmacological Activators o f  RISK 
Agents that activate the RISK pathway have been used as potentially beneficial
interventions in protecting against reperfusion injury. There have been many agents that
have been studied and found to improve myocardial function and/or reduce the level of
infarction. For example, Jonassen et al demonstrated that insulin could limit reperfusion-
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induced injury in a p70s6 kinase- and PBK-dependent manner in both a primary cell 
culture and an isolated heart perfused model69. Urocortin, a hormone related to the 
hypothalamic corticotrophin releasing hormone, was also shown to demonstrate 
protective properties when administered at the point of reperfusion. This protection was 
shown to be due to the activation of ERK 1/2. Furthermore, the ERK 1/2 inhibitor, 
PD98059, abrogated protection provided by urocortin thus indicating that ERK 1/2 was 
indeed a key component of protection70. In addition, a study by Brar et al, in neonatal 
cardiomyocytes, demonstrated that urocortin’s reperfusion injury-limiting properties were 
PBK dependent as the use of PBK inhibitors abrogated the protection seen by urocortin 
administration at reoxygenation71.
Despite being better known for its cholesterol-reducing properties, atorvastatin, an 
HMG-CoA reductase inhibitor, has also been shown to inhibit reperfusion injury in a 
PBK-dependent manner72. Interestingly, a study by Bell & Yellon demonstrated that this 
protection was lost if an eNOS knockout strain of mouse was used, thus implying the 
significance of eNOS in atorvastatin-mediated injury73. The importance of these studies is 
that they indicate that atorvastatin exerts its action within the cell rather than acting as an 
agonist on external cell receptors as with the majority of compounds studied in the 
reperfusion setting.
Some adenosine receptor agonists have also been demonstrated to have a beneficial effect 
when administered at the point o f reperfusion. The Al/A2a agonist AMP 579 is one such 
agonist that provided protection in an in vivo rabbit model of reperfusion-induced injury 
via an ERK 1/2-dependent mechanism74. Whilst the A1/A2 receptor agonist NECA has 
also been shown to reproduce the protection demonstrated by AMP 579, the failure of
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adenosine itself and the Al agonist, CGS21680, to similarly protect75 exemplifies the 
complicated relationship adenosine receptor agonists have with protection in the 
reperfusion setting.
The aforementioned studies demonstrated how various agents, some already in clinical 
use, have an ability to limit reperfusion-induced injury and highlight the potential that 
other such agents may act in a similar way. One such agent is the glycoprotein 
erythropoietin (see below).
1.5 Erythropoietin
Erythropoietin (EPO) is a 30.4 kDa glycoprotein that has proven to be a vital hormone 
whose main function is considered to be the regulation of erythropoiesis, the production 
of red blood cells by bone marrow tissue.
1.5.1 EPO and Erythropoiesis
Erythropoiesis is the process by which pluripotent stem cells become, by various cellular 
intermediates, red blood cells (erythrocytes). It takes place in normal healthy humans 
within the bone marrow predominantly in the vertebrae, sternum and ribs, although the 
tibia and femur are also sites for erythropoiesis in persons under the age of about 25. The 
cells undergo a maturation process from pluripotential stem cells under the influence of 
different humoral factors, one of which is EPO.
There has been much research focusing on the characterisation of the mechanisms by 
which EPO promotes the erythropoiesis. Thus far two main processes have been 
described. Firstly, an increase in free EPO within the blood appears to cause an apparent
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stimulation of haemoglobin synthesis in days 2 and 7 of the erythrocyte production 
process . This increase in synthesis of a vital component of the mature erythrocyte 
allows the erythropoietic process to proceed. Secondly, EPO has been shown to prevent 
the programmed cell death of late erythroid precursor cells (Colony Forming Units- 
Erythroid, CFU-E) and erythroblasts in the bone marrow77,78. These pre-cursors of 
erythrocytes are then allowed to proliferate and undergo the maturation process of 
erythropoiesis and form the mature red blood cell.
The EPO-derived inhibition of apoptosis in CFU-E is mediated through the up-regulation
7Qof Bc1-Xl via Stat 5 , preventing cytochrome c release from the mitochondria. The 
activation of PI3-K by EPO leads to a downstream activation of Akt, a known member 
of the ‘survival kinase* pathways, providing an additional means by which EPO can 
prevent apoptosis, as discussed in section 1.2. An influx of Ca2+ into the cell via a 
voltage-independent ion channel, after EPO binds to its receptor, also seems to have a 
protective effect as it plays an important messenger role in the survival and proliferation 
of erythroid precursor cells81.
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Figure 1. 5 The regulatory effect of EPO on erythropoiesis adapted from Sasaki et al
In the erythropoietic process EPO seems to act in a self-regulating negative feedback 
loop by binding to red blood cells and thus no longer being ‘free’ and active to bind to its 
receptor. By this means, the more red blood cells there are in the bloodstream the more 
EPO is bound and active levels are diminished.
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1.5.2 Structure o f  EPO
Purified for the first time by Miyake et al from the urine of patients83, EPO was the first 
protein to be produced in recombinant form and used as a clinical therapy, after being 
cloned, in the first instance to correct anaemia in patients with end-stage renal disease84, 
85. This was made possible after the location of the gene was discovered on chromosome 
7 (7pter-q22)86 in the human, and the size and sequence of the gene subsequently 
determined87. Produced as a 193 amino acid protein initially, EPO is cleaved down to its 
active form of 165 amino acids88 and has two isoforms, an a and a p form, with the a 
isoform having 31% content carbohydrate, and the p isoform 24% 88,89. The carbohydrate 
content is represented by 4 polysaccharide chains. Three of these chains are N-linked 
with the fourth being O-linked. As the O-linked polysaccharide is absent in the rodent 
form of the protein, without any seeming alteration in function, it can be assumed that 
this polysaccharide chain has little or no functionality90. However, examination of the 
other 3 chains suggests that they are important for bioavailability and prevention of 
excretion91. One component of the polysaccharide chains is sialic acid that binds to 
galactose residues92. Interestingly, if  the sialic acid is removed, EPO shows a greater 
affinity for its receptor in vitro increasing its activity by up to 5 fold93. However, its in 
vivo erythropoietic effect is lost as the protein is rapidly degraded by the liver94, 
indicating that the chain and the sialic acid play a role in preventing degradation of EPO.
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Figure 1. 6, Structure of EPO and its receptor from Sasaki et al 82
Experimental nephrectomy in animals resulted in an absence of increase in serum levels 
of EPO in response to anaemia or administration of cobalt. This suggests that EPO is 
predominantly released from the kidney.95,96 This data was further supported by evidence 
that patients with renal failure have lower serum EPO levels. It is estimated that 70% of 
EPO is produced in the kidney from the juxtatubular cells with the other 30% being 
released from the liver. However, EPO mRNA has also been discovered in brain, spinal 
cord, retina, testes and spleen in significant quantities97,98. Being 30.4 kDa in size, it is a 
matter of conjecture whether the molecule is able to cross the blood brain barrier and take 
its effect systemically rather than locally. Some studies do indeed suggest that it can cross 
the blood brain barrier99101, whereas others imply that EPO can only cross if the blood
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brain barrier is damaged as a result of pathological conditions such as hypoxia, 
haemorrhage and/or meningitis102,103. However, the concentrations of EPO produced 
within the brain indicate that this EPO production is insufficient to affect erythropoiesis 
regardless o f the ability to cross the blood brain barrier. In addition, the concentration of 
EPO within the cerebrospinal fluid tends to reflect any effects of trauma within the brain 
rather than correlating to the systemic levels of EPO104. Therefore, the evidence points 
towards a paradigm according to which EPO production within the brain is likely to have 
its effect in a localized environment and that EPO has pleiotropic effects beyond 
erythropoiesis.
1.5.3 Upregulation o f  EPO
As EPO is a regulator of erythropoiesis it is natural that, when the system needs to 
increase the oxygen-carrying capacity of the blood in response to hypoxia, an increase of 
the EPO levels will occur. This phenomenon has been well known in examples such as 
high altitude, where the oxygen level is low 105, or dilated cardiomyopathy resulting from 
renal hypoxia106. In fact, EPO production has become so closely related to ischaemia that 
semm EPO levels have been considered as a potential prognostic marker in the case of
107clinically-controlled congestive chronic heart failure .
The increase in EPO levels can take place via a variety of oxygen-sensitive mechanisms. 
One such mechanism depends upon an oxygen-sensing system whereby low oxygen 
tensions cause the iron ion in haem to lose association by equilibrium with oxygen108. An 
artificial way to mimic this situation is to use cobalt, nickel or manganese to substitute for 
iron in the porphyrin ring of haem. The inability of these ions to bind oxygen ensures that
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the haem group remains in a deoxy form108,109. One suggested explanation by which the 
haem causes an increase in EPO production is that a deficiency in iron or a maintenance 
of haem in the deoxy form will cause a reduction in H2O2 within the cell. H2O2 in this 
scenario acts as a secondary messenger to inhibit Hyoxia Inducible Factor (HIF-1), a 
transcription factor associated with the upregulation of EPO110. Alternatively, it has been 
suggested that NAD(P)H Oxidase could act as an inverse oxygen sensor by producing 
ROS from oxygen that ultimately acts as a messenger to inhibit EPO gene transcription 
via H2O2 , as described before111. Reduced oxygen tension, therefore, would reduce the 
level of free radicals and remove the inhibiting barrier to EPO gene transcription.
Another proposed mechanism by which EPO is upregulated is by the stabilisation of 
Hypoxia Inducible Factor la  (HIF-1 a). This transcription factor is continuously 
manufactured but rapidly degraded by the proteosome to prevent its action. However, 
during periods of low oxygen tension the protein becomes stabilised by prolyl 
hydroxylases112 and is able to migrate to the nucleus where it causes transcription of, 
amongst others, the EPO and VEGF genes by binding to the Hypoxia Inducible Enhancer 
(HIE)"3 " 4.
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Figure 1. 7, The heme and H IF-la oxygen-sensing mechanism by which EPO is 
upregulated. Adapted from Bunn et al.115
HIF-1 a itself seems to act by binding to p300, which acts as a scaffolding protein 
enhancing transcription116 and binds to the consensus sequence 5’- TACGTGCT -3’ on 
the EPO gene117. Incorporated as part of this macromolecular assembly is the enhancer 
protein Hepatic Nuclear Factor 4 (HNF 4) binding to HIF-1 p on the assembly and 
demonstrating enhancement of EPO gene transcription118,119. EPO has also been 
demonstrated to modulate cellular iron metabolism by increasing the affinity of iron
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receptors to their enhancer elements leading to an increase in iron receptors on the cell 
surface. The result of this activity is a greater uptake of iron into the cell in a manner 
similar to, but not as potent as, desferrioxamine. This phenomenon thus far has only been 
linked to the erythrocyte precursor, reticulocytes120.
1.5.4 The EPO Receptor
The EPO receptor (EPOR) is known to be found on a variety o f different tissue types 
including the heart121. Its structure consists of 1 subunit with a single transmembrane 
domain to yield a total protein size of 66 kDa122. Upon binding with its ligand, EPOR 
seems to form a perfect dimer whereby it is activated123, although it has also been 
proposed that the common p receptor also heterodimerises with EPOR to promulgate its 
signal124. EPO initiates its signal by binding to the receptor and causing its tyrosine 
phosphorylation 122, resulting in activation of JAK2 and ST AT 5 on one pathway system, 
and Ras/Raf as an alternative signalling pathway.
1.5.5 Signalling Pathways o f  EPO
Research has demonstrated that the binding of EPO to its receptor causes phosphorylation 
of tyrosine residues on the internal cellular domain of the EPOR 122. Further activation of 
Gi protein 125 leads to downstream activation of the protein kinases PDK and Akt, albeit 
in CHO Cells126. More recently EPO has been shown to cause activation of Jak 1/2, Stat 
3, Stat 5A, PKC and p38 MAPK127.
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As has been mentioned in section 1.3, activation of Akt and PKC prior to an ischaemic 
insult has been associated with limitation of ischaemia-induced injuiy. It was logical,
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therefore, to hypothesise that EPO could limit injury when administered prior to or during 
ischaemia. As table 12  shows, EPO does indeed afford protection in a variety of tissues 
including neurons, brain and liver.
Tissue Type Model Signalling Pathways Study
Neurons Primary culture Scavenging of free radicals Sakanaka et alU8
Brain In vivo rat N/A Brines et a l"
Brain/Neuron In vivo rat 
Primary culture
ERK, Akt, Stat 5 Siren et al129
Brain In vivo gerbils Bel xl Wen et al130
Fetal liver In vitro rat Lipid peroxidation Solaroglu et al131
Cerebellar,
hippocampal
Primary culture Jak 2, Glutamate Kawakami et al132
Table 1.2, Selection of non-myocardial studies that demonstrate EPO’s protection
in a variety of tissues and mediated by various signalling pathways
With components including Akt, PKC, Jak 2 and Erk, it seems likely that EPO’s 
protection is mediated through many of the same pathways associated with ischaemic 
preconditioning and successful pharmacological mimicry of preconditioning. During the
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course of the research undertaken in this thesis, a number of studies investigating pre- 
ischaemic cardioprotection with EPO have been forthcoming. These studies will be 
discussed in the context of the work carried out in this thesis.
1.5.6 Clinical Use o f  EPO
EPO being a hormone that promotes erythropoiesis and the production of red blood cells, 
exogenous administration of recombinant EPO is, naturally, used as a clinical therapy 
predominantly in cases o f chronic anaemia. Instances of anaemia tend to occur in cases of 
renal failure, as a result of renal carcinoma for example, and also in the setting of 
coronary heart failure that is associated with anaemia. As such, the use of EPO in chronic 
heart failure is not unknown and has been demonstrated to provide a beneficial effect by 
supposedly correcting the anaemia133. However, new research suggests that EPO 
activates certain protein kinases that have been associated with limitation of injury 
against ischaemia/reperfusion injury in many tissue types. This is the basis of the 
hypotheses that have led to an investigation of the ability of EPO to protect the 
myocardium from lethal ischaemia/reperfusion-induced injury and is the subject of this 
thesis.
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Chapter 2 - Methods
2.1 General
Male Sprague-Dawley rats were obtained from Charles River (UK) and were treated in 
accordance with the United Kingdom Animal (Scientific Procedures) Act of 1986. All 
animals were acclimatised for a minimum of 5 days prior to use in a cage of no more than 
5 animals containing access to water and standard pellet chow. Cages were maintained at 
19-22°C with 55% ±10 humidity and subject to 12-hour light-dark cycle.
22  Chemicals and Drugs Used
EPO was supplied by Roche (Welwyn Garden City, Herts, UK). All constituents for the 
Krebs-Henseleit buffer were supplied by BDH Laboratory supplies (Poole, Dorset, UK). 
Triphenyltetrazolium chloride (TTC), all Western blot reagents and all tissue culture 
chemicals were provided by Sigma-Aldrich Company Ltd (Gillingham, Dorset, UK). The 
BCA protein determination kit was purchased from Pierce Biotechnology (Rockford, IL, 
USA). Tetramethylrhodamine methyl ester (TMRM) was supplied by Molecular Probes 
(Eugene, OR, USA). PBS was provided by Gibco Ltd (Paisley, Scotland, UK).
23  Langendorff Perfusion Model
The Langendorff model for perfusion of isolated hearts has been in use for over 100 
years. Devised by Oscar Langendorff in 1895134, this method of measuring cardiac 
function and infarction in vitro has become recognised as a robust reproducible model. 
The technique involves retrograde perfusion of a crystalloid buffer into the aorta under 
constant pressure. Langendorff himself used a fixed height reservoir to maintain constant
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pressure. However, we used equipment from ADI instruments (UK) that employs 
pressure transducers to measure the perfusion pressure of the buffer entering the heart, 
and peristaltic pumps that control the rate of perfusion in order to maintain a constant 
perfusion pressure.
Male Sprague-Dawley rats (300-400g) were anaesthetised with sodium pentobarbital (50 
mg/Kg ip). Heparin (300IU) was administered concomitantly. Hearts were rapidly 
excised and placed in ice-cold buffer and mounted on a constant pressure (80 mm Hg) 
Langendorff-perfusion apparatus. They were perfused retrogradely through the aorta with 
modified Krebs-Henseleit buffer containing (in mM): NaCl 118, NaHCC>3 25, KC14.8, 
MgSC>4 1.2, KH2PO4 1.2, CaCh 1.7 and glucose 12 and aerated with carbogen pH 13-1.5 
at 37°C. Temperature was continuously monitored using a thermo-probe inserted into the 
pulmonary artery and maintained between 36 and 38°C. A latex balloon was introduced 
into the left ventricle through the left atrial appendage and inflated to give an end- 
diastolic pressure of 5-10 mm Hg. Regional ischaemia was achieved by tightening a 3/0 
Mersilk suture around the main branch of the left coronary artery, using a round bodied 
curved surgical needle, and confirmed by a substantial drop in both left ventricular 
developed pressure and coronary flow rate. Hearts underwent 10 minutes of stabilisation, 
followed by 35 minutes of regional ischaemia. Loosening of the suture at the end of this 
period induced reperfiision as confirmed by a rise in the coronary flow, although 
coronary flow diminished throughout the 120 minute reperfusion period.
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2.3.1 Exclusion Criteria
Hearts were excluded if a Rate-Pressure Product (RPP, heart rate multiplied by left 
ventricular developed pressure) did not achieve 17,000 beats/min.mmHg during 
stabilisation or the coronary flow fell below 10 ml/min. Hearts were also excluded if 
there was no drop in pressure and coronary flow on induction of ischaemia and a 
corresponding increase in coronary flow upon reperfusion. Finally, hearts were excluded 
if  the risk volume was determined to be outside the range 0.3 cm to 0.7 cm or if  the 
infarct to risk ratio fell beneath 5% as this level of injury was deemed to be due to 
mechanical means caused by the snare.
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Krebs-Henseleit Buffer
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Figure 2.1, Schematic representation of the Langendorff perfusion apparatus used
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Figure 2. 2, Langendorff perfusion apparatus used in experimentation
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2.3.2 Determination o f  Infarct Size
After the 120 minute perfusion period, the snare surrounding the LAD was pulled tight 
and a saline solution containing 0.25% Evans blue dye perfused into the heart in order to 
demarcate the risk area. The area of the heart that stains blue is considered non-risk tissue 
with unstained tissue being the risk area, see figure 2.4.
The heart is then frozen at -20° C for a minimum of 1 hour before being sliced into 5 x 
2mm transverse sections from apex to base. The slices were then incubated at 37°C for 15 
minutes in triphenyltetrazolium chloride (TTC) solution (in 1% phosphate buffer, pH 
7.4).
TTC staining has become a standard and accurate technique in measuring infarct size 135. 
The technique relies upon dehydrogenase enzymes and cofactors converting the 
tetrazolium salts to a red formazan pigment. As these enzyme and cofactors are washed 
away from the dead cells during reperfusion, infarction will be devoid of red pigment and 
will thus appear white. Any tissue appearing white is measured as infarcted and tissue 
appearing red is measured as viable. In order to ensure that these dehydrogenase 
enzymes and cofactors are washed away from the infarcted regions, there needs to be an 
adequate reperfusion period to avoid a false positive of infarcted tissue appearing to be 
viable . For this reason a 2 hour period of reperfusion was used as part of a standard 
protocol.
Subsequent to TTC staining, heart slices were placed in 4% formalin (BDH, Poole UK) 
in saline for 24 hours. The formalin had the effect of bleaching the infarct area in order to 
demarcate it more clearly. The slices were then placed between 2 perspex sheets and
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clamped by bulldog clips. An acetate sheet was placed over the top and the slices were 
traced blindly by an independent observer, the same person being used for all 
experiments to ensure consistency. A computerised planimetry package (Summa Sketch 
III, Summagraphics, Seymour, CT, USA) was used to determine the percentage of infarct 
size volume compared to risk zone and expressed as infarct-risk volume ration (I/R%), 
see fig 2.5.
Figure 2. 3, Heart that has had the snare tied around the LAD and Evans blue dye 
injected down the aorta to demarcate the risk zone
Anthony J. Bullard 52
Chapter 2
Risk area
Non-risk area
Infarcted
area
Figure 2. 4, Tetrazolium stained heart slices. Example of heart slices that have 
undergone TTC staining with the infarct area showing up white, viable risk tissue as red, 
and non-risk tissue staining blue.
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Figure 2. 5, Planimetred heart slices of samples in fig 2.4. Yellow colouring represents 
non-risk area, green risk area and red infarcted area.
2.4 Western Blotting
2.4.1 Tissue Collection
Rat hearts were prepared, mounted and underwent ischaemia/reperfusion as per the 
isolated heart preparation. Hearts were made ischaemic for 35 minutes followed by 15 
minutes reperfusion, at which point the risk zone was identified using Evan’s blue dye, 
excised, snap frozen in liquid nitrogen using pre-chilled tongs and stored at minus 80°C
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for later use. When global ischaemia was used, i.e. the whole heart was subject to 
ischaemia, only ventricular tissue was excised and frozen.
2.4.2 Protein Extraction
Approximately lOOmg of frozen tissue per sample were extracted by homogenising on 
ice in 250 pL suspension buffer (in mM): NaCl 100, Tris 10 (pH 7.6), EDTA 1 (pH 8), 
sodium pyrophosphate 2, sodium fluoride 2, [beta]-glycerophosphate 2, Sigma proteases 
inhibitor cocktail; using a Plytron model T25 homogeniser (DCA Labortechnik T25,
Janke & Kunkel GmbH & Co., Germany). Samples were centrifuged at 10,000 rev/min, 
for 10 minutes at 4°C on a bench centrifuge, the supernatant was collected, and protein 
concentrations were estimated using BCA protein assay reagent (Pierce, UK). The 
remaining supernatant was further diluted 1:1 in sample buffer (in mM): Tris 100 (pH 
6.8), DTT 200, SDS 2%, bromophenol blue 0.2%, and glycerol 20%, and subsequently 
boiled for 10 minutes at 100°C.
2.4.3 Protein Estimation
The protein concentrations for each sample were determined in order to be able to use the 
same amount of protein per sample on the Western blot.
The BCA protein assay works on the premise that cysteine, tryptophan, tyrosine and the 
peptide bond are capable of reducing Cu2+ in a copper sulphate reagent to Cu+137. 
Bicinchoninic acid is then able to bind to Cu+to give a purple colouration that is 
measurable in a linear manner at an absorbance of 562 nm. The protein content of the
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samples can then be measured by comparison to a standard curve (20-2000 |Jg/ml) using 
bovine serum albumin (BSA) as the standard protein to give a concentration for the 
samples (|Jg/|Jl) and enable equal loading of the polyacrylamaide gel.
2.4.4 Polyacrylamide Gel Preparation 
SDS-PAGE was used comprising:
a) 5% stacking gel (consisting o f 7ml de-ionised H2 0 , 3ml stacking gel base [consisting 
o f 0.5M TRIS, 0.4% SDS in de-ionised H2O, pH 6.8], 2ml 30% acrylamide, 20|Jl 8% 
bromophenol blue, 24 |Jl TEMED and 120|Jl 10% ammonium persulphate)
b) 12.5% running gel x  (consisting o f 12 ml de-ionised H2 0 , 9ml running gel base 
[consisting of 1.5M TRIS, 0.4% SDS in de-ionised H2O, pH 8.8], 15ml 30% acylamide, 
40|Jl TEMED and 200[Jl ammonium persulphate)
The SDS in the sample buffer gives the sample proteins a negative charge allowing them 
to move towards the positive terminal when an electric current is applied. The gel 
provides a resisting medium for the sample proteins to pass through so that smaller 
proteins will pass through more easily and therefore faster. In this way the proteins within 
the sample become separated according to size. A stacking gel is used in order to 
condense the sample into a thin band when the sample comes across the much higher 
concentrated running gel. This means that even though the proteins will separate out on 
the running gel according to size, those proteins with the same size will still be 
accumulated into a narrow band as that is how they entered the running gel.
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A total protein quantity of 60 pg for each sample was loaded into each well in the 
stacking gel with a broad range Rainbow marker (10|Jl) loaded into the first well. The gel 
was then mounted onto a vertical electrophoresis system containing running buffer 
(glycine 14.4g/L, SDS l.Og/L, Tris 3 g/L, 1 litre de-ionised H2O). Running water was 
passed through die central core of the electrophoresis system in order to dissipate heat 
built up as a result of the electric current from the gel. Gels were run at 200V for 2-4 
hours.
2.4.5 Protein Transfer
After the completion of protein separation by electrophoresis, the stacking gel was 
trimmed off and the running gel was mounted in a transfer system containing transfer 
buffer (200ml methanol, 700ml de-ionised H2 0 ,100ml lOx transfer buffer [glycine 
14.4g/L, Tris 3 g/L, 1 litre de-ionised H2O]). Hybond ECL nitrocellulose membrane 
(Amersham, UK) was cut to the same size as the gel and placed on the gel. The gel and 
membrane were then placed between 2 pieces of Whatman 4mm paper taking care to 
remove any air bubbles. Following this, the proteins were transferred to the membrane by 
passing a current of 140mA overnight (16-20 hours). Adequate transfer could be 
determined by staining the membrane with Ponceau Red (Sigma Chemicals, Poole, UK).
2.4.6 Immunoblotting
The membranes were then washed in PBS-Tween (Na2HPC>4 1.6 g/L, NaCl 8.0 g/L, de­
ionised H20 1 litre, Tween 20 1ml, pH 7.2), before being placed in blocking buffer (PBS-
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Tween with 5% non-fat Marvel) for 1 hour. Blocking buffer was used to block potentially 
unfilled sites on the membrane and so prevent non-specific binding of any antibodies in 
the future. The membrane was then washed 3 times in PBS-Tween before incubating in 
the primary antibody (PBS-Tween, antibody at 1:1000 dilution, 5% BSA) for 2 hours. 
After washing again 3 times in PBS-Tween, the secondary anti-rabbit antibody (PBS- 
Tween, secondary antibody 1:1000 dilution, % non-fat Marvel) was placed on the 
membrane. After washing for a final 3 times, ECL chemi-luminescence reagent was 
added to the membrane and agitated for 1-2 minutes. Membrane was exposed onto Kodak 
AR film and developed using Kodak developer and fixer.
2.4.7 Quantification o f Bands
The developed films were scanned on using a flatbed document scanner and the digital 
image produced was analysed using National Institute of Health (NIH) Image version 
1.63. Using the supplied ‘Gel Plotting Macro* the density of bands was determined 
employing the grey scale technique.
The loading of the gels was corrected for by measuring each well for (3-actin or the total 
protein of the phosphorylated protein probed for.
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2.5 H9c2 Culture
H9c2 culture was provided by the European Collection of Cell Cultures (ECACC) and 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) catalogue number D-5671, 
supplemented with 10% v/v foetal calf serum (cat no N-4637), 1% v/v glutamine (cat no 
G-7513) and 1% v/v penicillin +streptomycin (cat no P^1333).
H9c2 cells were cultured at 37°C and 5% CO2 (incubator C028IR, New Brunswick 
Scientific, USA) and passaged when 80% confluent.
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Figure 2. 6, H9c2 cells in culture
2.5.1 Hypoxia/Re-oxygenation
To mimic hypoxia and re-oxygenation a hypoxic chamber was used, see figure 2.7. The 
chamber consisted of perspex walls and lid to form an air-tight container, heating pads to 
maintain the temperature at 37°C and an inflow and outflow for inert gas (95% argon, 5% 
CO2) to flush out the air. At the bottom of the chamber a dish of sodium dithionite was 
used to scavenge any oxygen that may linger.
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To mimic the physiological conditions of ischaemia the D-5030 medium (Sigma-Aldrich) 
was used. The main difference between this medium and that used to culture the cells is 
the presence of 2.2 g/1 sodium bicarbonate and 14 mM KC1. The hypoxic medium was 
supplemented with lactate acid to a final concentration of 20 |JM and 1% v/v penicillin- 
streptomycin, as mentioned above. The pH was measured and found to be 6.5.
In order to induce hypoxia the cell plates were placed in the chamber, which was 
subsequently sealed. The air in the chamber was removed by vacuum pump and replaced 
with a 95% argon, 5% CO2 gas mix. Re-oxygenation was performed by replacing the 
hypoxic medium with the original culture medium. Any drugs to be administered at re­
oxygenation were pre-mixed into the culture medium. Normoxic samples were kept in 
culture medium. Any washes and medium changes in the hypoxia/reoxygenation groups 
were matched in the normoxic group.
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Figure 2. 7, Hypoxic chamber
2.5.2 Flow Cytometry
Flow cytometry is an experimental method whereby cells are passed through a laser and 
fluorescent markers on or in the cells become excited in a manner that makes it possible 
to measure the subsequent emmission. In addition, the relative size and density of the 
cells can be determined by the forward and side scatter of the laser as the cells pass 
through the beam.
For this purpose, a Partec flow cytometer (Partec, Munster, Germany) with an argon laser 
emitting light at 488 nm was used.
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Figure 2. 8, Flow cytometer
In the present study annexin v was used as a marker of apoptosis -  and Propidium Iodide 
(PI) as a marker of necrosis. Annexin v belongs to a family of coagulants known as 
annexins. It has been shown that annexin binds to phosphatidylserine (PS), which 
becomes externalised in the early stages of apoptosis. By conjugating the fluorescent 
marker Fluorescein Isothiocyanate (FITC) to annexin v it is possible to measure the 
extemalisation of PS on the cell membrane and characterise that cell as undergoing 
apoptosis138*140.
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Figure 2. 9, Representation of the mechanics of flow cytometry -  Light is emitted by 
an argon laser and excites the fluorescent probe in the cell passing through the flow 
cuvette. The light emitted from the cells passes through dichroic filters to the appropriate 
detector, green to FL1 (annexin v) and red to FL2 (PI).
Similarly, PI enters the cell when the membrane is ruptured making it a useful marker of 
necrosis. The fact that FITC emits green light when excited and PI red enables the two 
markers to be used in combination140.
H9c2 myoblasts that have undergone the experimental protocol are trypsinised 
(Clonetics, New Jersey, USA) and then incubated for 10 minutes with annexin v (2 
|Jl/ml) in annexin buffer consisting of HEPES (10 mM), NaCl (150 mM), KC1 (5 mM) 
MgCb (1 mM) and CaCI2, pH 7.4, at 37°C in the dark. Cells were spun and washed in
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phosphate buffered saline (Gibco, Paisley, UK). Just prior to analysis by flow cytometry, 
PI (50 was added to the sample and mixed.
2.6 Preparation of Adult Rat Myocytes
In order to focus more closely on the cellular mechanisms without interfering with factors 
such as inter-cellular communication and immunological response and to provide a more 
homogeneous response we undertook studies using adult rat caidiomyocytes.
Male Sprague Dawley rats were anaesthetised and the heart excised in the same manner 
as for the Langendorff perfusion model, see section 2.3. The heart was hung on a 
perfusion apparatus and perfused at a constant rate of 14 ml/min. All buffers were made 
from the central component of Krebs-Ringer’s-HEPES buffer (KRH) which consisted of 
(mM): NaCl 116, HEPES 10, Glucose (pH 7.4) 10, KC15.4, Na2HP04 0.9, MgSO40.4, 
taurine 20 and pyruvate 5. Water used in the production of KRH buffer was autoclaved 
and KRH buffer was filter sterilised prior to use.
All buffers were bubbled with 100% 0 2 and maintained at 37°C by a heated water jacket. 
In addition a heart perfusion chamber that acts as a bubble trap just prior to the cannula 
was also heated by a water jacket.
The heart was initially perfused with buffer 1 consisting of KRH supplemented with 
1 mg/ml BSA for 5 minutes. The heart was then perfused with buffer 2 consisting of 
KRH buffer supplemented with 0.75 mg/ml Type II collagenase and 25 |JM CaCl2 for 10 
minutes. Finally the heart was perfused with buffer 3 consisting of KRH buffer and 
supplemented with 50 |JM CaCl2 for 5 minutes. At the end of this period the ventricles 
were excised from the atria and roughly chopped in a Petri dish containing buffer 2. The
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mixture was transferred to a 50ml Falcon tube that was gently agitated at 37°C and 
bubbled with 100% O2 for 10 minutes. After the first digestion any loose material, 
usually comprising of dead cells as a result of physical injury from the scissors, was 
removed and discarded. The remaining material was covered in the collagenase buffer 2 
and agitated again for 20 minutes. This was repeated until such time that the myocytes 
appeared to be at least 70% viable by light microscope. At this point the cells were 
pipetted off and washed twice in Phosphate Buffered Saline (PBS) and spun at 300g for 2 
minutes to remove extraneous fluid. Cells were then resuspended in M-199 medium and 
500 |Jl of the suspension seeded onto coverslips that had had 200 |Jl of 1 mg/ml laminin 
coated and dried on them. The coverslips were incubated at 37°C with 5% CO2 
(incubator C028IR, New Brunswick Scientific, USA) to allow the cells to stick to the 
laminin. At this point 2 ml M-199 were added per well/coverslip.
2.6.1 Confocal Microscopy
Confocal microscopy was performed in order to study the importance of mitochondrial 
permeability transition. This research was undertaken and conducted in the Mitochondrial 
Biology laboratories of Professor Michael Duchen using a Zeiss 510 CLSM.
The microscope was set up using a henna laser that was filtered to 543nm with TMRM 
fluorescence measured at 585 nm by using a long pass filter. Cells were visualised using 
a 40x oil immersion objective.
The coverslip containing the myocytes was incubated for 15 minutes in 1 |Jl/ml 
TMRM and then placed in a custom-made chamber that was inserted onto the objective.
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Once suitably healthy cells, as asserted by morphology, had been identified for use within 
the experiment the cell was scanned by the laser with TMRM emission measured. The 
timings to the initiation of the mitochondrial wave of membrane depolarisation were 
measured.
Figure 2.10, Confocal microscope
2.7 Statistics
Data were statistically analysed by one-way ANOVA. Where a significant F-value was 
obtained, the Fishers protected least significant difference (PLSD) post hoc test was 
applied for between group comparisons. All statistics were performed using Statview 4.5 
(Abacus Concepts Inc., Berkley, California, USA.). A p-value of <0.05 was considered to 
be statistically significant. Results are presented as means ± SEM.
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Chapter 3 - Erythropoietin Mimics Preconditioning
3.1 Hypothesis, Aims and Protocol
In chapter 1 the phenomenon of preconditioning (brief periods of sub-lethal ischaemia 
leading to protection against lethal ischaemia) was described. The use of pharmacological 
agents to mimic this Classical* preconditioning was also mentioned. Section 1.5.5 
explained how recent research had discovered a preconditioning-like phenomenon for 
EPO in models of stroke. In a similar manner to ischaemic preconditioning (IPC), 
successful pharmacological preconditioning involves the activation of certain protein 
kinases such as Akt and PKC. These are kinases that EPO is known to activate 126. It is 
reasonable to hypothesise, therefore, that EPO can itself pharmacologically precondition 
the myocardium via these protein kinases
The aims of the studies included in this chapter were therefore to determine whether EPO 
can precondition the myocardium in a Langendorff perfusion model and to examine 
whether the same signal pathways are activated in EPO-mediated protection as that seen 
in the setting of preconditioning.
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3.2 Experimental Protocols
All hearts underwent the standard protocol of 35 minutes ischaemia (index ischaemia) 
and 2 hours reperfusion, see section 2.3. The following protocols were used:
1. Control -  no drug administration, but a stabilisation period of 30 minutes (n=3)
2. Ischaemic Preconditioning -  2 cycles of 5 minutes ischaemia followed by 10 minutes 
reperfusion prior to index ischaemia (n=3)
3. EPO -  administered at a dose of 50 ng/ml for 10 minutes followed by a 10 minute 
washout prior to entering the index ischaemia (n=5)
4. Wortmannin -  this PBK inhibitor141 was administered at a dose o f200 nM either on its 
own (n=3) or in combination with EPO (n=5)
5. U0126 -  this ERK 1/2 inhibitor was administered at a dose of 10 pM either on its own 
(n=3) or in combination with EPO (n=6)
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33 Results
Groups Body Weight 
(g)
Ventricle Volume 
(cm3)
Risk Volume 
(cm3)
Ischaemic Control 375 ±12 0.992 ±0.079 0.573 ±0.055
Isch Preconditioning 364 ±22 0.939 ±0.065 0.471 ±0.028
EPO 382 ±7 1.042 ±0.122 0.557 ±0.052
EPO + Wort 373 ±12 1.059±0.027 0.587 ±0.044
EPO + UO 379 ±2 1.057 ±0.049 0.542 ±0.050
Wort 350 ±24 0.959 ±0.065 0.569 ±0.060
UO 359 ±14 1.004 ±0.060 0.501 ±0.033
Table 3.1, Characteristics of animals in the treatment groups
As Table 3.1 demonstrates, there was no statistical difference between any of the groups 
in animal weight, ventricular volume or risk volume.
Exclusions
One animal from the ischaemic preconditioning group was excluded due to too large a 
risk zone, two animals were excluded from the EPO group for either having too large or 
too small a risk zone, one animal was excluded from the UO group due to a failure to 
instigate ischaemia.
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Figure 3.1, Representation of the change in Rate-Pressure Product (RPP) 
throughout the experimental protocol from stabilisation (Stab) through ischaemia 
(Isch) and into reperfusion (Rep)
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Figure 3. 2, The effect of ischaemic preconditioning (IPC), and of a 50 ng/ml dose of 
EPO when administered as a preconditioning mimetic solely, or with the PDK 
inhibitor wortmannin (Wort) or the ERK 1/2 inhibitor UO 126 (UO). The effect of Wort 
and UO alone on infarction is also presented. Values are represented as % infarct to risk 
ratio (%I/R) and expressed as mean ±SEM. *p<0.05 vs control.
Fig 3.2 describes the significant reduction in infarct size when EPO is administered prior 
to the index ischaemia compared to control (%I/R 28.6 ±4.8 v 48.1 ±8.1, p<0.05). This 
reduction in infarct size is lost when EPO is perfused in combination with wortmannin 
(%I/R 54.2 ±7.6 v 28.6 ±4.8, p<0.05). U0126 did not significantly reduce the infarct- 
limiting effects of EPO when co-perfused (%I/R 38.4 ±8.1 v 28.6 ±4.8). Neither 
wortmannin nor UO 126 administered solely significantly altered infarct size compared to 
control (%I/R 52.2 ±10.6; 39.5 ±3.7 v 48.1 ±8.1, respectively). As expected, ischaemic
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preconditioning reduced infarct size significantly compared to control (%I/R 29.8 ±6.3 v
48.1 ±8.1,p<0.05).
3.4 Discussion
Ischaemic preconditioning (IPC) is a well-accepted cardioprotective phenomenon that 
has been known for many years. Due to the strength of die protection observed much 
focus has been on examining the mechanisms of protection associated with it with the 
intention of replicating the protection by pharmacological means, see section 1.3. The 
aim of the research presented in this chapter was to determine whether EPO could mimic 
IPC when administered prior to the index ischaemia and whether any protection observed 
is achieved via similar pathways as described for IPC and other successful 
preconditioning mimetics.
3.4.1 EPO Mimics Preconditioning
EPO-mediated cardioprotection against ischaemia/reperfusion injury has begun to be 
well characterised in the last few years as discussed in chapter 1. Commonly, the effect 
has been seen when EPO is administered during the ischaemic period or just prior to 
commencement of ischaemia. Calvillo et al were the first to describe EPO-mediated 
protection when they administered the agent pre-ischaemically in an in vivo model of 
infarction and in adult rat cardiomyocytes142. Tramontano et al also demonstrated this 
cardioprotective effect in a neonatal rat cardiomyocyte model in addition to an in vivo rat 
open chest model143. Parsa et al used adult rat cardiomyocytes and the rat-derived
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ventricular myoblast cell line, H9c2, to show that EPO could protect against H2O2- 
induced injury144. These studies have been supported by the findings of several other 
papers examining the effect of EPO in cellular models of hypoxia142,144. Importantly, the 
phenomenon has not only been seen in cellular models but has been reproduced using 
both in vitro and in vivo models of ischaemia/reperfusion121,145,146, discussed in detail 
later on. The effect shown was not merely to delay tissue death to beyond the point of a 
short period of reperfusion. Moon et al gave EPO in an in vivo rat model at the point of 
ligation of the coronary artery to induce ischaemia without reperfusion. As an end-point 
they measured apoptosis 24 hours later and infarct size and ventricle size 8 weeks later147. 
They found a positive effect in all parameters thus showing that the effect was not merely 
a delay but a long-lasting prevention of cell death. A contradictory study, however, by 
Hale et al found that the infarct size in a permanent coronary occlusion rat model 6 weeks 
after commencement of ischaemia was no different in EPO-treated hearts than control148. 
As the authors themselves conceded, however, timing and dosage of EPO seems to be 
important and their decision to dose daily for the first 7 days may have meant that the 
dose of EPO was outside the therapeutic window. One study by Kristensen et al also 
contradicts the data in the literature presented here. They found that EPO had no effect on 
infarct size when administered prior to ischaemia in an in vivo porcine model of 
ischaemia/reperfusion149. The differences reported by this group may be attributed to the 
species used in the experiment. The pig model is known to have less collateral flow than 
the ra t150,151 and thus may contribute to the difference in the data produced. The pig may 
also respond differently to human recombinant EPO than the rat. Another major
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difference is that the Kristensen study used a dose of 500 U/Kg which is 10-fold less than 
the dose used habitually within the rat.
All the models mentioned thus far have involved EPO being present up to at least the 
commencement of index ischaemia/hypoxia. However, one of the main features of 
preconditioning is the memory effect affording a protected state within the tissue even 
after the stimulus has been removed. As can be observed from the results presented in 
this chapter, EPO clearly managed to elicit just such a memory effect within the 
myocardium since EPO still limited ischaemia/reperfusion-induced injury despite having 
been washed out. Therefore, the data presented within this chapter are the first to show 
that EPO can precondition the myocardium. A memory effect of EPO has only been 
produced in a neuronal setting152. Most other studies that have investigated the effects of 
EPO pre-treatment did not include a wash-out period prior to index ischaemia. Thus it 
cannot be argued that the protection seen is due to the memory effect characteristic of 
preconditioning 127 ’153.
3.4.2 EPO Mimics Preconditioning through PI3K
From the data presented in figure 3.2 it can quite clearly be seen that EPO-mediated 
protection is abolished when EPO is co-administered with the PDK blocker 
wortmannin141, suggesting that the protection is PDK-dependent. The fact that PDK 
seems to be involved in the protective effects of EPO should not come as a surprise as it 
has been found that the method EPO uses to prevent apoptosis in erythroid progenitor 
cells is by PDK activation154,155. Indeed, IPC itself has been associated with being PDK-
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dependent . Our data suggest that EPO utilises at least some of the same protein kinase 
signalling pathways as IPC. Other studies regarding the EPO-mediated cardioprotection 
have likewise implicated PDK as an important kinase activated by EPO156. This includes 
data produced by Tramontano et al, who found that PDK was an important factor in 
EPO-mediated protection against hypoxia in cardiomyocytes143. hi addition, Hanlon et 
al145 used the alternative PDK blocker, LY294002, as well as wortmannin, to 
demonstrate that EPO-mediated protection was PBK-dependent in a similar rat 
Langendorff perfusion model. This model involved a protocol consisting of 20 minutes of 
global ischaemia and 40 minutes of reperfusion. Interestingly, they found that the co- 
administration of blockers with EPO prior to ischaemia had no effect on the reduced 
infarct size shown by EPO administered solely145. However, when the blockers were 
given at reperfusion, protection was abolished. This fact seems to suggest that the 
protective effect of EPO is effective against reperfusion-induced injury. Interestingly, 
Hausenloy et al demonstrated that P C  could be inhibited when LY294002 was 
administered not only prior to ischaemia44 but, more importantly, when it was given at 
reperfusion. Against this argument is the data published by Moon et al, as mentioned in 
section 3.4.1, which indicated that EPO could limit injury in a model that did not include 
reperfusion147. Hanlon et al go on to suggest that PKCs, and in particular the epsilon 
isoform of PKC, are important in mediating the protection afforded by EPO as shown by 
the movement of PKC epsilon to the intercalated disc subsequent to EPO administration. 
The importance of PKC was shown by the fact that the PKC inhibitor chelerythrine 
abolished EPO-mediated protection in their model145. Both the movement of PKC epsilon
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and the attenuation of protection by cheleiythrine applies to IPC-mediated protection 157' 
162 , suggesting further similarities in protective pathways between the two stimuli.
3.4.3 EPO-induced Preconditioning is not ER K 1/2-dependent
The data presented in this chapter appears to indicate that the ERK inhibitor, U0126,
failed to significantly abolish the protection seen by pre-ischaemic administration of
EPO. It should be noted, however, that the infarct size for EPO+UO and UO alone were
similar making the result ambiguous. Interestingly, ERK 1/2 has not been implicated in
mediating the cardioprotection seen as a result of the effects of IPC39. The same can be
said for EPO, as shown by Hanlon et al145, although Rafiee et al managed to inhibit the
protection provided by EPO in the rabbit infant heart with the ERK 1/2 inhibitor
PD98059127. The difference in response could be attributed to the different inhibitor, the
different species or different age of the animal used. This absence of ERK involvement in
preconditioning is in contrast to the importance attributed to ERK in EPO-mediated
protection at reperfusion, see chapter 4. The ERK-independent nature of the protective
effects of a pre-treatment of EPO may be specific to the heart. In this regard Kilic et al
have shown that in the brain ERK does seem to be involved in protection induced prior to
1 A3and during ischaemia . There are, as yet, no further studies that have examined the role 
of ERK within EPO-mediated protection. Thus, these findings have yet to be confirmed 
by additional studies. It should be noted that the control U0126 value is very similar to 
the UO + EPO group, suggesting that the dmg itself may be having an effect. The body of 
studies using U0126 and examining the role of ERK 1/2 at preconditioning suggests that 
the U0126 group result is likely to be an artefact. Therefore, more research needs to be 
undertaken to clarify the data.
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3.4.4 Clinical Implications o f EPO Preconditioning
The difficulty in transferring the positive results of preconditioning to the clinic has 
always been one of the predictability of adverse events in patients. As the window of 
protection provided by preconditioning stimuli is relatively short at 1-2 hours24,164,165, it 
requires knowledge of a pending coronary occlusion to be best able to utilise the 
intervention, in this case EPO. There are instances where the ischaemic period is 
predictable, such as the elective operation Coronary Artery Bypass Grafts (CABG). In 
this technique there is scope to use EPO to mimic preconditioning in the heart prior to the 
operation in order to reduce any damage caused by the procedure. So as to provide a 
wide-ranging use for the protective qualities of EPO, an alternative setting is required, hi 
this regard, using EPO as an adjunct to reperfusion may provide a more effective clinical 
use.
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Chapter 4
4.1 Introduction and Alms
There has been a significant amount of research surrounding the possible triggers and 
end-effectors of preconditioning, but the difficulty has always been establishing this into 
clinical practice. By its very nature, to use preconditioning effectively would require the 
ability to predict a sustained ischaemic occurrence which would lead to an infarction, see 
chapter 3. Certainly in emergency cases the ischaemic period has already commenced 
and so the main treatment required is to remove the obstructive thrombus causing the 
myocardial ischaemia and institute a reperfusion of the tissue as quickly as possible. 
While this treatment is clearly necessary, paradoxically this reperfusion can cause injury 
to the tissue over and above that caused by ischaemia, a phenomenon known as 
‘reperfusion-induced injury’ 45. Research has shown that a variety of agents can limit cell 
death when given at reperfusion, see section 1.4, thus confirming the phenomenon and 
opening up potential therapeutic possibilities.
As described in chapter 1, reperfusion injury is a concept that has profound implications 
in the treatment of patients in both an elective and emergency scenario. As the use of 
EPO has been demonstrated to limit cell death in a number of settings and is able to 
activate mechanisms proven to be effective against reperfusion injury, it is hypothesised 
that EPO could reduce myocardial injury when administered at the point of reperfusion.
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4.1.1 Mechanisms o f Intervention
Recently it has been hypothesised that reperfusion-induced injury is triggered by the 
opening of the mPTP. This causes cytochrome c release, leading to initiation of 
apoptosis166"168 and ATP depletion resulting in necrotic cell death 169,17°. Early research 
into reperfusion injury suggested that free radical scavengers could reduce reperfusion-
A f l  1 ^ 1  1 7 ^
induced injury ’ ’ , implying that oxidative stress was a main factor in reperfusion
injury. However, results of this type could not be replicated in the clinical setting by 
improving the outcome of patients despite the biochemical markers of their stress being
11 % 17^improved ' . Studies elucidating the role of ROS within the cell have demonstrated 
that lower concentrations of ROS can have a beneficial effect by activating pro-survival 
kinase pathways such as the ERK pathway via G proteins.176’178 
Research focus has shifted to the protein kinase survival pathways, highlighting in 
particular a beneficial pathway at reperfusion, the so-called RISK (Reperfusion Injury 
Salvage Kinase) pathway 61. EPO is known to activate certain elements of this pathway 
such as ERK 1/2 126 and Akt. It is therefore possible to hypothesise not only that EPO 
limits reperfusion-induced injury, but also that it does so utilising the RISK pathway.
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4.2 Experimental Protocol
All hearts were prepared and subject to a standard ischaemia/reperfusion protocol using 
the Langendorff apparatus described in chapter 2. Due to the novel nature of the work, a 
dose response curve was produced initially in order to try and determine the most 
effective dose to study. In choosing the range we were guided by a study by Calvillo et al 
that used an in vivo dose of 5,000 U/kg, equivalent to 50 ng/ml142.
EPO was dissolved in Krebs-Heinselet buffer to produce the following concentrations: 0 
(n=6 ), 20 (n=5), 50 (n=5), 100 (n=8 ), 200 (n=8 ) ng/ml and perfused 5 minutes prior to 
reperfusion for a total of 2 0  minutes as outlined below.
Drug administration 
2 0  mins i
Determination 
of infarct size
1 0  mins 35 mins 1 2 0  mins
Stabilisation Ischaemia Reperfusion
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Once the dose had been confirmed, the mechanism of protection was studied using 
pharmacological inhibitors. The following protocols were used:
1. Control -  where no drag was administered (n=7)
2. EPO -  administered at a dose of 50ng/ml (n=7)
3. Wortmannin -  the PDK inhibitor was administered at a dose of200nM both on its own 
(n=7) and in combination with 50ng/ml EPO (n=5)
4 LY 294002 -  the PDK inhibitor was administered solely (n=6) and in combination with 
50 ng/ml EPO (n=6)
5. U0126 -  the ERK 1/2 inhibitor was administered at a dose of 10 pM both on its own 
(n=5) and in combination with 50 ng/ml EPO (n=6)
6. Denatured EPO -  EPO sample was boiled at 100°C for 10 minutes in order to change 
the protein structure and administered at a dose of 50 ng/ml (n=5)
7. L-NAME -  the NOS inhibitor was administered at a dose of 100 pM both on its own 
(n=5) and in combination with 50 ng/ml EPO (n=5)
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4.2.1 Western Blotting
In order to determine the phosphorylation status of certain key protein kinases, Western 
blots were performed as described in chapter 2. Pharmacological inhibitors were also 
used to establish the effect of eliminating a kinase’s activity on survival pathways. The 
protocols used were as followed:
1. Control -  no drug administration (n=6)
2. EPO -  EPO was administered at a dose of 50 ng/ml (n=6)
3. Wortmannin -  the PDK inhibitor was administered at a dose o f200 nM both on its 
own (n=6) and in combination with 50 ng/ml EPO (n=6)
4. U0126 -  the ERK 1/2 inhibitor was administered at a dose of 10 pM both on its own 
(n=6) and in combination with 50 ng/ml EPO (n=6).
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Two protocols of ischaemia/reperfusion were used to prepare samples for Western 
blotting: a) regional ischaemia involved ligating the LAD in exactly the same way as for 
the infarct model and b) global ischaemia involved stopping all flow to the myocardium:
Regional Ischaemia
1 0  mins 35 mins
Drug administration 
2 0  mins
Stabilisation Ischaemia Reperfusion
Global Ischaemia
Drug administration
Evans blue dye 
injected and risk 
zone excised 
and snap-frozen
1 0  mins 2 0  mins 1 0  mins
Ventricle 
excised and 
snap-frozen
Stabilisation Ischaemia Reperfusion
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The phosphorylation states of Akt and ERK were measured in both protocols whereas the 
phosphorylated state of eNOS was determined only in the global ischaemia protocol.
43 Results
4.3.1 Dose Response
Groups Body Weight(g) Muscle Volume (cm3) Risk Volume(cm^)
Ischaemic Control 361 ±6.6 0.979 ±0.075 0.443 ±0.024
20 ng/ml EPO 353 ±22.7 0.965 ±0.103 0.454 ±0.052
50 ng/ml EPO 370 ±12 2 1.074 ±0.150 0.531 ±0.072
100 ng/ml EPO 358 ±15.5 1.008 ±0.055 0.488 ±0.060
200 ng/ml EPO 369 ±7.9 1.033 ±0.040 0.522 ±0.032
Table 4.1, Characteristics of animals in the treatment groups 
Exclusions
In the 20ng/ml EPO group one animal was excluded due to too large a risk zone, one 
animal from the 200 ng/ml EPO group was excluded for a failure to instigate ischaemia 
and an additiona 200 ng/ml EPO group animal was excluded due to too large a risk zone.
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30 - 
25 
20 -  
15 
10 
5 - 
0
Ischaemia Reperfusion
Stab lsch5 Isch30 Rep 5 Rep 60 Rep
120
—  Ischaemic control 
20 ng/ml EPO 
50 ng/ml EPO 
100 ng/ml EPO
—  200 ng/ni EPO
Figure 4.1 Representation of the change in Rate-Pressure Product (RPP) 
throughout the experimental protocol from stabilisation (Stab) through ischaemia 
(Isch) and into reperfusion (Rep)
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Figure 4. 2, Dose-response curve measuring the infarct to risk ratio of 20-200 ng/ml 
doses of EPO given at reperfusion. Test EPO 50ng/ml was also performed by an 
external observer in order to assess the reproducibility of the findings. Values are 
represented as % infarct developed in the risk ratio (% I/R) and expressed as mean 
±SEM. * p<0.05 vs control.
As figure 4.2 describes, only the 50 ng/ml dose group significantly reduced infarct size 
compared to the ischaemic control (%I/R 18.6 ±5.9 v 54.5 ±7.4, p<0.05). The doses of 
20 ng/ml (%IR 44.8 ±12.5), 100 ng/ml (%IR 46.1 ±6.9) and 200 ng/ml (%IR 37.9 ±9.0) 
all failed to show significant protection compared to control.
Anthony J. Bullard 87
Chapter 4
The data obtained by the external observer confirm the findings that the 50 ng/ml EPO 
induces significant protection compared to external observer’s control (IR% 25.5 ±10.1 v 
49.8 ±3.8, p<0.05, data not included in figure).
4.3.2 Protein Kinase Inhibitors at Reperjusion
Groups Body Weight 
(g)
Ventricular Volume 
(cm3)
Risk Volume 
(cm3)
Ischaemic Control 364 ±8.6 1.093 ±0.050 0.619 ±0.039
EPO 370 ±12.2 0.908 ±0.042 0.567 ±0.041
EPO + UO 313 ±7.9 0.959 ±0.051 0.464 ±0.031
EPO + Wort 317 ±4.2 0.974 ±0.043 0.502 ±0.034
EPO + L-NAME 368 ±16.5 0.950 ±0.023 0.526 ±0.026
EPO + LY 348 ±6.0 1.010 ±0.026 0.525 ±0.036
UO 321 ±10.0 1.038 ±0.049 0.421 ±0.045
Wort 333 ±9.4 1.049 ±0.049 0.583 ±0.040
L-NAME 368 ±16.5 0.969 ±0.042 0.523 ±0.034
Den EPO 342 ±12.5 0.953 ±0.050 0.527 ±0.019
Table 4.2, Characteristics of animals in the treatment groups 
Exclusions
One animal from the EPO + Wort group was excluded due to too large a risk zone, one 
animal from the EPO + UO group was excluded due to an infarct size of less than 5% and 
another EPO + UO animal was excluded as the perfusion pressure failed mid-experiment.
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30
25
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15
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Ischaemia Reperfusion
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0
Stab Isch 5 Isch 30 Rep 5 Rep 60 Rep
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—  Ischaemic Control 
EPO
EPO + U0 
EPO + Wort
—  EPO + L-NAME
—  EPO + LY
—  U0
—  Wort 
L-NAME 
Den EPO
Figure 4. 3, Representation of the change in Rate-Pressure Product (RPP) 
throughout the reperfusion experimental protocol from stabilisation (Stab) through 
ischaemia (Isch) and into reperfusion (Rep)
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Figure 4.4, The effect of a 50ng/ml dose of EPO when administered at reperfusion 
on its own, and with the lOOnM dose of PI3K inhibitor wortmannin (Wort), a 10 [JM dose 
of the ERK 1/2 inhibitor UO 126 (UO) or denatured (den EPO). Values are represented as 
% infarct to risk ratio (%I/R) and expressed as mean ±SEM. *p<0.05 vs control.
As with the dose response curve, a 50 ng/ml dose of EPO significantly reduced the 
infarct to risk percentage compared to control (%I/R 22.5 ±5.5 v 56.3 ±6.5, p<0.05). The 
PI3K inhibitor, wortmannin, significantly abolished the infarct-limiting properties of 
EPO when given in combination (%IR 46.1 ±5.4 v 22.5 ±5.5). Interestingly, wortmannin 
administered alone showed a significantly beneficial effect compared to control (%IR
3 7 . 4  ±7 . 4  v 56.3 ±6.5, p<0.05).
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Likewise, LY294002, a PDK inhibitor, abrogated the beneficial effect of EPO compared 
to EPO administered alone (%IR 49.9 ±6.1 v 22.5 ±5.5, p<0.05). LY294002 administered 
on its own showed no effect compared to control (%IR 43.0 ±9.0 v 56.3 ±6.5).
U0126, a p42/44 MAP Kinase inhibitor, significantly eliminated the infarct-limiting 
effects of EPO when given in combination (%IR 49.2 ±5.6 v 22.5 ±5.5, p<0.05). U0126 
administered alone showed no effect compared to control (%IR 58.2 ±6.0 v 56.3 ±6.5).
The administration of the denatured EPO (denatured by 10 minutes of boiling) showed no 
significant difference compared to control (%IR 43.9 ±4.7 v 56.3 ±6.5).
70 1 
60 -
50 |
40 j
30 -
20
10 -
0
Figure 4. 5, The effect of a 50ng/ml dose of EPO when administered at reperfusion
solely, and with a 10[JM dose of NOS inhibitor L-NAME. Values are represented as % 
infarct to risk ratio (%I/R) and expressed as mean ±SEM. *p<0.05 vs control.
IschCont EPO EPO + L-NAME L-NAME
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EPO+L-NAME demonstrated a significantly smaller infarct size compared to control 
(%IR 33.1 ±7.5 v 56.3 ±6.5, p<0.05). L-NAME administered on its own also showed a 
significant decrease compared to control (%IR 34.1 ±3.8 v 56.3 ±6.5).
4.3.3 Western Blotting
4.3.3.1 Regional Ischaemia
500 - 
450 
400 J 
350 - 
& 300
^  250 -
200 1 
150 - 
100 
50 
0
Control EPO EPO+UO EPO + U0 Wort
Wort
Figure 4. 6, The effect of a 50ng/ml dose of EPO on phospho-Akt levels in a model of 
regional ischaemia with or without the Erk inhibtor U0126 (UO) and the PDK inhibitor 
wortmannin (Wort).Values are represented as arbitrary units (AU) and expressed as mean 
±SEM. * p<0.05 vs Saline Naive
i
*
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Figure 4. 7, The effect of a 50ng/ml dose of EPO on phospho-eNOS levels in a model 
of regional ischaemia. Values are represented as arbitrary units (AU) and expressed as 
mean ±SEM. * p<0.05 v Control
As can be seen in figure 4.6, in a model of regional ischaemia EPO showed a 38% 
increase in phosphorylation of Akt which was not statistically significantly different 
compared to control (409 au ±55 v 296 au ±131). The groups that included U0126 did not 
show any significant change compared to control (EPO + UO, 324 au ±79; UO 300 au 
±108). Groups that were treated with wortmannin showed a 75% (EPO + Wortmannin,
76 au ±37) and 70% (Wortmannin, 91 au ±42) reduction in phospho-Akt levels that was 
statistically significantly different from control (296 ±131, p<0.05).
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Figure 4.7 shows a 100% increase in phospho-eNOS levels for the EPO treated group 
compared to control that was statistically significant (1168 au ±181 v 582 au ±147, 
p<0.05).
4.3.3.2 Global Ischaemia
Figure 4.8, shows a 110% increase in levels of phospho-Akt compared to control (206 au 
±126 v 96 au ±30). However, this difference was not statistically significantly different.
pAkt
350 
300  -  
250  -  
200 
150 
100 -  
50 
0
Control
i
X
Hi J
EPO EPO + U0 EPO + 
Wort
~
■
U0 Wort
Figure 4. 8, The effect of a 50ng/ml dose of EPO on phospho-Akt levels in a model of 
global ischaemia. Values are represented as arbitrary units (AU) and expressed as mean 
±SEM. * p<0.05 vs Control
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Groups treated with U0126 also did not show any statistical difference compared to 
control (EPO + UO, 148 au ±19; UO, 188 au ±73).
Figure 4.9 shows that hearts treated solely with EPO showed a non-significant increase 
compared to control of 40% in phospho-ERKl levels (267 au ±128 v 190 au ±45) and 
60% in phospho-ERK2 levels (285 au ±150 v 177 ±36). Hearts treated with EPO plus 
wortmannin did not vary significantly from either ERK1 (194 au ±35) or ERK2 (172 au 
±30) phosphorylation levels compared to control. The same can be said of the groups 
treated solely with wortmannin for (ERK1,260 au ±47; ERK2 au ±47). Hearts treated 
with U0126 + EPO showed a significant 98% drop in ERK1 phosphorylation levels (5 au 
±5) as well as a total absence of a signal for ERK2 (0 au ±0).
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Figure 4. 9, The effect of a 50ng/ml dose of EPO on phospho-ERK levels in a model 
of global ischaemia. Values are represented as arbitrary units (AU) and expressed as 
mean ±SEM. * p<0.05 v Control
4.4 Discussion
4.4.1 Dose Response
The data outlined within the results confirms that EPO can limit the cardiac infarct size in 
a model of reperfusion-injury when administered after a period of ischaemia in an 
isolated perfused heart model. The dose response clearly demonstrates that a 50 ng/ml
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dose is the most effective. Indeed, only the 50 ng/ml dose out of all those measured 
elicited a cardio-protective effect suggesting that EPO has a very narrow therapeutic 
window in this model. It is a curious anomaly that some receptor agonists lose their
i 7 0  i s obeneficial properties in higher doses ’ . Possibly at higher doses additional signalling
pathways counteract the beneficial signals seen at lower doses, or the phosphatases are 
triggered much more quickly at higher doses of EPO and dampen down the EPO 
signal181. Other possibilities include a non-specific effect of EPO or components of the 
buffer that are detrimental at higher doses. The 50 ng/ml dose corresponds to 10 U/ml in 
an isolated organ model or 5,000 U/Kg in vivo. These doses are widely used in rat 
cardio-protective studies in the literature 121,146,182,183. Slightly at odds with these 
findings are the series of experiments performed by Parsa et al who demonstrated that 
two doses, 1,000 U/Kg and 5,000 U/Kg, afforded a protective effect in their rat in vivo 
model of regional ischaemia/reperfusion184.
4.4.2 Involvement o f RISK Pathway
Confirmation that the cardioprotection is caused by EPO, rather than the vehicle in 
which the protein is dissolved, is provided by the data indicating abolishment of 
protection when EPO is denatured by boiling for 10 minutes. The EPO vehicle contains 
urea, glycine, polysorbate 20, calcium chloride, a complex of 5 amino acids and 
phosphate buffer. However, the suppliers of the dmg were not willing to specify the exact 
component of the dmg.
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The cardioprotective effect of EPO in these experiments seems to be as a result of a direct 
action on the heart. Indeed, the isolated perfused heart model uses a crystalloid buffer 
rather than blood, and is mediated by the known protective signalling moieties PI3K and 
ERK 1/2, as shown by the ability of their respective inhibitors to abolish EPO-mediated 
protection. Activation of these kinases has been shown to provide protection at 
reperfusion by many other pharmacological agents, as described in chapter 1. Thus the 
results were as hypothesised. What was not predicted was that L-NAME would fail to 
block the protection when co-administered with EPO. It should be noted, however, that 
the control L-NAME group had similar infarct sizes. NO production has been considered 
to be beneficial at reperfusion, albeit less effective than NO donation prior to 
ischaemia185. However, Shi et al discovered that L-NAME failed to block EPO-mediated 
cardioprotection, albeit when administered prior to index ischaemia153. It was even found 
by Woolfson et al that a continuous perfusion of L-NAME throughout the perfusion 
protocol actually reduced infarct size186. In our model L-NAME cannot be providing 
protection in its own right in this setting or the activation of eNOS by EPO would be 
detrimental, which is clearly not the case here. One possible explanation is that nitric 
oxide produced from a different source to eNOS is combining with the ROS present at 
reperfusion to form the pro-injury peroxynitrite. The haemodynamic data provided no 
distinctive features for the L-NAME groups nor did the risk volumes or animal sizes. 
Therefore, nitric oxide must be playing no contributory part (as suggested by Shi), nitric 
oxide is detrimental at reperfusion in this model or the infarct data provided is misleading 
and requires an additional study to directly compare the co-administration of EPO and L- 
NAME with EPO administered solely, rather than incorporated as part of a larger study.
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Western blot analysis showed non-significant increases in phosphorylation of both ERK 
and Akt in the EPO group compared to control. However, EPO produced a significant 2- 
fold increase in phosphorylation of eNOS, which is known to be downstream of Akt in 
the signalling cascade 187,188. The inability of L-NAME to significantly block EPO- 
mediated protection at reperfusion suggests that, despite being phosphorylated, eNOS has 
no functional role in the protective pathway in this model. Within the experience of our 
group, the use of pharmacological intervention at reperfusion, but not prior to ischaemia, 
does not always provide unequivocal blots establishing significant increases in kinase 
phosphorylation of Akt and ERK despite a clear ability for the inhibitors of these kinases 
to eliminate the drug-induced protection. In an attempt to try and prevent non-viable cells 
skewing the results, a global ischaemia model incorporating a shorter ischaemic period 
was used. In addition a shorter period of reperfusion was included in this global 
ischaemia protocol in order to ensure that the window of phosphorylation might not be 
missed. However, the results from this global ischaemia protocol proved to be very 
similar to that of the regional ischaemia.
There are a number of possibilities that may account for the difficulty in observing 
increased phosphorylation of kinases by Western blot that the pharmacological inhibition 
studies suggest should be involved:
1. The drugs that have a tendency to provide inconclusive results in a laboratory 
setting are agonists for extracellular receptors such as GLP-1 and leptin. The
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signals passed on from these receptors may be insufficient to be demonstrated on 
a technique as insensitive as Western blotting.
2. There could be a small window of activation around die commencement of 
reperfusion. By the time the samples were taken, i.e. after 10 and 15 minutes of 
reperfusion, the signal may have become dissipated or regulated by phosphatases. 
The use of global ischaemia and a shorter reperfusion time point for the Western 
blots did not resolve the issue any further.
3. In order to elicit cardioprotection, EPO may only require a small increase in 
phosphorylation of the target kinases compared to the control. Such an increase in 
phosphorylation may be too small to be detected by a technique as cmde as 
Western blotting.
4. Standard protocols were used within the group as recommended by suppliers of 
the antibodies (Cell Signalling Technology and Santa Cruz), but there potentially 
could have been some defect within the protocol, the antibodies or operator error. 
However, the Western blotting procedure was repeated at least 4 times with much 
care for detail (new antibodies, preparation of new samples, changes in the 
moment of collecting the samples) with similar results.
It is worth noting that none of the 3 papers published thus far demonstrating EPO- 
mediated protection at the point of reperfusion have included Western blots showing an
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increase in kinase phosphorylation as a result of EPO administration at reperfusion 183,189, 
100. Those publications where EPO has been shown to successfully and significantly 
increase kinase phosphorylation have almost exclusively been as a result of EPO 
administration prior to index ischaemia. This feet may be coincidental or it may be as a 
result of a general difficulty in establishing the activation pattern of these pro-survival 
kinases at reperfusion.
4.4.3 EPO at Reperjusion In Vivo
In tandem with these experiments, Paul Govewalla from our group performed similar 
experiments administering a 5000 U/Kg dose of EPO at reperfusion in a rat open chest 
model of ischaemia-reperfusion. Similarly, he showed that EPO significantly limited 
infarct size, an effect that was abolished totally by wortmannin and partially by 
LY294002 191. Importantly, these in vivo studies included a reperfusion period of 24 
hours, indicating feat the beneficial effect of EPO is not merely an artefactual delaying of 
cell death, but a long-term salvage of the non-infarcted tissue.
4.5 Conclusion
Reperfusion is necessary to salvage ischaemic myocardium from cell death. However
109reperfusion has been shown to exacerbate the injury caused by ischaemia . Therefore, 
reliable intervention to limit reperfusion-induced cell death will improve patient long­
term prognosis following myocardial infarction. The RISK pathway has recently been 
proposed as a method of protection against reperfusion injury61 that includes two key 
mediators, PBK/AKT and ERK 1/2. EPO has been shown to activate these signalling 
moieties126 making EPO a viable candidate agent to limit reperfusion injury.
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As an established clinical treatment, EPO may represent a viable therapeutic option in the 
reperfusion setting as an adjunct to a thrombolytic agent or administered solely during 
angioplasty.
Anthony J. Bullard 102
Chapter 5
Chapter 5 - EPO within a Cellular Model
5.1 Aims and Protocols
Cellular models have long been used as an alternative method of examining similar 
phenomena in order to gain a deeper understanding of the cellular mechanics involved. In 
this instance, cell death as a consequence of hypoxia/re-oxygenation and protection from 
this death by pharmacological means were the aims of the following studies.
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Figure 5.1, H9c2 ceils in culture under 20x magnification light microscope
We decided to use the H9c2 cell line as a cellular model for hypoxia/reoxygenation 
studies, as it is a well-known undifferentiated neonatal rat cardiomyoblast cell line 193,194
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that has been used previously to examine hypoxic cell death and prevention of injury by 
hypoxia195. Prior to using EPO in this cellular model, we initially thought it would be 
prudent to assess whether we could demonstrate protection in this model using a tried and 
tested cardio-protective agent, namely atorvastatin72,731196,197.
Taking into account the complications related to the identification of the contribution of 
apoptosis and necrosis to the infarction in an intact heart, discussed in section 1.2, we 
decided to use a cell model in order to differentiate between these two forms of cell death 
and thereafter to use sensitive and specific inhibitors in order to examine the mechanism 
of death and the possibility of increasing cell survival. To achieve this, in the first 
instance we attempted to characterise the level of cell death in relation to the duration of 
hypoxia and re-oxygenation. Thereafter we choose the experimental protocol that 
induced sufficient cell death to allow protection to be seen but not so much as to make 
prevention of death impossible.
5.1.1 Experimentation
In order to replicate the ischaemia/reperfusion setting, a model of hypoxia/reoxygenation 
using a hypoxic chamber was established as described in chapter 2. Flow cytometry 
measurements were performed using a Partec flow cytometer, see chapter 2.The marker 
of necrosis, propidium iodide (PI), and of apoptosis, annexin v, were used to establish the 
quantity and type of cell death, as described in chapter 2.
Anthony J. Bullard 104
Chapter 5
Cells underwent the following protocol: 
Normoxic Protocol
Normoxia
22 Hours
Hypoxia/Re-oxygenation
Protocol
Hypoxia Re-Oxygenation
^ _________ 1
20 Hours 2 Hours
Atorvastatin
Administered
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The following groups were used:
1. Normoxic control -  Cells kept in normoxic culture medium and conditions for 22 
hours (n=3)
2. Hypoxia/Reoxygenation -  Cells underwent 20 hours hypoxia and 2 hours 
reoxygenation (n=4)
3. Atorvastatin -  Atorvastatin (50 |JM) was administered at re-oxygenation in the 
hypoxia/re-oxygenation protocol (n=5)
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5.2 Results
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Figure 5. 2, The dot plot raw data produced by the flow cytometer. FL1 detects green 
fluourescence and therefore annexin v positive cells. FL2 detects red fluourescence and 
therefore propidium iodide positive cells. Cells that are ‘apoptotic’ appear in the Q4 
segment as they stain for annexin only. Cells that are ‘necrotic’ appear in the Q2 segment 
as they are positive for both annexin and propidium iodide (annexin enters the holes in 
the necrotic cell membrane and stain phosphatidyl serine on the inner leaflet of the 
membrane). Cells that are negative for both annexin and propidium iodide appear in Q3 
and are considered unstained or viable.
Anthony J. Bullard 107
Chapter 5
18 1 
16 -
1 4 -
Normoxia H/R Atorvastatin
Figure 5. 3, The effects of hypoxia/re-oxygenation (H/R) and atorvastatin 
administered at re-oxygenation on propidium iodide (PI) positivity in H9c2 cells. 
Values are represented as percentage of cells being counted as PI positive by flow 
cytometry and expressed as mean ±SEM.
5.2.1 Propidium Iodide
As demonstrated in figure 5.3, there was no significant difference in PI positivity 
between the normoxic and hypoxia/re-oxygenation (h/r) groups (%PI+ 5.81 ±1.2 v 9.72 
±2.7). There was no significant difference between the atorvastatin and h/r groups (%PI+ 
13.18% ±2.4 v 9.72 ±2.7).
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Normoxia H/R Atorvastatin
Figure 5. 4, The effects of hypoxia/re-oxygenation (H/R) and atorvastatin 
administered at re-oxygenation on annexin v (ann) positivity in H9c2 cells. Values are 
represented as percentage of cells being counted as PI positive by flow cytometry and 
expressed as mean ±SEM, * p<0.05 vs normoxia ** p<0.05 H/R
5.2.2 Annexin v
There was a significant difference in annexin v positivity between the normoxic and h/r 
groups (% ann+ 16.55 ±3.6 v 37.05 ±4.7, p<0.05). There was a significant difference 
between the atorvastatin and h/r groups (% ann± 22.56 ±2.07 v 37.05 ±4.7, p<0.05). 
There was no significant difference between the normoxic and atorvastatin group.
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Figure 5. 5, The effects of hypoxia/re-oxyge nation (H/R) and atorvastatin 
administered at re-oxygenation on cell viability. Values are represented as percentage 
of cells being counted as unstained by both PI and annexin v by flow cytometry and 
expressed as mean ±SEM, * p<0.05 vs normoxia
5.2.3 Viable Cells
Cells that stained for neither annexin v nor PI were considered to be viable. There was a 
significant difference in the percentage of unstained cells in the sample between the 
normoxic and h/r groups (% 77.64 ±4.7 v 53.38 ±5.6, p<0.05). There was no statistical 
difference between the atorvastatin and h/r groups (% 64.27 ±3.7 v 53.38 ±5.6).
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5.2.4 The Role o f mPTP Opening in EPO-mediated Protection
As discussed in section 1.4, the mitochondrial membrane permeability transition pore has 
been associated with protection as opening of the pore has been demonstrated to result in 
a collapse of mitochondrial potential and cytochrome c release causing cell death50. 
Inhibition of pore opening has been suggested to limit, if  not prevent, the mitochondrial- 
dependent cell death caused by oxidative stress, such as that induced by reperfusion, see 
chapter 1. Work by Hausenloy et al clearly demonstrated that inhibition of pore opening 
by chemical means at the point of reperfusion significantly limited the infarct size in rate 
perfusion model198. Thus it could be hypothesised that a pharmacological intervention 
that had the effect of preventing or delaying pore opening, directly or indirectly, may 
limit the injury caused by reperfusion-induced oxidative stress and death.
Subsequent to the recent independent research of Yellon’s group and the 
Halestrap group52,55,198'200, there have been a number of studies that have demonstrated a 
delay in mPTP opening as a result of oxidative stress by a number of compounds. One 
particular study by Juhaszova et al examined a series of compounds and their abilities to 
delay pore opening by the same method described in this chapter^01. As this study 
included EPO, it was natural to assume that the data could be replicated in our hands. In 
addition, as EPO takes its effect by acting as an agonist to its receptor, it can also be 
hypothesised that any delay in pore opening seen as a result of experimentation could be 
as a result of the protein kinase pathways highlighted in chapter 1.
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To confirm the involvement of the mPTP in mediating the protective effects of EPO, a 
method was used that involved utilising the lipophilic cation TMRM and its prevalence 
to accumulate into the mitochondria due to die membrane potential of the mitochondria
AAA AAA AAJ ____
. In a method established by Duchen's group ’ , TMRM loaded in mitochondria is
illuminated by a laser to provide a model of oxidative stress. The mitochondria will 
appear stained red due to the TMRM as long as the mitochondrial membrane remains 
polarised. Thus depolarisation of mitochondria can be seen as a drop out of signal. 
Initially, there are brief flashes of intensity which Duchen et al have demonstrated to be 
dependent upon local sarcoplasmic reticular calcium release 205. There are also patchy 
dropouts in signal due to localised depolarisation of mitochondria. Depolarisation itself 
manifests as a wave usually commencing at one end of the myocytes, although it 
occasionally is initiated in the middle or at both ends of the myocyte simultaneously. This 
wave then spreads through the rest of the myocyte. Subsequent to the depolarisation there 
is a rapid depletion of ATP that is consumed by ATPase as a result of pore opening 203,
206. When the ATP levels become sufficiently depleted the myocyte begins to shorten into 
rigor contracture.
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53 Experimentation for mPTP Opening
Myocytes were isolated from four different Sprague Dawley rats and prepared for use as 
described in section 2.6.
Myocytes were incubated with TMRM (3 |JM) for 15 minutes and 10 minutes with the 
drug(s) prior to undergoing the oxidative stress protocol. The following drug protocols 
were used:
1. Control -  where no drug was administered (n=21)
2. EPO -  administered at a dose of 50 ng/ml (n=29) and in combination with 0.01% 
DMSO vehicle control (n=7)
3. L-NAME -  the NOS inhibitor, was administered at a dose of 100 jiM both solely 
(n=l 1) and in combination with 50 ng/ml EPO (n=22)
4. Wortmannin -  the PI3K inhibitor, was administered at a dose o f200 nM both solely 
(n=16) and in combination with 50ng/ml EPO (n=14)
5. U0126 -  the ERK 1/2 inhibitor, was administered at a dose of 10 pM both solely 
(n=14) and in combination with (n=8)
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Suitable healthy appearing cells were identified by fight microscope and scanned by laser 
until all cells within the field had commenced rigor contracture.
The time to the initiation of the wave of depolarisation and rigor were measured 
independently. As the time to depolarisation has been shown to be affected by such 
environmental conditions as laser fight strength and oxygen concentration, all results for 
each isolation were normalised against the control of that isolation such that the average 
for the control was 1 in order to eliminate inter-experimental variations.
5.4 Results
5.4.1 mPTP Opening
As can be seen from figure 5.6 the progression from normal healthy cell through local 
depolarisation and general wave of depolarisation to final rigor is quite marked. The time 
points measured include when the wave of depolarisation becomes first identifiable and 
when cell shortening first commences.
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Figure 5. 6, Representation of the myocytes throughout confocal laser
experimentation
Confocal images of myocytes loaded with TMRM and exposed to an argon laser.
a) Represents the myocytes at the commencement of the experiment with the TMRM- 
loaded mitochondria clearly lined up in striata along the length of the cell.
b) Demonstrates the drop-outs that occur in mitochondria signal after a period of 
exposure to oxidative stress caused by individual mitochondria depolarising 
completely (see arrows).
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c) Subsequent to dropping out of signal in the individual mitochondria a general wave 
of depolarisation occurs, usually commencing from one end of the cell (see arrows).
d) As a result of mPTP opening, the cell rapidly has its ATP supply depleted and, 
consequentially, undergoes cell shortening, known as rigor.
1. 2 -  
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Control EPO EPO+ L-NAME L-NAME
Figure 5. 7, The effect of EPO (50 ng/ml) and inhibition of NOS by L-NAME
(100 |JM) on the time to depolarisation due to oxidant stress. Values are represented 
as arbitrary units normalized against control (represented as 1 ) and expressed as mean 
±SEM. * p<0.05 vs control, EPO+L-NAME and L-NAME
5.4.2 Effect o f EPO and L-NAME on mPTP Opening
As can be seen from figure 5.7, EPO significantly increased the time to depolarisation 
versus control (1.000 ±0.051 v 1.255 ±0.059, p<0.05), thus the time to depolarisation was 
increased by 25.5%. The addition of L-NAME to EPO significantly reduced the time to
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depolarisation back to control levels (1.016 ±0.83 L-NAME + EPO v 1.255 ±0.059 EPO, 
p<0.05). L-NAME administered solely seemed to have no significant effect compared 
with control (1.026 ±0.102 v 1 ±0.051).
1.8
Control EPO EPO + EPO + UO Wort UO
Wort
Figure 5. 8, The effect of EPO (50 ng/ml) and inhibitors of PI3K by wortmannin 
(Wort,100 nM) and ERK 1/2 by U0126 (UO, 10 pM) on the time to depolarisation 
due to oxidant stress. Values are represented as arbitrary units normalized against 
control (represented as 1) and expressed as mean ±SEM. * p<0.05 vs control, EPO±Wort 
and Wort. ** p<0.05 vs all other groups.
5.4.3 The Involvement ofP B K  and ERK 1/2 in EPO-mediated Delay o f  mPTP Opening 
The effect of administering the PI3K blocker wortmannin in combination with EPO is to
significantly reduce the time to depolarisation (1.086±.069 v 1.255 ±.059, p<0.05).
Wortmannin administered on its own seemed to shorten the time to depolarisation versus
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control (0.742 ±.047 v 1.000 ±.051, p<0.05). The ERK 1/2 inhibitor, U0126, was given in 
combination and seemed to have no significant effect on EPO- mediated delay of mPTP 
opening (1.190 ±0.11 v 1.255 ±.059). However, U0126 when administered on its own 
seemed to have a distinct delaying effect on depolarisation compared to control (1.469 ± 
07 v 1.000 ±0.051, p<0.05). The presence of wortmannin in combination with EPO had 
no significant effect on time to rigor contracture compared to EPO alone (1.221 ±0.046 v 
1.154 ±0.08) or when administered solely compared to control (1.076 ±0.081 v 1.000 
±0.059).
5.5 Discussion
5.5.1 Atorvastatin Intervention at Re-Oxygenation
Replicating ischaemia/reperfusion in a cellular model with the intention of limiting cell 
death as a result of that ischaemia/reperfusion has been successfully achieved in a 
number of studies. In the H9c2 ventricular derived cell line, markers of cell death such as 
MTT staining , lactate dehydrogenase release , propidium iodide accumulation , 
morphology209, caspase 3 and PARP cleavage210 have been used. These studies have 
exclusively examined intervention that was activated prior to index hypoxia. In our 
model we have attempted to use the cellular model to replicate intervention at re­
oxygenation using atorvastatin, a drug that has been shown to protect the myocardium 
directly, both when administered prior to ischaemia211 and at the point of reperfusion72,
73. As can be seen from the data, the propidium iodide results showed no significant 
difference between any of the groups. As mentioned in the methods chapter, propidium
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iodide (PI) is meant to be a marker for necrosis. In theory PI should measure cells 
damaged during hypoxia as necrosis is an ATP and oxygen independent method of cell 
death. It would therefore be expected that the hypoxia/re-oxygenation group would have 
a higher level of PI positive cells compared to control even if atorvastatin foiled to limit 
such increase in PI positive cells. It must be concluded from this data, therefore, that the 
hypoxia/re-oxygenation protocol was providing insufficient stimulus for cell death. 
However, the annexin v results demonstrated that hypoxia/reoxygenation produced an 
increase in the number of annexin positive cells with atorvastatin limiting this increase. 
This result would be entirely expected especially as annexin v positivity is associated 
with apoptosis and reperfusion/re-oxygenation injury.
So why did we get strong predictable results for annexin v but not PI? A study by Eijnde 
indicated that phosphatidyl serine becomes expressed on the surface of H9c2 cells during 
myotube formation212. Since phosphatidyl serine is the cell surface marker that annexin 
binds to, any data that includes annexin v staining in this H9c2 cell line cannot be relied 
upon as hypoxia/re-oxygenation could alter the cell surface expression of phosphatidyl 
serine independently of apoptosis. Many other periods of both hypoxia and reoxygenation 
were used. However, it proved impossible to find a period of hypoxia and re-oxygenation 
whereby either sufficient cell death was caused by re-oxygenation alone to allow an agent 
to limit that injury successfully, or cell death was so extreme as to preclude the possibility 
to limit any injury at all. In addition many other markers of cell death were used, 
including MTT, Trypan Blue, TUNEL and the fluorescent marker of caspase 3 cleavage, 
phiphilux. The experiments were repeated using cells that had been caused to
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differentiate by limiting the foetal calf serum in the medium, in addition to using a 
primary culture of rat ventricular myocytes, although the myocytes proved too fragile to 
use in this model. None of these experiments provided a robust reproducible model. It 
was for this reason that we decided that an alternative cellular model of reperfiision injury 
should be used, and as such we undertook this in a series of confocal microscopy studies.
5.5.2 EPO-mediated Delay in mPTP Opening
Inhibiting the opening of the mPTP has been demonstrated to limit infarct size both prior 
to index ischaemia and at reperfiision in a Langendorff model of ischaemia/reperfusion51. 
It can be deduced, therefore, that by preventing or delaying pore opening you can limit 
reperfusion-induced injury. This confocal microscope model mimics reperfiision by 
causing oxidative stress as previously mentioned ,see methods chapter, section 2.6.1, as 
such a delay in pore opening would be interpreted as a beneficial effect against 
reperfusion injury and indicate that the protective effect by EPO at reperfiision would be 
achieved via the mPTP. Our results demonstrate that EPO clearly delays opening of the 
mPTP. The PI3K inhibitor wortmannin abolishes the protective effect of EPO, 
suggesting that PDK is involved in this protection that leads to an inhibition of the 
mPTP opening. These findings are in line with research by Juhaszova et al who not only 
showed that EPO could delay pore opening but also found that wortmannin could abolish 
a beneficial delaying effect using insulin as the protective agent201. The exact mechanism 
by which PDK, and its downstream kinase Akt, limit pore opening is currently poorly 
understood. The suggestion put forward by Juhaszova et al is that Akt functions by 
inhibition of glycogen synthase kinase-3 p (GSK 3(3). However, they could not elucidate
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precisely how inhibition of GSK 3(3 would lead to an inhibition of pore opening, although 
they did hypothesise that GSK 3p phosphorylates and inactivates Bcl-2. There is some 
suggestion that Bcl-2 could raise the ROS threshold to which the mPTP is sensitive, thus 
inhibiting or delaying its opening201. However, there is no indication whether the ROS 
levels in the TMRM confocal study are physiological and therefore directly relevant 
when it comes to ROS threshold levels. Similarly, the Bel family members Bax and BAD 
have been suggested as being mPTP openers213. Both these molecules are known targets 
of Akt214, which inactivates them through phosphorylation.
One other possible mechanisms by which PBK/Akt could possibly lead to inhibition of 
pore opening is by nitric oxide release via the downstream target of PI3K/Akt, eNOS.
5.5.3 The Effect o f U0126
The U0126 data is surprising and unexpected. As U0126 is an inhibitor of ERK 1/2, a 
kinase which when strongly activated is known to be beneficial at reperfiision, it was 
expected that the use of U0126 would abolish the protective effects of EPO. However, 
what the data demonstrates is that the concomitant administration of EPO and U0126 
results in a similar time to depolarisation as EPO by itself. It might be concluded from 
this data that ERK 1/2 was not involved in the inhibition of mPTP opening if the sole 
administration of U0126 had given a similar time to depolarisation as the control. 
However, surprisingly, we saw that U0126 by itself increases the time to depolarisation 
much more than EPO alone.
There are a myriad of possibilities to explain the phenomenon:
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1. Operator error is the most obvious solution, but it can be seen from figure 5.9 that an 
independent observer found exactly the same phenomenon in a completely different set 
of experiments, suggesting that operator error is an unlikely explanation.
X
Control Insulin Insulin + UO
Figure 5. 9, Confocal microscopy experiment using exactly the same protocol as 
mentioned in section 5.3, performed by an independent observer. Values are 
represented time to depolarisation wave initiation measured in seconds expressed as 
mean ±SEM. * p<0.05 vs control
2. U0126 solubility. U0126 is a substance that does not dissolve in aqueous solutions 
very easily. Even when pre-dissolved in DMSO the drug can still precipitate when being 
dissolved in an aqueous solution. It is therefore possible that some precipitate of the drug 
could be diffracting the laser beam and thus reducing the oxidant stress which the 
myocytes undergoes, resulting in a delayed time to the wave of depolarisation.
3. Increase in Ca2+ levels are known to decrease TMRM fluorescence so it is possible 
that U0126 caused an increase in Ca2+ and, by reducing the intensity of TMRM, also 
reduced the oxidant stress.
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4. ERK inhibition within this model could be protective where it is not used in vivo or in 
an isolated perfusion model, although exactly how this might be manifest seems unclear, 
making the possibility unlikely.
5.5.4 Involvement o f  NOS in EPO-mediated Delay in mPTP Opening
As figure 5.7 shows, L-NAME clearly inhibits the depolarisation-delaying effects of EPO
when the drugs are co-administered, reverting the time to the baseline control level. The
control L-NAME group, as expected, showed no effect. As L-NAME is a general NOS
inhibitor, it can be argued that nitric oxide (NO) has a positive effect, but from this data it
is not possible to determine which isoform is responsible for mediating the delay in
mPTP opening as a result of EPO administration. There is a growing body of data
studying the effect of NO on the mPTP. One pivotal study by Brookes et al used the
NONOate group of nitric oxide donors to examine the effect NO on cytochrome c
71 ^release, membrane polarisation and calcium efflux from rat liver mitochondria . They 
found that NO inhibited mPTP opening with an IC50 of 11 nM, which represents a 
physiological concentration. In addition they saw reduced cytochrome c release, reduced
^ I
mitochondrial Ca accumulation and mitochondrial membrane depolarisation. This 
effect has been largely replicated in bovine endothelial cells by Dedkova and Blatter216
9 1 7and in mouse striatal neurons by Horn et al , thus indicating that the effect is not tissue 
specific. This common appearance of depolarisation may well be a key occurrence. Ichas 
et al described a common intracellular calcium spike that appeared when mitochondrial 
depolarisation occurred 218. The source of the calcium has been identified as 
mitochondrial219 and attributed to a ‘transitional’ opening of the mPTP219,22°. It has been
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suggested that this form of reversible mPTP opening works as an energetically favourable 
Ca2+ release valve, preventing a dangerous over-accumulation of Ca2+ within the 
mitochondrion221. Dedkova and Blatter argue that the depolarisation itself actually limits 
influx and efflux of calcium and that in this way over-accumulation of calcium within the 
mitochondria does not occur. It is important to note that during transitional mPTP 
opening mitochondrial swelling did not occur as the pore seems impermeable to any 
molecule over 300 Da in size. Thus it should not be confused with ‘pore opening’, which 
is measured in these experiments, whereby cytochrome c is released and apoptosis 
initiated.
5.6 Conclusion
Prevention of mPTP pore opening has been demonstrated to have a direct consequence 
on limiting infarct size in organ perfusion heart models. Thus it seems likely that the 
beneficial effect can be transposed into the clinical setting. EPO is well documented to 
have a beneficial effect in the clinical setting and the data presented within this chapter 
suggests that this effect could well be due to prevention of pore opening. In addition to a 
myriad of other pathways, PBK/Akt has been shown here to have a direct effect on the 
mPTP within the myocardium in addition to NOSs, as shown by the ability of L-NAME 
also to abolish the protective effect of EPO. It is entirely conceivable that protective 
pathways initiated by EPO, as discussed in chapter 1, have the mPTP as their end 
effector.
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Chapter 6 - The effect of chronic EPO treatment on the
myocardium
6.1 Introduction and Aims
Since the cloning of its gene and subsequent production of recombinant proteins, EPO 
has come to be used in chronic treatment mainly to correct anaemia as a result of such 
disorders as kidney or chronic heart failure, as described in chapter 1. Research relating 
to die clinical use of EPO demonstrates it has beneficial effects, usually ascribed to the 
correction of anaemia. This research has extended to cases of chronic heart failure, a 
known cause of anaemia. However, with recent research uncovering the beneficial effects 
of EPO directly on the myocardium, i.e. unrelated to the correction of anaemia, there 
seems to be a question regarding the nature of the effect which EPO has on patients when 
administered as a chronic treatment. Other studies examining the chronic effect of 
atorvastatin on the heart demonstrated that the phosphatase PTEN was negatively 
regulating the beneficial PI3K pathway, thus eliminating the protection seen when 
atorvastatin was administered acutely. We therefore set out to determine whether chronic 
administration of EPO can have a beneficial effect in a model of myocardial 
ischaemia/reperfusion and by what mechanism any observable effect could be achieved.
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6.2 Experimental Protocol
Sprague Dawley rats were treated for 3 weeks according to the following protocols:
A. Saline injected sub-cutaneously three times a week
B. EPO injected sub-cutaneously at a dose o f5,000 units/kg once a week (IxWk EPO)
C. EPO injected sub-cutaneously at a dose o f5,000 units/kg three times a week (3xWk 
EPO)
At the completion of the 3 week treatment all rats weighed between 300-400g, without 
any significant difference between the groups. Hearts were excised in the normal manner 
for perfusion on the Langendorff apparatus, and the blood was sampled and analysed for 
the measurements of haematocrit and plasma EPO concentrations.
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Hearts were mounted on the Langendorff apparatus and put through the following 
perfusion protocols:
Control Protocol: 
(A + B + C groups)
30 mins
Stabilisation Ischaemia Reperfusion
Determination 
of infarct size
35 mins 1 2 0  mins I
Inhibitor Protocol 
(C groups)
Wortmaniu/UO 126/L-Name
Determination 
of infarct size
1 0  mins J  . lOmiins 35 mins 1 2 0  mins I
Stabilisation Ischaemia Reperfusion
In detail, the groups presented in the above figures were:
1. Saline control -  saline (200 pL) was administered three times a week for three weeks 
(n=6 )
2. lxWk EPO -  EPO (200 pL, 5000 U/kg) was administered once a week for three weeks 
(n=6 )
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3. 3xWkEPO - EPO (200 jaL, 5000 U/kg) was administered three times a week for three 
weeks (n=7)
4. EPO + Wort -  3xWkEPO  group received wortmannin (200 nM) for 10 minutes with 
10 minutes washout prior to index ischaemia (n=6)
5. EPO + U0 - 3xWkEPO group received U0126 (10 pM) for 10 minutes with 10 minutes 
washout prior to index ischaemia (n=6)
6. EPO + L-NAME - 3xWk EPO group received L-NAME (100 pM) for 10 minutes with 
10 minutes washout prior to index ischaemia (n=5)
6.2.1 24 hour Treatment o f EPO
In order to determine whether any protection observed in the chronic model was due to 
the increase in haematocrit and, consequently, to the improved oxygen supply, we 
administered a single sub cutaneous dose of either 5000 Units/kg EPO (n=) or 200 |Jl 
saline (n=5) 24 hours before the index ischaemia. The Langendorff protocol was the same 
as per control in the chronically treated groups.
6.2.2 Western Blotting
In order to determine the phosphorylation status of certain key protein kinases, Western 
blots were performed as described in chapter 2. The protocols used were as follows:
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Naive -  Hearts from animals which received a 3 week treatment of saline (n=5) or 3x 
week treatment of EPO (n=5) were excised, briefly washed in ice-cold Krebs buffer to 
remove blood and then snap frozen in liquid nitrogen
Standard Protocol -  Hearts from animals which received a 3 week treatment of saline 
(n=3) or 3x week treatment of EPO (n=3) were excised and underwent the experimental 
protocol illustrated below:
10 mins 35 mins 15 minutes Evans blue dye
The levels of the total and the phosphorylated Akt, ERK, eNOS, PTEN were measured. 
The level of total iNOS was also assessed. Results were corrected for protein loading by 
comparing concentrations of (3-actin present in each sample.
Stabilsation Ischaemia
injected and the 
risk zone 
excised and 
snap-frozen
Reperfusion
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63 Results 
0.7 -j
0.6 J
0.5 J
0.4 J
0.3 J
0.2 J 
0.1 J
0 J-----
Saline 1x Wk EPO 3x Wk EPO
Figure 6.1, The effect of a chronic 3 week treatment of EPO on rat haematocrit
when a 5000U/kg dose of EPO is given once a week (lx  Wk EPO) or three times a week 
(3x Wk EPO), compared to a three times-a-week administered saline control. Values are 
represented as Haematocrit (Hct) and expressed as mean ±SEM. * p<0.05 vs control
6.3.1 Haematocrit
As demonstrated in figure 6.1, the once a week dose of EPO demonstrated a significant 
increase in haematocrit compared to the saline control (0.436 ±.006 v 0.386 ±0.008, 
p<0.05). The 3 times a week dose had a significantly increased haematocrit compared to 
bolh the control saline group and the once-a-week dose group (0.595 ±0.018 v 0.386 
±0.08; v 0.436 ±0.06, p<0.05). There was no significant difference in haematocrit for the 
acute EPO dose group compared to the saline control (0.410 ±0.008 v 0.410 ±0.008).
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0.5 
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0.3 
0.2 
0.1 
0.0
Saline EPO
Figure 6.2, The effect of the acute treatment with EPO on the rat haematocrit 24 
hours after a single 5000U/kg dose of EPO. Values are represented as Haematocrit 
(Hct) and expressed as mean ±SEM.
The haematocrit content for both the saline control and acute EPO groups were identical 
(0.41 ±0.008), see figure 6.2.
Anthony J. Bullard 131
(u
ra
i/a
H
in
u
i 
t0
I
x
> 
J
J
H
Chapter 6
6.3.2 Langendorff Results
Groups Body Weight (g) Muscle Volume (cm3) Risk Volume (cm3)
Saline Control 
lxWkEPO 
3x Wk EPO 
EPO + Wort 
EPO + UO 
EPO + L-NAME
Table 6.1,
384 ±7.5
348 ±4.9 
336 ±15.9 
333 ±8 . 8  
382 ±2.8
349 ±2.3
1.107 ±0.034 
0.996±0.032 
0.929 ±0.046 
0.927 ±0.056 
0.982 ±0.054 
0.913 ±0.051
0.535 ±0.025 
0.526 ±0.043 
0.517 ±0.041 
0.419 ±0.025 
0.545 ±0.029 
0.557 ±0.037
30 -I 
25 
20 
15 
10 
5
Saline Control 
1xWk EPO 
3xWk EPO 
- x - EPO + Wort 
EPO + U0 
EPO + L-NAME
Characteristics of animals in the chronic treatment groups
Ischaemia Reperfusion
1
Stab Isch5 Isch30 Rep 5 Rep 60 Rep 120
Figure 6.3, Representation of the change in Rate-Pressure Product (RPP) 
throughout the experimental protocol from stabilisation (Stab) through ischaemia 
(Isch) and into reperfusion (Rep)
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Exclusions
Two animals from the 3x Wk EPO group were excluded due to too large a risk zone, one 
animal from the saline control group was excluded due to too large a risk zone, one 
animal from the EPO+UO group was excluded due to an infarct of less than 5%
70 1 
60 -
Saline 1x Wk 3x Wk EPO + EPO + L- EPO+UO 
Control EPO EPO Wort NAME
Figure 6. 4, The effect of a chronic treatment of EPO on infarct size of a once a week 
(lx  Wk) and three times a week (3x Wk) treatment with a 100 nM dose of PI3K inhibitor 
wortmannin (Wort), a 10 |JM dose of the ERK 1/2 inhibitor U0126 (U0) or a 100 |JM 
dose of the NOS inhibitor L-NAME. Values are represented as % infarct to risk ratio 
(%I/R) and expressed as mean ±SEM. *p<0.05 v control
As figure 6.4 describes a once-a-week dose of EPO failed to afford protection against 
reperfusion by comparison to a saline control group (%IR 54.07 ±8.7 v 52.25 ±4.4), 
whereas a three times a week regime did reduce infarct size significantly compared to 
control (%IR 36.23 ± 3.2 v 52.25 ±4.4, p<0.05). The PDK inhibitor wortmannin did not
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block the protective effect of this three times a week dose of EPO (%IR 31.7 ±6.0 v 36.2 
±3.2). However, the NOS inhibitor L-NAME did abrogate the protection provided by a 
three times a week regime (%IR 51.6 ±5.6 v 36.2 ±3.2, p<0.05). The ERK 1/2 inhibitor 
U0126 showed no significant difference against the EPO group (%IR 45.1 ±7.1 v 36.2 
±3.2) or the saline control (%IR 45.1 ±7.1 v 52.3 ±4.4).
6.3.3 24 hour EPO Group
Groups Body Weight (g) Muscle Volume (cm3) Risk Volume (cm3)
Saline Control 390±2.3 0.960 ±0.034 0.510 ±0.017
EPO 373 ±5.5 0.999 ±0.022 0.552 ±0.024
Table 6.2, Characteristics of animals in the 24 hour treatment groups
70 -
Saline EPO
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Figure 6. 5, The acute effect of EPO at a dose of 5000U/kg given 24 hours prior to 
index ischaemia. Values are represented as % infarct to risk ratio (%I/R) and expressed 
as mean ±SEM. *p<0.05 vs control
An acute dose of EPO significantly reduced infarct size when compared to its control 
(IR% 39.9 ±4.4 v 58.4 ±4.9, p<0.05), see figure 6.5.
6.3.4 Western Blot Results
a)
Akt
b)
pAkt
<
<
Saline Nate EPO NaKe Saline Pn* EPO Prut Saline Nate EPO Nate Saline Protocol EPO Protocol
Figure 6. 6, The effect of a 3 week treatment of 5,000 U/kg EPO or Saline with or 
without an ischaemia/reperfusion protocol on a) total Akt and b) phospho-Akt levels 
within the myocardium. Values are represented as arbitrary units (AU) and expressed as 
mean +SEM.
There was no difference in the total Akt content between the saline naive, EPO naive, 
saline protocol and EPO protocol groups (1434 ±214, 1651 ±154, 1750 ±133 and 1649 
±134 arbitrary units, respectively). The same holds true for the phospho-Akt content 
between the same groups (1024 ±164, 1139 ±114, 1072 ±185, 1081 ±47 arbitrary units, 
respectively).
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PTEN b) Phospho-PTEN
p<
P
Saline Nave EPO Nate Saline Prat EPO Prat Saline Nate EPO Nate Saline Prat EPO Prat
Figure 6. 7, The effect of a 3 week treatment of 5,000 U/Kg EPO or Saline with or 
without an ischaemia/reperfusion protocol on a) total PTEN levels and b) phospho- 
PTEN levels within the myocardium. Values are represented as arbitrary units (AU) 
and expressed as mean ±SEM. * p<0.05 vs Saline Naive
In order to understand whether the PDK pathway was being regulated by the enzyme 
PTEN (see discussion), we measured the total and phosphorylated levels of PTEN. As 
figure 6.7 shows, there was no difference in total PTEN content between the saline naive, 
EPO naive, saline protocol and EPO protocol groups (1534 ±429,2111 ±416,1676 ±61,
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1531 ±96 arbitrary units, respectively). There was no significant difference in phospho- 
PTEN levels between the saline naive and EPO naive groups (1008 ±407 v 460 ±69, 
respectively). However both the saline protocol (0 ±0 v 1008 ±407 arbitrary units, 
p<0.05) and the EPO protocol (0 ±0 v 1008 ±407 arbitrary units, p<0.05) groups showed 
significant difference versus control.
p44
p42
800 i
700 - 
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400 - 
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200 -  
100 -j
0 4-
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Saline Naive EPO Naive Saline Prot EPO Prot
D p44 
■ p42
Figure 6. 8, The effect of a 3 week treatment of 5,000 U/kg EPO or Saline with or 
without an ischaemia/reperfusion protocol on total p42 levels and total p44 levels 
within the myocardium. Values are represented as arbitrary units (AU) and expressed as 
mean ±SEM.
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Figure 6. 9, The effect of a 3 week treatment of 5,000 U/kg EPO or Saline with or 
without an ischaemia/reperfusion protocol on phospho-p42 levels and phospho-p44 
levels within the myocardium. Values are represented as arbitrary units (AU) and 
expressed as mean ±SEM. * p<0.05 vs Saline Naive
As figure 6 . 8  shows, there was no significant difference in total p42 content between the 
saline naive, EPO naive, saline protocol and EPO protocol groups (393 ±44,320 ±54, 
365 ±0.5, 371 ±25 arbitrary units, respectively). The same is true for total p42 content 
(610 ±61,439,439 ±84, 364 ±0.5,396 ±46 arbitrary units, respectively). For phospho- 
p42 there was no significant difference between saline naive, EPO naive, and EPO 
protocol groups (692 ±178, 6 8 6  ±102,1994 ±1075 arbitrary units, respectively). 
However, there was a significant difference between saline protocol versus saline naive 
(3314 ±1309 v 692 ±178, arbitrary units p<0.05). There was no statistical difference 
between saline protocol and EPO protocol. With regard to phospho-p44 levels, there was
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no statistical difference in these levels and the saline naive and EPO naive (952 ±236, 
1936 ±260 arbitrary units). However, the saline protocol group showed a significant 
increase compared to saline naive (3250 ±659 v 952 ±236, p<0.05) as did EPO protocol 
(3034 ±1526 v 952 ±236 arbitrary units). There was no statistical difference between the 
saline protocol and EPO protocol groups.
a) b)
Phospho
eNOSeNOS
Saline Nate EPO Nate SdlneProt S ’O Prrt Saline N ate EPO Nate Saline Pnct EPO Prot
Figure 6.10, The effect of a 3 week treatment of 5,000 U/kg EPO or Saline with or 
without an ischaemia/reperfusion protocol on a) total eNOS levels and b) phospho- 
eNOS levels within the myocardium. Values are represented as arbitrary units (AU) and 
expressed as mean ±SEM.
As figure 6.10 shows there was also no significant difference in total eNOS content 
between the saline naive, EPO naive, saline protocol and EPO protocol groups (4366 
±546, 5317 ±451,4699 ±1170,4299 ±379 arbitrary units, respectively). Likewise, there
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was no significant difference between those same groups for phospho-eNOS (1143 ±531, 
2085 ±730, 3113 ±618,2225 ±172 arbitrary units, respectively).
iNOS
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Figure
without an ischaemia/reperfusion protocol on total iNOS levels within the 
myocardium. Values are represented as arbitrary and expressed as mean ±SEM.
As figure 6.11 shows, there was no significant difference in total iNOS content between 
the saline naive, EPO naive, saline protocol and EPO protocol groups (1041 ±221,1256 
±179,957 ±186, 1087 ±205 arbitrary units, respectively)
Saline Naive EPO Naive Saline Prot EPO Prot
>. 11, The effect of a 3 week treatment of 5,000 U/kg EPO or Saline with or
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6.4 Discussion
EPO is a drug currently in general clinical use to correct anaemia, with some patients on 
treatments lasting many years. Our study of EPO in a chronic setting, therefore, has 
potential clinical relevance. The potentially cardio-protective effect of chronic EPO 
treatment directly on the myocardium has not been considered as clinical studies 
examining long-term EPO treatment attribute any beneficial effects arising from EPO use 
attributed to the increased oxygen-carrying capacity of the blood. To examine whether 
this is a direct cardio-protective effect of chronic EPO treatment on the heart and 
ascertain whether raised haematocrit could account for any protection observed, we 
established a chronic rat model involving treatment with human recombinant EPO for a 
period of 3 weeks.
Initially it was important to establish whether a human version of the protein would 
function in a rat model. The increases in haematocrit (figure 6.1) in both the ‘once-a- 
week’ and ‘3 times-a-week’ model clearly show that human EPO works in the rat. 
Thereafter, it was shown that a chronic treatment of EPO could limit myocardial injury 
induced by a standard Langendorff protocol of 35 minutes ischaemia and 2 hours 
reperfusion.
The ability of EPO to continue to protect the myocardium, shown in this chapter, after a 
period of chronic treatment is in some ways surprising. For example, atorvastatin, like 
EPO, is a drug that elicits protection via the PBK/Akt pathway, but this protection is lost 
when atorvastatin is administered chronically and only restored with an additional acute
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treatment211. In this way it is to be expected that, similarly, EPO’s protective effects 
would be lost in a chronic-dosing regime. In support of our basic research data, there is
clinical data suggesting that a chronic treatment with EPO, in order to correct anaemia,
1 000  000significantly improves the outcome of patients suffering chronic heart failure ’ ’ ,
even in patients where maximum tolerated therapy had previously failed to alleviate their 
chronic heart failure222. In addition, one study managed to reproduce this improved 
outcome in diabetic patients224. All these studies suggest that the effect we observe with 
EPO in the isolated perfused heart may be reproducible in the clinical setting in the 
patients at risk of myocardial infarction. It is worth noting that, in any clinical model, 
EPO would still have been present at the time of an ischaemic event, whereas in the 
animal model we use hearts that have been excised. Therefore, the EPO that was in the 
circulation is not present at the time that we make the heart ischaemic, but the protective 
effect remains in much the same way as EPO mimics preconditioning (see chapter 3).
6.4.1 The Role o f PISK/Akt in the Chronic Setting
As reported in chapter 4, EPO was able to limit infarct size in vivo and in vitro when 
administered at the point of reperfusion following a period of ischaemia in an Akt- and 
ERK-dependent manner. This involvement of PD-kinase in mediating the protection of 
EPO in a cardiac setting has been reported by other groups143,144,156 at a variety of time 
points and settings. It is thus interesting that wortmannin in our model should fail to 
abrogate the protection afforded by EPO in our chronic setting. One possibility to explain 
this finding is that the activation o f PB-kinase and Akt is a short-lived signal being 
regulated by phosphatases such as PP2A225 and PHLPP 226. The initial signal is sufficient
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to provide acute protection, but is suppressed by phosphatases in the chronic setting. It 
has been shown in the past, within the myocardium, that eNOS is downstream of PI3K- 
Akt in an insulin-induced signalling cascade and confers a limitation in infarct size in an 
in vivo model o f ischemia/reperfusion227. It is, therefore, possible that PBK conferred 
activation o f eNOS prior to its signal being suppressed, and that the eNOS activation was 
sufficient to provide long-term protection, also explaining the blocking effects of the 
NOS inhibitor L-NAME. An additional possibility, not examined in this study, is that the 
effect is mediated via PKC, which is known to be downstream of PBK and to be 
activated by EPO228. In the previously mentioned study performed by Mensah et al21 \  the 
authors found that atorvastatin could not protect in the chronic setting probably due to the 
elevation in levels of the phosphatase and tensin homolog deleted on chromosome ten 
(PTEN). The activation of PBK can be beneficial in an acute setting by limiting cell 
death. However, prolonged activation of these protective pathways can have detrimental 
tumorigenic effects. In order to regulate the PBK pathway, PTEN acts in equilibrium to 
the formation of the PBK substrate PI-3,4,5-trisphosphate converting it back to PI- 
4,5ibiphosphate . PTEN usually increases its activity by raising PTEN levels within the 
cell . As can be seen from figure 6.7, there is no difference between groups in total 
PTEN levels. The role of phosphorylated PTEN is slightly ambiguous but, again, as 
there is no difference between the groups, it could be argued that PTEN may be excluded 
from having any effect in this model.
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6.4.2 The Role o f Nitric Oxide in Chronic EPO Treatment
It has been shown that chronic treatment of endothelial cells with EPO can cause a
marked rise in nitric oxide synthase (NOS) levels 232. Furthermore, it has also been
demonstrated, in rats, kept at high altitude, that they also had a raised haematocrit and
increased iNOS levels233. As NOS has been implicated in protection from
'y'ic
ischemia/reperfusion using other agents ’ , it is feasible to assume that NOS could be 
playing a mediatory role in this chronic setting. Interestingly, there has been one study 
examining the role of NOS that found EPO-mediated protection could not be blocked 
using L-NAME153. However, it should be noted that this study examined the role of NOS 
in an acute pre-treatment context Therefore, it was important to determine die role of 
NOS in the chronic setting. The NOS-specific blocker L-NAME totally abrogated the 
reduction of infarction seen; this suggests that NOS does indeed play a key mediating 
role in protection as a result of chronic EPO treatment. In contrast, there were no 
significant observable increases in levels or activity of either eNOS or iNOS (see figures 
6.10 and 6.10). There are a number of possibilities to account for this:
1. The Western blot is not sensitive enough to determine such subtle changes (as 
discussed in chapter 4)
2. The source of nitric oxide is nNOS (not measured in this study)
3. The difference between saline and EPO-treated groups is the location rather than 
level of NOS. For example, Gonzales et al managed to locate the increase in 
iNOS to the mitochondrial fraction . Therefore, a localised increase in NOS 
within the mitochondria may not be detectable in the whole cell fraction.
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It has been shown that nitric oxide inhibits mPTP opening in a number of studies215,235,
23g ^
. There is some suggestion that a localised release of nitric oxide at the
• • 9 1 7  9*1®mitochondria ' may be protective against apoptosis by inhibiting mitochondrial 
respiration and free radical formation239,240, although it should be noted that Ghafourifar 
et al demonstrated that an increase in mitochondrial NOS (mtNOS) activity resulted in an 
increase in cytochrome c release241. Nitric oxide has been demonstrated to play an 
ambiguous role in apoptosis, capable of either preventing or inducing cell death242. We 
believe that in this setting NO plays an important anti-apoptotic role.
6.4.3 EPO-mediated Chronic Protection is Not Due to Raised Haematocrit 
An ‘acute’ dose o f EPO given 24 hours prior to index ischemia caused a limitation of
infarct size compared to its saline control, despite the fact that there was no increase in
haematocrit. Similarly, Xu et al demonstrated that administration of EPO 24 hours prior
to index ischaemia elevated the heat shock protein HSP 70 and diminished the
expression of NFkappaB, both phenomena have previously been associated with
improved protection in ischaemia/reperfusion243. Additionally, in studies where EPO has
been made non-erythropoietic by asialytion and carbamylation, protection was still
observed2441245. One explanation for this contradiction of absence of erythropoietic
function, yet continuation of protection, is that the beneficial effect of EPO is mediated
through its recently discovered effect on the common beta-receptor124 rather than solely
acting upon the EPO receptor. The common p receptor (PcR) subunit is known to
increase affinity for such receptors as for granulocyte-macrophage colony-stimulating
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factor (GM CSF) IL-3 and IL-5246. As PcR has been shown to functionally interact with 
the receptof247,248, it had been assumed that PcR would play a similar role for the EPO 
receptor. However, a knockout mouse model of pcR failed to eliminate the haemopoietic 
process suggesting that EPO was not functionally dependent upon pcR249. Brines et al 
subsequently established that the PcR heterodimerises with EPOR in cells that have been 
treated with EPO124. Finally, the authors demonstrated that carbamylated EPO (CEPO) 
failed to prevent staurosporine-induced apoptosis in PcR knockout mice, implying that 
the protective effects of EPO and CEPO are PcR-dependent and establishing a dual role 
for EPO.
The data presented in this chapter, in conjunction with the use of the blood free perfusion 
apparatus and the protective effects of non-erythropoietic EPO, suggests that the 
protection due to chronic administration o f EPO is not due to any increase in oxygen 
supply to the myocardium from the blood.
In conclusion, our findings suggest that improved outcome of chronic heart failure 
patients undergoing chronic treatment with EPO may well be at least partially due to a 
direct effect on the myocardium via a nitric oxide-dependent pathway, rather than solely 
due to improved oxygen supply from the blood and that this direct effect on the 
myocardium could explain the beneficial effects seen by EPO in clinical studies.
Anthony J. Bullard 146
Chapter 7
Chapter 7 - The Effect of EPO when Administered After 
Reperfusion
7.1 Introduction and Aims
Reperfusion is necessary to salvage the myocardium subsequent to a period of ischaemia 
but, paradoxically, can itself cause additional injury, as discussed in detail in chapter 3. 
However, in unstable angina the thrombus may have partially disintegrated, allowing 
reperfusion before medical attention can be received by the patient. It has been shown 
that, if  putative protective agents such as insulin have their administration delayed by 15 
minutes, then it is not possible to protect the myocardium69. Thus, in a clinical scenario 
whereby reperfusion has already commenced, the protective adjunct is ineffective. EPO 
has been shown to be protective when administered by intra-peritoneal injection 5 
minutes into reperfusion in an in vivo rat model which included a 24 hour period of 
reperfusion183. Intra-peritoneal injections are considered to take approximately 10 
minutes to enter the bloodstream, so it could be argued that the time of EPO 
administration was 15 minutes after reperfusion had commenced. Based upon this study 
we hypothesised that we could protect the myocardium in an in vitro model of 
ischaemia/reperfusion by administering EPO subsequent to the commencement of 
reperfusion.
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7.2 Experimental Protocol
Hearts from rats weighing 300-400g were excised and mounted on a Langendorff 
perfusion apparatus as described in chapter 2. The following protocols were used:
1. Ischaemic control -  standard 35 minutes ischaemia and 2 hours reperfusion with 
no treatment (n=7)
2. EPO 15 -  EPO administered 15 minutes after commencement of reperfusion and 
continued throughout the reperfusion period (n=8)
3. EPO 30 - EPO administered 30 minutes after commencement of reperfusion and 
continued throughout the reperfusion period (n=8)
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Control Ischaemia Protocol Determination 
o f infarct size
lOmins 35 mins
Stabilisation Ischaemia
120 mins
Reperfusion
EPO Delayed 15 Mins Protocol
Determination 
of infarct size
10 mins 35 mins
Stabilisation Ischaemia
EPO administration
105 mins
Reperfusion
EPO Delayed 30 Mins Protocol
10 mins 35 mins
Stabilisation Ischaemia
Determination 
of infarct size
EPO administration 
90 mins
Reperfusion
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73 Results
Groups Body Weight (g) Ventricle Volume (cm3) Risk Volumefcm3)
Ischaemic Control 361 ±6.6 0.979 ±0.075 0.443 ±0.024
Delayed 15 358 ±15.5 0.979 ±0.051 0.500 ±0.047
Delayed 30 369 ±7.9 0.973 ±0.032 0.529 ±0.037
Table 7.1, Characteristics of animals in the treatment groups
Ischaemia Reperfusion
25
20 -
15
10
Stab Isch 5 Isch 30 Rep 5 Rep 60 Rep 120
Control 
Delayed 15 
Delayed 30
Figure 7.1, Representation of the change in Rate_Pressure Product (RPP) 
throughout the experimental protocol from stabilisation (Stab) through ischaemia 
(Isch) and into reperfusion (Rep)
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Exclusions
There was one exclusion from the EPO 15 group due to too large a risk zone.
70 -
Control E P 0 15 EPO 30
Figure 7. 2, The effect of EPO administration 15 minutes (EPO 15) and 30 minutes 
(EPO 30) after reperfusion. Values are represented as % infarct to risk ratio (%I/R) and 
expressed as mean ±SEM. *p<0.05 vs control
As figure 7.2 shows, the administration of EPO 15 minutes after reperfusion had 
commenced reduced infarct size significantly compared to control (%I/R 34.4 ±4.4 v 56.3 
±6.5 respectively, p<0.05). Similarly, EPO administration 30 minutes after reperfusion 
had commenced also significantly limited infarct size compared to control (%I/R 39.6 
±6.2 v 56.3 ±6.5 respectively, p<0.05).
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Results performed by an independent observer, demonstrated in our laboratory that there 
was no significant difference between the group delayed by 15 minutes (EPO 15) and 
control (%IR 49.2 ±5.4 v 58.7 ±5.7, respectively). However, there was a statistically 
significant difference between EPO 30 and control (% I/R 42.1 ±4.1 v 58.7 ±5.7, 
respectively, p<0.05)
7.4 Discussion
Lipsic et al found in an in vivo rat model of ischaemia/reperfusion that administering 
EPO at different time points from pre-ischaemia to 5 minutes into reperfusion provided 
very similar reductions in infarct size compared to control (from a 19 to 23%
183reduction) . As the injection given at reperfusion was intra-peritoneal, it can be assumed 
that the time to absorption into the bloodstream was approximately 10 minutes, making 
the actual timing for administration 15 minutes after reperfusion has commenced. The 
data presented in figure 7.2 indicates that EPO does indeed reduce injury when perfused 
15 minutes into reperfusion, although not by as much as when administered prior to 
ischaemia or at the point of reperfusion, see chapters 3 and 4. Indeed even delaying 
administration until 30 minutes into reperfusion still provides a significant level of 
protection. The alternative observer noted a significant reduction in infarct size when
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EPO was given 30 but not 15 minutes into reperfusion. This may seem counter-intuitive 
but may just be a function of the comparatively low levels of protection presented in this 
setting and thus requires additional numbers to clarify whether protection is present in 
that model.
As a general rule it is considered necessary to administer any protective agent within 15 
minutes of reperfusion if any limitation of injury is to be observed69. The data presented 
within this chapter seems to be at odds with this paradigm. However, there is evidence 
within the literature that supports the theory that treatment later into reperfusion can still 
be protective. The Lipsic data183 and that provided by the alternative observer suggest 
that die original results obtained may represent a real occurrence. A greater level of 
protection may have been seen by Lipsic et al as a result of their extended, 24 hour period 
of reperfusion indicating that not only is cell death on-going, but that injury occurring 
some time after ischaemia/reperfusion is salvageable. In addition, further supporting data 
is provided by Paul Govewalla from our laboratory. He observed in an in vivo recovery 
model of rat myocardial ischaemia reperfusion 191 that, when he co-administered the 
PI3K blocker, LY294002, with EPO, there was only a partial reduction in EPO-mediated 
protection. When an alternative PI3K blocker, wortmannin, was co-administered with 
EPO, the protection was completely abrogated. The explanation for this difference in 
results could lie in the reversible nature of LY294002250. It may be assumed that, as soon 
as the reversible inhibitor was washed out from the system, EPO, which was still present 
in the circulation, could activate protective mechanisms inducing the partial results 
observed. In other words, the irreversible wortmannin does not allow any later activation 
of PI3K and thus protection was completely abrogated. It is possible that the later
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activation of PBK, in animals treated with LY294002, would explain the partial 
protection induced by EPO in this group.
Solenkova et al conducted a series o f experiments where they used wortmannin at 
differing points in reperfusion in preconditioned hearts. They found that they could block 
the effects of preconditioning by administering wortmannin as late as 30 minutes into 
reperfusion251. The feet that PI3K is still having an active protective effect at 30 minutes 
after reperfusion lends support to the data presented in this chapter. The important 
question, however, is how the protection is manifest.
7.4.1 A New Paradigm fo r Myocardial Salvage?
The ability for EPO to reduce inferct size at a much later stage in the apoptotic/necrotic 
process than any other agent thus far studied asks the question: at what point in the 
apoptotic/necrotic process does the cell pass the point of salvage? Previously, it had been 
considered to be the point at which the mPTP opens, mitochondrial membrane potential 
collapses and cytochrome c is released. This pore opening occurs within a few minutes of 
the commencement of reperfusion ’ . Therefore, an ability to protect when given at a
much more delayed time-point suggests that pore opening by itself cannot irreversibly 
lead to cell death. It is known that EPO limits apoptosis within erythroid precursor cells 
in the haemopoietic process by the inhibition of caspases, see chapter 1 254. This 
inhibitory effect on caspases is not limited solely to erythroid precursor cells as EPO has 
also been shown to inhibit caspases 1,3,8 and 9 within neuronal cells, preventing injury 
in the process255,256. Inhibition of caspases has also been shown previously to have a 
protective effect upon infarction in an ischaemic/reperfused isolated rat heart14.
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Therefore, at this stage we cannot be confident that this delayed protection is due to the 
effect of EPO upon the inhibition of caspases or upon the activation of the pro-survival 
kinases PBK/Akt, or both.
7.4.2 Clinical Implications ofEPO-mediated Protection after Reperjusion
EPO could be given in conjunction with a thrombolytic agent in instances where the
patient undergoing an acute myocardial infarction (AMI) is also suffering from anaemia.
By comparison, insulin is also routinely administered in AMI patients that have high
glucose levels. In a number of studies examining the effect of insulin given in
combination with glucose and potassium (GIK) at reperfusion, it has been found that GDC
ff\
infusion has a positive effect in improving outcome and prognosis in patients 
However, in the more recent CREATE-ECLA trial conducted in South America and 
India, GIK was found to have no positive effect compared to control. The reasoning 
behind this failure was due to the possible delay in administering GIK261, thus indicating 
the narrowness of the time-window available after reperfusion in order to observe any 
protection. In basic research studies, the narrow time-window is also seen in the study 
where insulin administration was given within 15 minutes after reperfusion had started 
with no protection observed262. However, the data presented in this chapter suggests that 
even a later treatment of EPO, after the commencement of the reperfusion, might still 
provide a significantly better outcome for the patient.
The ability to prevent cell death at a much later point in the cell death process than other 
beneficial drugs could have the effect of being able to improve the outcome and
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prognosis of patients that have had a delay in receiving medical attention. This added 
ability of delayed protection from infarction gives EPO a potential advantage in the 
clinical setting compared to other putative protective agents.
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Chapter 8 - Summary, Conclusions and Future Directions
The primary aim o f this thesis was to examine the potential protective effects of EPO in a 
variety of myocardial ischaemia/reperfusion settings and to examine the mechanisms by 
which such protection could occur. The central focus was related to the mechanism and 
involved an investigation o f the PBK/Akt, ERK pathway and mPTP as well as the 
isoforms of NOS, which have been demonstrated to induce protection against the 
ischaemia reperfusion injury and also to be cellular targets for EPO in many cell systems.
8.1 Summary of Findings
8.2.1 EPO as a Preconditioning Mimetic
Previous studies involving EPO-mediated protection within the myocardium have used 
models in which EPO was still present at the commencement of index ischaemia. The 
data presented within this thesis demonstrates for the first time that EPO is able to exert a 
protective “memory” effect within the heart and appears to mimic the phenomenon of 
ischaemic preconditioning. In a manner similar to ischaemic preconditioning (IPC) our 
data also demonstrates that EPO appears to use die PI3K signalling pathway and not ERK 
1/2 to achieve this protection. This initial study confirms the protective effects of EPO 
when administered pre-ischaemicly to the heart, in which a significant reduction of 
infarct size was observed. Interestingly, previous studies from other laboratories have 
also demonstrated an ability for EPO to mimic preconditioning in a neuronal model of 
ischaemia/reperfusion129.
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8.2.2 EPO at Reperfusion
Recent studies have shown that administration of EPO when given at reperfusion limits 
injury within the myocardium. We have reproduced the data within a Langendorff 
perfusion model demonstrating that a 50ng/ml, or lOU/ml, is the most effective dose.
This protection was seen to be mediated by PBK, ERK 1/2 and eNOS, as demonstrated 
by the ability of PBK inhibitors wortmannin and LY294002, the ERK inhibitor and the 
NOS inhibitor to abolish EPO-mediated protection. However, Western blot analysis of 
protein kinase activation proved problematic in that it proved difficult with this technique 
to demonstrate activation of protein kinase members of the putative protective pathways. 
However, eNOS was shown to be activated subsequent to EPO perfusion within the heart 
and may account for some of the protection observed.
8.2.3 EPO within a Cellular Model
EPO-mediated protection in the heart has been associated with a delay in mPTP opening. 
These findings were confirmed in this thesis using a myocyte model o f pore opening that 
utilised oxidative stress produced from laser excitation of TMRM pre-loaded into the 
cell. This protective effect on the mPTP was found to be dependent on PBK and NOS as 
wortmannin and L-NAME abolished the beneficial effect observed with EPO. The ERK 
1/2 inhibitor U0126 had the unexpected effect of strongly delaying pore opening in its 
own right. It seems likely that this outcome o f  U0126 may be artefactual and specific to 
this cellular model as U0126 has not been seen to be protective in any other myocardial 
model of ischaemia/reperfusion.
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8.2.4 A Model o f  Chronic EPO Treatment
Sprague Dawley rats were treated for 3 weeks with EPO in order to try and produce a 
more clinical scenario similar to that observed when patients receive a chronic treatment 
with this drug. A once-a-week treatment of 5,000 U/Kg of EPO failed to reduce infarct 
size in hearts that had been excised and underwent a standard protocol of ischaemia and 
reperfusion in a Langendorff model of heart perfusion. A three times-a-week treatment 
did, however, significantly limit injury o f hearts in the same model. This protective effect 
was abolished by the NOS inhibitor L-NAME but not the PBK inhibitor wortmannin. 
Western blot studies highlighted the absence of a raised level of PTEN, which is 
normally associated with longer-term activation of PBK in order to repress die PBK 
signal which chronically could be detrimental263. No elevation in levels or activation of 
NOS, Akt or ERK was observed. In order to eliminate the possibility of raised 
haematocrit as a possible mediator of protection, EPO was administered 24 hours prior to 
index ischaemia and was also shown to protect in the same manner without any raised 
haematocrit.
8.2.5 EPO Protects After Delayed Administration in Reperjusion
It has been shown that it may be possible to limit infarct size when agents are given up to
15 minutes of reperfusion69. However, a study by Lipsic et al also demonstrated that it 
was possible to protect the myocardium when EPO was given after 15 minutes of 
reperfusion183. The data in this thesis also showed that EPO could limit infarct size even 
when given up to 30 minutes into reperfusion and may represent an important aspect of 
the drug’s pharmacology. However, an in-depth study of the potential mechanism 
associated with this delayed effect needs to be undertaken.
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83 Conclusions
In the last 3 years EPO has become well established as a potential cardio-protective agent 
both in basic research and clinical studies. Within this thesis we have shown that EPO is 
beneficial in a variety o f settings, time-points and models. The method by which EPO 
protects seems to be multi-faceted, i.e. using multiple pathways, and depends upon the 
time of administration. PBK is an important mediator of all acute methods of 
administration of EPO but appears to become more tightly regulated in the chronic 
setting. NOS is the one ubiquitous factor seemingly involved at every stage of EPO 
treatment from acute to chronic administration, although different NOS isoforms may be 
responsible for eliciting protection in these settings. ERK 1/2 seems to be only involved 
in EPO-mediated protection when administration occurs at the time of reperfusion.
As observed in the literature, EPO seems to activate a series of beneficial signalling 
pathways, from PKC to caspase inhibition, all of which may explain the potential 
beneficial effects of this agent in such a wide range of settings, not just within models of 
ischaemic heart disease but also within a whole host of differing pathologies.
8.4 Potential Clinical Implications
8.4.1 Elective Surgery
In circumstances where elective surgery involves periods of myocardial ischaemia, pre­
treatment of EPO could limit any injury caused by the ischaemic period and the 
subsequent reperfusion of the tissue. There are reports that EPO also has the effect of
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damping down inflammation264,265, which would have an additive beneficial effect to that 
directly on the cell within this clinical setting.
8.4.2 Emergency Intervention
With the strong protective effect of EPO given at reperfusion and the ability to protect 
even when administration is delayed, EPO could be singularly effective as an agent to be 
used in emergency acute myocardial infarctions in conjunction with a thrombolytic, 
particularly in those patients who have not received prompt medical intervention.
8.4.3 General Treatment o f  Heart Disease
A series o f clinical studies have shown that treatment of patients with chronic heart 
disease suffered reduced hospitalisations, ischaemic events and a generally improved 
quality of life when treated with EPO. EPO intervention was even effective within aged 
patients and those with diabetes. With the advent of non-erythropoietic versions of EPO, 
the problematic side-effects of EPO, namely thrombus formation due to blood thickening, 
should be circumvented making the compound safe to use with non-anaemic patients.
8.5 Limitations and Further Investigations
The thesis did not and could not cover all aspects related to the involvement of EPO in 
preventing ischaemia/reperfusion injury. However, the data presented opens up other 
avenues of interest for further research:
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8.5.1 Preconditioning Studies
Activation of NOS has been shown to limit injury in other settings of 
ischaemia/reperfusion. Could it also mediate protection when EPO is administered prior 
to index ischaemia?
IPC was shown to be abolished when various kinase inhibitors were administered at 
reperfusion. Can this effect be repeated in EPO-mediated mimicry of preconditioning?
8.5.2 EPO at Reperfusion
The Western blot experiments within this study did not show any increase in activation of 
target kinases. The blots should be repeated for different timepoints in reperfusion in 
order to establish whether there is a window of activation.
In addition, it would be important to establish the source of the NOS involved in EPO- 
mediated protection, i.e. is the NOS responsible located at the mitochondria?
8.5.3 EPO Within a Cellular Model
The ability of U0126 to strongly delay mPTP opening in myocytes needs to be examined. 
Will a different ERK inhibitor have the same effect suggesting that ERK inhibition does 
indeed delay pore opening? Or will U0124, which is structurally similar but inactive, also 
delay pore opening, suggesting that the phenomenon is artefactual?
It was not established in this study which isoform of NOS was mediating the delay in 
pore opening provided by EPO. The location of the enzyme, cytosol or mitochondria, 
also needs to be determined.
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There has been some suggestion that the connecting point between protein kinases and 
prevention of mPTP opening could be mediated by GSK 3 p. The involvement of GSK 3p 
in the EPO-induced protective pathways in this model needs to be established.
8.5.4 Chronic EPO Treatment
It has been suggested that rats maintained at high altitude show increased levels of 
mitochondrial NOS. Is there a similar increase in mtNOS levels in rats chronically treated 
with EPO? Is mtNOS responsible for mediating protection in a chronic EPO model?
Also, EPO still managed to afford protection after chronic treatment. Have the 
phosphatases that regulate such key kinases as ERK and PBK/Akt been inactivated?
8.5.5 EPO at Delayed Reperjusion
This thesis demonstrated that EPO could limit protection even when administered 30 
minutes after the commencement of reperfusion. The maximum length of possible delay 
prior to EPO administration needs to be established.
The experiments in this study need to be repeated in an in vivo model with an extended 
reperfusion protocol to ensure that this ability to protect after a delay in administration 
occurs within a whole animal. The extended reperfusion period will establish whether
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any protection seen is merely a temporary delay in cell death or permanent salvage of 
tissue.
Furthermore, the protective pathways that mediate protection in this model need to be 
established by using pharmacological inhibitors in conjunction with EPO.
Using a pan-caspase inhibitors would establish whether inhibition of caspases is 
sufficient by itself to limit injury at this delayed.
If EPO is able to prevent cell death in cells where the mPTP has already been opened 
prior to administration, is it possible to prevent cell death in myocardium where the 
mPTP has been forcibly opened pharmacologically, e.g. by atractyloside?
Anthony J. Bullard 164
Publications & Communications
Publications and Communications
Bullard, AJ, Yellon, DM (2003) Erythropoietin protects the myocardium from  
ischaemia/reperjiision injury. University College London Cardiovascular Science and 
Medicine Meeting, Institute of Child Health, London.
Bullard, AJ, Govewalla, P, Yellon, DM, (2004), Erythropoietin protects the myocardium 
from  ischaemia/reperjusion injury. November 2004, New Orleans meeting of the 
American Heart Association.
Bullard, AJ, Govewalla, P, Yellon, DM, Erythropoietin protects Ihe myocardium against 
reperfusion injury in vitro and in vivo, Basic Res Cardiol. 2005 Sep;100(5):397-403.
Bullard AJ, Yellon, DM, Chronic Erythropoietin Treatment Limits Infarct-size in the 
Myocardium in Vitro, Cardiovasc Drugs Ther. In press
Anthony J. Bullard 165
References
Reference List
(1) WHO. Atlas o f  Heart Disease and Stroke. 2004.
(2) Petersen S, Peto V, Rayner M, Leal J, Luengo-Femandez R, Gray A. European 
cardiovascular disease statistics. 2005 ed. 2005.
(3) Jennings RB, Schaper J, Hill ML, Steenbergen C, Jr., Reimer KA. Effect of 
reperfusion late in the phase of reversible ischemic injury. Changes in cell 
volume, electrolytes, metabolites, and ultrastructure. Circ Res 1985 
February;56(2):262-78.
(4) Rovetto MJ, Lamberton WF, Neely JR. Mechanisms of glycolytic inhibition in 
ischemic rat hearts. Circ Res 1975 December;37(6):742-51.
(5) Neely JR, Rovetto MJ, Whitmer JT. Rate-limiting steps of carbohydrate and fatty 
acid metabolism in ischemic hearts. Acta Med Scand Suppl 1976;587:9-15.
(6) Williamson JR, Steenbergen C, Deleeuw G, Barlow C. Control of energy 
production in cardiac muscle: effects of ischemia in acidosis. Recent Adv Stud 
Cardiac Struct Metab 1976 May 26; 11:521 -31.
(7) Fleckenstein A, Frey M, Fleckenstein-Grun G. Consequences of uncontrolled 
calcium entry and its prevention with calcium antagonists. Eur Heart J 1983 
December;4 Suppl H:43-50.
(8) Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning 
slows energy metabolism and delays ultrastructural damage during a sustained 
ischemic episode. Circ Res 1990 April;66(4):913-31.
(9) Sawyer DB, Suter TM, Apstein CS. The sting of salt on an old, but open, wound-- 
is Na(+) the cause of mitochondrial and myocardial injury during 
ischemia/reperfusion? J  Mol Cell Cardiol 2002 July;34(7):699-702.
(10) Jennings RB, Ganote CE. Mitochondrial structure and function in acute 
myocardial ischemic injury. Circ Res 1976 May;38(5 Suppl 1):I80-I91.
(11) Kajstura J, Cheng W, Reiss K et al. Apoptotic and necrotic myocyte cell deaths 
are independent contributing variables of infarct size in rats. Lab Invest 1996 
January;74(l ):86-l 07.
(12) Dumont EA, Reutelingspeiger CP, Smits JF et al. Real-time imaging of apoptotic 
cell-membrane changes at the single-cell level in the beating murine heart. Nat 
Med 2001 December;7(12):l 352-5.
Anthony J. Bullard 166
References
(13) Ohno M, Takemura G, Ohno A et al. "Apoptotic" myocytes in infarct area in 
rabbit hearts may be oncotic myocytes with DNA fragmentation: analysis by 
immunogold electron microscopy combined with In situ nick end-labeling. 
Circulation 1998 October 6;98(14):1422-30.
(14) Mocanu MM, Baxter GF, Yellon DM. Caspase inhibition and limitation of 
myocardial infarct size: protection against lethal reperfusion injury. B rJ  
Pharmacol 2000 May; 130(2):197-200.
(15) Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ 
Res 1996 November;79(5):949-56.
(16) Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion 
injury induces apoptosis in rabbit cardiomyocytes. J  Clin Invest 1994 
October;94(4):1621-8.
(17) Buja LM, Eigenbrodt ML, Eigenbrodt EH. Apoptosis and necrosis. Basic types 
and mechanisms of cell death. Arch Pathol Lab Med 1993
December;117(12):1208-14.
(18) Buja LM, Entman ML. Modes of myocardial cell injury and cell death in 
ischemic heart disease. Circulation 1998 October 6;98(14):1355-7.
(19) Higuchi M, Aggarwal BB, Yeh ET. Activation of CPP32-like protease in tumor 
necrosis factor-induced apoptosis is dependent on mitochondrial function. J  Clin 
Invest 1997 April l;99(7):1751-8.
(20) Maulik N, Kagan VE, Tyurin VA, Das DK. Redistribution of 
phosphatidylelhanolamine and phosphatidylserine precedes reperfusion-induced 
apoptosis. Am J  Physiol 1998 January;274(l Pt2):H242-H248.
(21) Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P. Intracellular adenosine 
triphosphate (ATP) concentration: a switch in the decision between apoptosis and 
necrosis. JE xp Med 1997 April 21;185(8):1481-6.
(22) Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life 
regulator in apoptosis and necrosis. Annu Rev Physiol 1998;60:619-42.
(23) Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of 
lethal cell injury in ischemic myocardium. Circulation 1986 
November;74(5):l 124-36.
(24) Yellon DM, Downey JM. Preconditioning the myocardium: from cellular 
physiology to clinical cardiology. Physiol Rev 2003 October;83(4):l 113-51.
(25) Uecker M, Da SR, Grampp T, Pasch T, Schaub MC, Zaugg M. Translocation of 
protein kinase C isoforms to subcellular targets in ischemic and anesthetic 
preconditioning. Anesthesiology 2003 July;99(l): 138-47.
Anthony J. Bullard 167
References
(26) Wang Y, Ashraf M. Activation of alpha 1 -adrenergic receptor during Ca2+ pre­
conditioning elicits strong protection against Ca2+ overload injury via protein 
kinase C signaling pathway. J  Mol Cell Cardiol 1998 November;30(l l):2423-35.
(27) Wang Y, Hirai K, Ashraf M. Activation of mitochondrial ATP-sensitive K(+) 
channel for cardiac protection against ischemic injury is dependent on protein 
kinase C activity. Circ Res 1999 October 15;85(8):731-41.
(28) Chen L, Hahn H, Wu G et al. Opposing cardioprotective actions and parallel 
hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci U SA  
2001 September 25;98(20):11114-9.
(29) Yao R, Cooper GM. Requirement for phosphatidylinositol-3 kinase in the 
prevention of apoptosis by nerve growth factor. Science 1995 March 
31^67(5206)^003-6.
(30) Casamayor A, Morrice NA, Alessi DR. Phosphorylation of Ser-241 is essential 
for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of 
five sites of phosphorylation in vivo. Biochem J 1999 September 1 ;342 ( Pt 
2):287-92.
(31) Stephens L, Anderson K, Stokoe D et al. Protein kinase B kinases that mediate 
phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. 
Science 1998 January 30;279(5351):71(M.
(32) Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a 
road to PKB. Biochem .72000 March 15;346 Pt 3:561-76.
(33) del PL, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced 
phosphorylation of BAD through the protein kinase Akt. Science 1997 October 
24£78(5338):687-9.
(34) Cardone MH, Roy N, Stennicke HR et al. Regulation of cell death protease 
caspase-9 by phosphorylation. Science 1998 November 13;282(5392): 1318-21.
(35) Brunet A, Bonni A, Zigmond MJ et al. Akt promotes cell survival by 
phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999 March 
19;96(6):857-68.
(36) Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the 
phosphatidylinositol 3-Kinase/Akt cell survival pathway. J  Biol Chem 1998 
August 7;273(32):19929-32.
(37) Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. 
Activation of nitric oxide synthase in endothelial cells by Akt-dependent 
phosphorylation. Nature 1999 June 10;399(6736):601-5.
Anthony J. Bullard 168
References
(38) Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ. Protein 
kinase C isotypes controlled by phosphoinositide 3-kinase through the protein 
kinase PDK1. Science 1998 September 25;281(5385):2042-5.
(39) Mocanu MM, Bell RM, Yellon DM. PI3 kinase and not p42/p44 appears to be 
implicated in the protection conferred by ischemic preconditioning. J  Mol Cell 
Cardiol 2002 June;34(6):661-8.
(40) Hausenloy DJ, Yellon DM, Mani-Babu S, Duchen MR. Preconditioning protects 
by inhibiting the mitochondrial permeability transition. Am J  Physiol Heart Circ 
Physiol 2004 August;287(2):H841-H849.
(41) Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. 
Protection against infarction afforded by preconditioning is mediated by Al 
adenosine receptors in rabbit heart. Circulation 1991 July;84(l):350-6.
(42) Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial 
preconditioning. J  Pharmacol Exp Ther 1994 August;270(2):681-9.
(43) Liang BT. Direct preconditioning of cardiac ventricular myocytes via adenosine 
A l receptor and KATP channel. Am J  Physiol 1996 November,271(5 Pt 
2):H1769-H1777.
(44) Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning 
protects by activating prosurvival kinases at reperfusion. Am J  Physiol Heart Circ 
Physiol 2005 February;288(2):H971-H976.
(45) Cerra FB, Lajos TZ, Montes M, Siegel JH. Hemorrhagic infarction: A reperfusion 
injury following prolonged myocardial ischemic anoxia. Surgery 1975 
July;78(l):95-104.
(46) Stewart JR, Blackwell WH, Crate SL, Loughlin V, Greenfield LJ, Hess ML. 
Inhibition of surgically induced ischemia/reperfusion injury by oxygen free 
radical scavengers. J  Thorac Cardiovasc Surg 1983 August;86(2):262-72.
(47) von HR, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced 
cardiomyocyte apoptosis. Circulation 1999 June 8;99(22):2934-41.
(48) Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion 
injury induces apoptosis in rabbit cardiomyocytes. J  Clin Invest 1994 
October;94(4):1621-8.
(49) Petrosillo G, Ruggiero FM, Pistolese M, Paradies G. Ca2+-induced reactive 
oxygen species production promotes cytochrome c release from rat liver 
mitochondria via mitochondrial permeability transition (MPT)-dependent and 
MPT-independent mechanisms: role of cardiolipin. J  Biol Chem 2004 December 
17;279(51):53103-8.
Anthony J. Bullard 169
References
(50) Halestrap AP, Doran E, Gillespie JP, O'Toole A. Mitochondria and cell death. 
Biochem Soc Trans 2000 Febraary;28(2):170-7.
(51) Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability 
transition pore opening at reperfusion protects against ischaemia-reperfusion 
injury. Cardiovasc Res 2003 December 1;60(3):617-25.
(52) Clarke SJ, McStay GP, Halestrap AP. Sanglifehrin A acts as a potent inhibitor of 
the mitochondrial permeability transition and reperfusion injury of the heart by 
binding to cyclophilin-D at a different site from cyclosporin A. J  Biol Chem 2002 
September 20;277(38):34793-9.
(53) Griffiths EJ, Halestrap AP. Protection by Cyclosporin A of ischemia/reperfusion- 
induced damage in isolated rat hearts. J  Mol Cell Cardiol 1993 
December£5(12):1461 -9.
(54) Halestrap AP, Connem CP, Griffiths EJ, Kerr PM. Cyclosporin A binding to 
mitochondrial cyclophilin inhibits the permeability transition pore and protects 
hearts from ischaemia/reperfusion injury. Mol Cell Biochem 1997 
September, 174(1-2):167-72.
(55) Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, Halestrap AP. Ischaemic 
preconditioning inhibits opening of mitochondrial permeability transition pores in 
the reperfused rat heart. J  Physiol 2003 June 1 ;549(Pt 2):513-24.
(56) Sato H, Jordan JE, Zhao ZQ, Sarvotham SS, Vinten-Johansen J. Gradual 
reperfusion reduces infarct size and endothelial injury but augments neutrophil 
accumulation. Ann ThoracSurg 1997 October,64(4):1099-107.
(57) Zhao ZQ, Corvera JS, Halkos ME et al. Inhibition of myocardial injury by 
ischemic postconditioning during reperfusion: comparison with ischemic 
preconditioning. Am J  Physiol Heart Circ Physiol 2003 August;285(2):H579- 
H588.
(58) Staat P, Rioufol G, Piot C et al. Postconditioning the human heart. Circulation 
2005 October 4;112(14):2143-8.
(59) Kin H, Zhao ZQ, Sun HY et al. Postconditioning attenuates myocardial ischemia- 
reperfusion injury by inhibiting events in the early minutes of reperfusion. 
Cardiovasc Res 2004 April l;62(l):74-85.
(60) Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of 
"modified reperfusion" protects the myocardium by activating the 
phosphatidylinositol 3-kinase-Akt pathway. Circ Res 2004 August 6;95(3):230-2.
(61) Hausenloy DJ, Yellon DM. New directions for protecting the heart against 
ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase 
(RISK)-pathway. Cardiovasc Res 2004 February 15;61(3):448-60.
Anthony J. Bullard 170
References
(62) Hefti MA, Harder BA, Eppenbeiger HM, Schaub MC. Signaling pathways in 
cardiac myocyte hypertrophy. JM ol Cell Cardiol 1997 November;29(l 1):2873- 
92.
(63) Sugden PH, Clerk A. "Stress-responsive" mitogen-activated protein kinases (c- 
Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the 
myocardium. Circ Res 1998 August 24;83(4):345-52.
(64) Ferrell JE, Jr., Bhatt RR. Mechanistic studies of the dual phosphorylation of 
mitogen-activated protein kinase. JB io l Chem 1997 July 25;272(30): 19008-16.
(65) Felton-Edkins ZA, Fairley JA, Graham EL, Johnston IM, White RJ, Scott PH. 
The mitogen-activated protein (MAP) kinase ERK induces tRNA synthesis by 
phosphorylating TFIIIB. E M B O J im  May 15£2(10)2422-32.
(66) Tanoue T, Adachi M, Moriguchi T, Nishida E. A conserved docking motif in 
MAP kinases common to substrates, activators and regulators. Nat Cell Biol 2000 
February;2(2):l 10-6.
(67) Allan LA, Morrice N, Brady S, Magee G, Pathak S, Clarke PR. Inhibition of 
caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 
2003 July;5(7):647-54.
(68) Zhu Y, Yang GY, Ahlemeyer B et al. Transforming growth factor-beta 1 
increases bad phosphorylation and protects neurons against damage. JNeurosci 
2002 May 15;22(10):3898-909.
(69) Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin 
at reperfusion requires early administration and is mediated via Akt and p70s6 
kinase cell-survival signaling. Circ Res 2001 December 7;89(12):1191-8.
(70) Schulman D, Latchman DS, Yellon DM. Urocortin protects the heart from 
reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am J  
Physiol Heart Circ Physiol 2002 October;283(4):H1481-H1488.
(71) Brar BK, Stephanou A, Knight R, Latchman DS. Activation of protein kinase 
B/Akt by urocortin is essential for its ability to protect cardiac cells against 
hypoxia/reoxygenation-induced cell death. JM ol Cell Cardiol 2002 
April;34(4) :483-92.
(72) Efihymiou CA, Mocanu MM, Yellon DM. Atorvastatin and myocardial 
reperfusion injury: new pleiotropic effect implicating multiple prosurvival 
signaling. J  Cardiovasc Pharmacol 2005 March;45(3):247-52.
(73) Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and 
independent of lipid lowering, protects the myocardium by up-regulating a pro­
survival pathway. J  Am Coll Cardiol 2003 February 5;41(3):508-15.
Anthony J. Bullard 171
References
(74) Kis A, Baxter GF, Yellon DM. Limitation of myocardial reperfusion injury by 
AMP579, an adenosine A1/A2A receptor agonist: role of A2A receptor and 
Eikl/2. Cardiovasc Drugs Ther 2003 September; 17(5-6):415-25.
(75) Xu Z, Downey JM, Cohen MV. Amp 579 reduces contracture and limits 
infarction in rabbit heart by activating adenosine A2 receptors. J  Cardiovasc 
Pharmacol 2001 September;38(3):474-81.
(76) Eliason IF, Van ZG, GOLDWASSER E. The relationship of hemoglobin 
synthesis to erythroid colony and burst formation. Blood 1979 May;53(5):935-45.
(77) Adamson JW. The relationship of erythropoietin and iron metabolism to red blood 
cell production in humans. Semin Oncol 1994 April;21(2 Suppl 3):9-15.
(78) Nijhof W, de HG, Pietens J, Dontje B. Mechanistic options of erythropoietin- 
stimulated erythropoiesis. Exp Hematol 1995 April;23(4):369-75.
(79) Silva M, Benito A, Sanz C et al. Erythropoietin can induce the expression of bcl- 
x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J  Biol Chem 
1999 August 6;274(32):22165-9.
(80) Haseyama Y, Sawada K, Oda A et al. Phosphatidylinositol 3-kinase is involved in 
the protection of primary cultured human erythroid precursor cells from 
apoptosis. Blood 1999 September 1;94(5):1568-77.
(81) Miller BA, Scaduto RC, Jr., T illotson DL, Botti J J, Cheung JY. Erythropoietin 
stimulates a rise in intracellular free calcium concentration in single early human 
erythroid precursors. J  Clin Invest 1988 July;82(l):309-15.
(82) Sasaki R, Masuda S, Nagao M. Erythropoietin: multiple physiological functions 
and regulation of biosynthesis. Biosci Biotechnol Biochem 2000 
September;64(9): 1775-93.
(83) Miyake T, Kung CK, GOLDWASSER E. Purification of human erythropoietin. J  
Biol Chem 1977 August 10;252(15):5558-64.
(84) Adamson JW, Eschbach JW. Management of the anaemia of chronic renal failure 
with recombinant erythropoietin. Q JM ed  1989 December;73(272):1093-101.
(85) Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of 
the anemia of end-stage renal disease with recombinant human erythropoietin. 
Results of a combined phase I and II clinical trial. N  Engl J  Med 1987 January 
8;316(2):73-8.
(86) Watkins PC, Eddy R, Hoffman N et al. Regional assignment of the erythropoietin 
gene to human chromosome region 7pter—-q22. Cytogenet Cell Genet 
1986;42(4):214-8.
Anthony J. Bullard 172
References
(87) Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human 
erythropoietin gene. Proc Natl Acad Sci U SA  1985 November,82(22):7580-4.
(88) Lai PH, Everett R, Wang FF, Arakawa T, GOLDWASSER E. Structural 
characterization of human erythropoietin. J  Biol Chem 1986 March 
5;261(7):3116-21.
(89) Dordal MS, Wang FF, GOLDWASSER E. The role of carbohydrate in 
erythropoietin action. Endocrinology 1985 June;l 16(6):2293-9.
(90) Takeuchi M, Inoue N, Strickland TW et al. Relationship between sugar chain 
structure and biological activity o f recombinant human erythropoietin produced in 
Chinese hamster ovary cells. Proc Natl Acad Sci U SA  1989
October;86(20):7819-22.
(91) Yamaguchi K, Akai K, Kawanishi G, Ueda M, Masuda S, Sasaki R. Effects of 
site-directed removal o f N-glycosylation sites in human erythropoietin on its 
production and biological properties. J  Biol Chem 1991 October
25 ;266(30):20434-9.
(92) Fukuda MN, Sasaki H, Lopez L, Fukuda M. Survival o f recombinant 
erythropoietin in the circulation: the role of carbohydrates. Blood 1989 
January;73(l ):84-9.
(93) Takeuchi M, Takasaki S, Shimada M, Kobata A. Role of sugar chains in the in 
vitro biological activity o f human erythropoietin produced in recombinant 
Chinese hamster ovary cells. JB io l Chem 1990 July 25;265(21):12127-30.
(94) Tsuda E, Kawanishi G, Ueda M, Masuda S, Sasaki R. The role of carbohydrate in 
recombinant human erythropoietin. Eur J  Biochem 1990 March 10;188(2):405-11.
(95) JACOBSON LO, GOLDWASSER E, FRIED W, PLZAK L. Role of the kidney 
in erythropoiesis. Nature 1957 March 23;179(4560):633-4.
(96) Krantz SB. Erythropoietin. Blood 1991 February 1;77(3):419-34.
(97) Tan CC, Eckardt KU, Firth JD, Ratcliffe PJ. Feedback modulation of renal and 
hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J  
Physiol 1992 September;263(3 Pt 2):F474-F481.
(98) Gassmann M, Heinicke K, Soliz J et al. Non-erythroid functions of erythropoietin. 
Adv Exp Med Biol 2003;543:323-30.
(99) Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the blood-brain 
barrier to protect against experimental brain injury. Proc Natl Acad Sci U SA  
2000 September 12;97(19): 10526-31.
Anthony J. Bullard 173
References
(100) Xenocostas A, Cheung WK, Farrell F et al. The pharmacokinetics of 
erythropoietin in the cerebrospinal fluid after intravenous administration of 
recombinant human erythropoietin. Eur J  Clin Pharmacol 2005 May;61 (3):189- 
95.
(101) Banks WA, Jumbe NL, Farrell CL, NiehofFML, Heatherington AC. Passage of 
erythropoietic agents across the blood-brain barrier: a comparison of human and 
murine erythropoietin and the analog darbepoetin alfa. Eur J  Pharmacol 2004 
November 28;505(l-3):93-101.
(102) Juul SE, Stallings SA, Christensen RD. Erythropoietin in the cerebrospinal fluid 
of neonates who sustained CNS injury. Pediatr Res 1999 November;46(5):543-7.
(103) Marti HH, Gassmann M, Wenger RH et al. Detection of erythropoietin in human 
liquor: intrinsic erythropoietin production in the brain. Kidney Int 1997 
February;51 (2) :416-8.
(104) Springborg JB, Sonne B, Frederiksen HJ et al. Erythropoietin in the cerebrospinal 
fluid of patients with aneurysmal subarachnoid haemorrhage originates from the 
brain. Brain Res 2003 September 12;984(l-2):143-8.
(105) Eckardt KU, Boutellier U, Kurtz A, Schopen M, Koller EA, Bauer C. Rate of 
erythropoietin formation in humans in response to acute hypobaric hypoxia. J  
Appl Physiol 1989 April;66(4):1785-8.
(106) Fyhrquist F, Karppinen K, Honkanen T, Saijonmaa O, Rosenlof K. High serum 
erythropoietin levels are normalized during treatment of congestive heart failure 
with enalapril. J  Intern Med 1989 October;226(4):257-60.
(107) George J, Patal S, Wexler D et al. Circulating erythropoietin levels and prognosis 
in patients with congestive heart failure: comparison with neurohormonal and 
inflammatory markers. Arch Intern Med 2005 June 13;165(11):1304-9.
(108) Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: 
evidence that the oxygen sensor is a heme protein. Science 1988 December 
9;242(4884):1412-5.
(109) Ho VT, Bunn HF. Effects of transition metals on the expression of the 
erythropoietin gene: further evidence that the oxygen sensor is a heme protein. 
Biochem Biophys Res Commun 1996 June 5;223(1):175-80.
(110) Gorlach A, Fandrey J, Holtermann G, Acker H. Effects of cobalt on haem 
proteins o f erythropoietin-producing HepG2 cells in multicellular spheroid 
culture. FEBSLett 1994 July 11;348(2):216-8.
(111) Fandrey J, Frede S, Jelkmann W. Role of hydrogen peroxide in hypoxia-induced 
erythropoietin production. Biochem J 1994 October 15;303 ( Pt 2):507-10.
Anthony J. Bullard 174
References
(112) Ratan RR, Siddiq A, Aminova L et al. Translation of ischemic preconditioning to 
the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel 
targets for stroke therapy. Stroke 2004 November;35(l 1 Suppl l):2687-9.
(113) Blanchard KL, Acquaviva AM, Galson DL, Bunn HF. Hypoxic induction of the 
human erythropoietin gene: cooperation between the promoter and enhancer, each 
of which contains steroid receptor response elements. Mol Cell Biol 1992 
December;12(12):5373-85.
(114) Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein 
synthesis binds to the human erythropoietin gene enhancer at a site required for 
transcriptional activation. M ol Cell Biol 1992 December;12(12):5447-54.
(115) Bunn HF, Gu J, Huang LE, Park JW, Zhu H. Erythropoietin: a model system for 
studying oxygen-dependent gene regulation. J  Exp Biol 1998 April;201(Pt
8):1197-201.
(116) Arany Z, Huang LE, Eckner R et al. An essential role for p300/CBP in the cellular 
response to hypoxia. Proc Natl Acad Sci U SA  1996 November 12;93(23): 12969- 
73.
(117) Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear 
factors bind to an enhancer element located 3' to the human erythropoietin gene. 
Proc Natl Acad Sci U S A  1991 July l;88(13):5680-4.
(118) Galson DL, Tsuchiya T, Tendler DS et al. The orphan receptor hepatic nuclear 
factor 4 functions as a transcriptional activator for tissue-specific and hypoxia- 
specific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1. 
Mol Cell Biol 1995 April;15(4):2135^4.
(119) Huang LE, Ho V, Arany Z et al. Erythropoietin gene regulation depends on heme- 
dependent oxygen sensing and assembly of interacting transcription factors. 
Kidney Int 1997 February;51(2):548-52.
(120) Weiss G, Houston T, Kastner S, Johrer K, Grunewald K, Brock JH. Regulation of 
cellular iron metabolism by erythropoietin: activation of iron-regulatoiy protein 
and upregulation of transferrin receptor expression in eiythroid cells. Blood 1997 
January 15;89(2):680-7.
(121) Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. 
Erythropoietin receptor expression in adult rat cardiomyocytes is associated with 
an acute cardioprotective effect for recombinant erythropoietin during ischemia- 
reperfusion injury. FASEB J  2004 June; 18(9): 1031 -3.
(122) Dusanter-Fourt I, Casadevall N, Lacombe C et al. Erythropoietin induces the 
tyrosine phosphorylation of its own receptor in human erythropoietin-responsive 
cells .J  Biol Chem 1992 May 25;267(15):10670-5.
Anthony J. Bullard 175
References
(123) Livnah O, Stura EA, Johnson DL et al. Functional mimicry of a protein hormone 
by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996 July 
26;273(5274):464-71.
(124) Brines M, Grasso G, Fiordaliso F et al. Erythropoietin mediates tissue protection 
through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl 
Acad Sci U S A  2004 October 12;101(41):14907-12.
(125) Guillard C, Chretien S, Jockers R, Fichelson S, Mayeux P, Duprez V. Coupling of 
heterotrimeiic Gi proteins to the erythropoietin receptor. J  Biol Chem 2001 
January 19;276(3):2007-14.
(126) Guillard C, Chretien S, Pelus AS et al. Activation of the mitogen-activated protein 
kinases Erkl/2 by erythropoietin receptor via a G(i )protein beta gamma-subunit- 
initiated pathway. J  Biol Chem 2003 March 28;278(13):11050-6.
(127) Rafiee P, Shi Y, Su J, Pritchard KA, Jr., Tweddell JS, Baker JE. Erythropoietin 
protects the infant heart against ischemia-reperfusion injury by triggering multiple 
signaling pathways. Basic Res Cardiol 2005 May;100(3):l 87-97.
(128) Sakanaka M, Wen TC, Matsuda S et al. In vivo evidence that erythropoietin 
protects neurons from ischemic damage. Proc Natl Acad Sci U SA  1998 April 
14;95(8):4635-40.
(129) Siren AL, Fratelli M, Brines M et al. Erythropoietin prevents neuronal apoptosis 
after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U SA  2001 
March 27;98(7):4044-9.
(130) Wen TC, Sadamoto Y, Tanaka J et al. Erythropoietin protects neurons against 
chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL 
expression. J  Neurosci Res 2002 March 15;67(6):795-803.
(131) Solaroglu A, Dede FS, Okutan E, Bayrak A, Haberal A, Kilinc K. A single dose 
of erythropoietin attenuates lipid peroxidation in experimental liver ischemia- 
reperfusion injury in the rat fetus. JM atem  Fetal Neonatal Med 2004 
October; 16(4):231 -4.
(132) Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin 
receptor-mediated inhibition of exocytotic glutamate release confers 
neuroprotection during chemical ischemia. J  Biol Chem 2001 October 
19;276(42):39469-75.
(133) Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect 
of erythropoietin on exercise capacity in patients with moderate to severe chronic 
heart failure. Circulation 2003 January 21 ;107(2):294-9.
Anthony J. Bullard 176
References
(134) Langendoiff O. Untersuchungen am uberebenden Saugethierherzen. Pflugers 
Archives ju r  die Gesamte Physiologie des Menschen and der Tiere 1895;61:291- 
332.
(135) Fishbein MC, Meerbaum S, Rit J et al. Early phase acute myocardial infarct size 
quantification: validation of the triphenyl tetrazolium chloride tissue enzyme 
staining technique. Am Heart J 1981 May;101(5):593-600.
(136) Ytrehus K, Liu Y, Tsuchida A et al. Rat and rabbit heart infarction: effects of 
anesthesia, perfusate, risk zone, and method of infarct sizing. Am J  Physiol 1994 
December;267(6 Pt 2):H2383-H2390.
(137) Wiechelman KJ, Braun RD, Fitzpatrick JD. Investigation of the bicinchoninic 
acid protein assay: identification of the groups responsible for color formation. 
Anal Biochem 1988 November 15;175(l):231-7.
(138) Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers 
MH. Annexin V for flow cytometric detection of phosphatidylserine expression 
on B cells undergoing apoptosis. Blood 1994 September l;84(5):1415-20.
(139) Martin SJ, Reutelingsperger CP, McGahon AJ et al. Early redistribution of plasma 
membrane phosphatidylserine is a general feature of apoptosis regardless of the 
initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J  Exp Med 
1995 November 1;182(5): 1545-56.
(140) Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for 
apoptosis. Flow cytometric detection of phosphatidylserine expression on early 
apoptotic cells using fluorescein labelled Annexin V. J  Immunol Methods 1995 
July 17;184(1):39-51.
(141) Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase 
inhibitor the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil 
responses. Biochem J 1993 December 1 ;296 ( Pt 2):297-301.
(142) Calvillo L, Latini R, Kajstura J et al. Recombinant human erythropoietin protects 
the myocardium from ischemia-reperfusion injury and promotes beneficial 
remodeling. Proc Natl Acad Sci U SA  2003 April 15;100(8):4802-6.
(143) Tramontano AF, Muniyappa R, Black AD et al. Erythropoietin protects cardiac 
myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. 
Biochem Biophys Res Commun 2003 September 5;308(4):990-4.
(144) Parsa CJ, Matsumoto A, Kim J et al. A novel protective effect of erythropoietin in 
the infarcted heart. J  Clin Invest 2003 October, 112(7):999-1007.
(145) Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E. 
Mechanisms of erythropoietin-mediated cardioprotection during ischemia-
Anthony J. Bullard 177
References
reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase 
signaling. F A SE B J2005 August;19(10):1323-5.
(146) van der MP, Lipsic E, Henning RH et al. Erythropoietin improves left ventricular 
function and coronary flow in an experimental model of ischemia-reperfusion 
injury. Eur J  Heart Fail 2004 December,6(7):853-9.
(147) Moon C, Krawczyk M, Ahn D et al. Erythropoietin reduces myocardial infarction 
and left ventricular functional decline after coronary artery ligation in rats. Proc 
Natl Acad Sci U SA  2003 September 30;100(20): 11612-7.
(148) Hale SL, Sesti C, Kloner RA. Administration of erythropoietin fails to improve 
long-term healing or cardiac function after myocardial infarction in the rat. J  
Cardiovasc Pharmacol 2005 August;46(2):211-5.
(149) Kristensen J, Maeng M, Rehling M et al. Lack of acute cardioprotective effect 
from preischaemic erythropoietin administration in a porcine coronary occlusion 
model. Clin Physiol Fund Imaging 2005 September;25(5):305-10.
(150) Maxwell MP, Hearse DJ, Yellon DM. Species variation in the coronary collateral 
circulation during regional myocardial ischaemia: a critical determinant of the rate 
of evolution and extent o f myocardial infarction. Cardiovasc Res 1987 
October# 1(10):737-46.
(151) Sjoquist PO, Duker G, Almgren O. Distribution of the collateral blood flow at the 
lateral border of the ischemic myocardium after acute coronary occlusion in the 
pig and the dog. Basic Res Cardiol 1984 March;79(2):164-75.
(152) Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves 
cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001 August 
9;412(6847):641-7.
(153) Shi Y, Rafiee P, Su J, Pritchard KA, Jr., Tweddell JS, Baker JE. Acute 
cardioprotective effects of erythropoietin in infant rabbits are mediated by 
activation o f protein kinases and potassium channels. Basic Res Cardiol 2004 
May;99(3): 173-82.
(154) Uddin S, Kottegoda S, Stigger D, Platanias LC, Wickrema A. Activation of the 
Akt/FKHRLl pathway mediates the antiapoptotic effects of erythropoietin in 
primary human erythroid progenitors. Biochem Biophys Res Commun 2000 
August 18;275(l):16-9.
(155) Sui X, Krantz SB, Zhao ZJ. Stem cell factor and erythropoietin inhibit apoptosis 
of human erythroid progenitor cells through different signalling pathways. B rJ  
Haematol 2000 July;l 10(l):63-70.
(156) Hirata A, Minamino T, Asanuma H et al. Erythropoietin Just Before Reperfusion 
Reduces Both Lethal Arrhythmias and Infarct Size via the Phosphatidylinositol-3
Anthony J. Bullard 178
References
Kinase-Dependent Pathway in Canine Hearts. Cardiovasc Drugs Ther 2005 
January; 19(1) :33-40.
(157) Cleveland JC, Jr., Meldrum DR, Rowland RT et al. Ischemic preconditioning of 
human myocardium: protein kinase C mediates a permissive role for alpha 1- 
adrenoceptors. Am J  Physiol 1997 August£73(2 Pt 2):H902-H908.
(158) Fryer RM, Schultz JE, Hsu AK, Gross GJ. Importance of PKC and tyrosine 
kinase in single or multiple cycles of preconditioning in rat hearts. Am J  Physiol 
1999 April;276(4 Pt2):H1229-H1235.
(159) Hassouna A, Matata BM, Galinanes M. PKC-epsilon is upstream and PKC-alpha 
is downstream of mitoKATP channels in the signal transduction pathway of 
ischemic preconditioning of human myocardium. Am J  Physiol Cell Physiol 2004 
November,287(5):C1418-C1425.
(160) Inagaki K, Hahn HS, Dom GW, Mochly-Rosen D. Additive protection of the 
ischemic heart ex vivo by combined treatment with delta-protein kinase C 
inhibitor and epsilon-protein kinase C activator. Circulation 2003 August
19;108(7):869-75.
(161) Ohnuma Y, Miura T, Miki T et al. Opening of mitochondrial K(ATP) channel 
occurs downstream o f PKC-epsilon activation in the mechanism of 
preconditioning. Am J  Physiol Heart Circ Physiol 2002 July;283(l):H440-H447.
(162) Valtchanova-Matchouganska A, Ojewole JA. Mechanisms of opioid delta (delta) 
and kappa ( kappa) receptors' cardioprotection in ischaemic preconditioning in a 
rat model of myocardial infarction. Cardiovasc J  S  Afr 2003 March; 14(2) :73-80.
(163) Kilic E, Kilic U, Soliz J, Bassetti CL, Gassmann M, Hermann DM. Brain-derived 
erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/- 
2 and Akt pathways. FASEB J  2005 October 5.
(164) Murry CE, Richard VJ, Jennings RB, Reimer KA. Myocardial protection is lost 
before contractile function recovers from ischemic preconditioning. Am J  Physiol 
1991 March;260(3 Pt 2):H796-H804.
(165) Sack S, Mohri M, Arras M, Schwarz ER, Schaper W. Ischaemic preconditioning- 
time course of renewal in the pig. Cardiovasc Res 1993 April;27(4):551-5.
(166) Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of 
cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. 
Science 1997 February 21 ;275(5303):1132-6.
(167) Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program 
in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996 July 
12;86(l):147-57.
Anthony J. Bullard 179
References
(168) Yang J, Liu X, Bhalla K et al. Prevention of apoptosis by Bcl-2: release of 
cytochrome c from mitochondria blocked. Science 1997 February
21 ;275(5303):1129-32.
(169) Borutaite V, Jekabsone A, Moikuniene R, Brown GC. Inhibition of mitochondrial 
permeability transition prevents mitochondrial dysfunction, cytochrome c release 
and apoptosis induced by heart ischemia. J  Mol Cell Cardiol 2003 
April;35(4):357-66.
(170) Ichas F, Mazat JP. From calcium signaling to cell death: two conformations for 
the mitochondrial permeability transition pore. Switching from low- to high- 
conductance state. Biochim Biophys Acta 1998 August 10; 1366(1-2):33-50.
(171) Gardner TJ, Stewart JR, Casale AS, Downey JM, Chambers DE. Reduction of 
myocardial ischemic injury with oxygen-derived free radical scavengers. Surgery 
1983 September,94(3):423-7.
(172) Shlafer M, Kane PF, Wiggins VY, Kirsh MM. Possible role for cytotoxic oxygen 
metabolites in the pathogenesis of cardiac ischemic injury. Circulation 1982 
August;66(2 Pt 2):I85-I92.
(173) Fischer UM, Tossios P, Huebner A, Geissler HJ, Bloch W, Mehlhom U. 
Myocardial apoptosis prevention by radical scavenging in patients undergoing 
cardiac surgery. JThorac Cardiovasc Surg 2004 July;128(l):103-8.
(174) Tossios P, Bloch W, Huebner A et al. N-acetylcysteine prevents reactive oxygen 
species-mediated myocardial stress in patients undergoing cardiac surgery: results 
of a randomized, double-blind, placebo-controlled clinical trial. J  Thorac 
Cardiovasc Surg 2003 November;126(5):1513-20.
(175) Westhuyzen J, Cochrane AD, T esar PJ et al. Effect of preoperative 
supplementation with alpha-tocopherol and ascorbic acid on myocardial injury in 
patients undergoing cardiac operations. J  Thorac Cardiovasc Surg 1997 
May;113(5):942-8.
(176) Gupta A, Rosenberger SF, Bowden GT. Increased ROS levels contribute to 
elevated transcription factor and MAP kinase activities in malignantly progressed 
mouse keratinocyte cell lines. Carcinogenesis 1999 November;20(l l):2063-73.
(177) Nishida M, Maruyama Y, Tanaka R, Kontani K, Nagao T, Kurose H. G alpha(i) 
and G alpha(o) are target proteins of reactive oxygen species. Nature 2000 
November 23 ;408(6811 ):492-5.
(178) Viedt C, Soto U, Krieger-Brauer HI et al. Differential activation of mitogen- 
activated protein kinases in smooth muscle cells by angiotensin II: involvement of 
p22phox and reactive oxygen species. Arterioscler Thromb Vase Biol 2000 
April;20(4):940-8.
Anthony J. Bullard 180
References
(179) Lasukova TV, Krylatov AV, Maslov LN, Lishmanov YB, Gross GJ, Stefano GB. 
Effect o f in vivo and in vitro stimulation of deltal-opioid receptors on myocardial 
resistance to arrhythmogenic action of ischemia and reperfusion. Bull Exp Biol 
Med 2002 October, 134(4):359-62.
(180) Patel HH, Hsu A, Moore J, Gross GJ. BW373U86, a delta opioid agonist, 
partially mediates delayed cardioprotection via a free radical mechanism that is 
independent of opioid receptor stimulation. J  Mol Cell Cardiol 2001 
August;33(8):1455-65.
(181) Brondello JM, Brunet A, Pouyssegur J, McKenzie FR. The dual specificity 
mitogen-activated protein kinase phosphatase-1 and -2 are induced by the 
p42/p44MAPK cascade. JB io l Chem 1997 Januaiy 10;272(2): 1368-76.
(182) Cai Z, Manalo DJ, Wei G et al. Hearts from rodents exposed to intermittent 
hypoxia or erythropoietin are protected against ischemia-reperfusion injury. 
Circulation 2003 July 8;108(l):79-85.
(183) Lipsic E, van der MP, Henning RH et al. Timing of erythropoietin treatment for 
cardioprotection in ischemia/reperfusion. J  Cardiovasc Pharmacol 2004 
October;44(4):473-9.
(184) Parsa CJ, Kim J, Riel RU et al. Cardioprotective effects of erythropoietin in the 
reperfused ischemic heart: a potential role for cardiac fibroblasts. JB io l Chem 
2004 May 14;279(20):20655-62.
(185) Zhang JM, Orihashi K, Sueda T, Matsuura Y. Cardioprotective effects of FK409, 
a nitric oxide donor, after isolated rat heart preservation for 16 hours. Ann Thorac 
Surg 2000 November;70(5):1601-6.
(186) Woolfson RG, Patel VC, Neild GH, Yellon DM. Inhibition of nitric oxide 
synthesis reduces infarct size by an adenosine-dependent mechanism. Circulation 
1995 March 1;91(5): 1545-51.
(187) Bell RM, Yellon DM. Bradykinin limits infarction when administered as an 
adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. JM ol 
Cell Cardiol 2003 February;35(2):185-93.
(188) Michell BJ, Griffiths JE, Mitchelhill KI et al. The Akt kinase signals directly to 
endothelial nitric oxide synthase. CurrBiol 1999 July 29;9(15):845-8.
(189) Abdelrahman M, Sharpies EJ, McDonald MC et al. Erythropoietin attenuates the 
tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 
2004 July;22(l):63-9.
(190) Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E. 
Mechanisms of erythropoietin-mediated cardioprotection during ischemia-
Anthony J. Bullard 181
References
reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase 
signaling. FASEB J 2005 June 9.
(191) Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium 
against reperfusion injury in vitro and in vivo. Basic Res Cardiol 2005 June 10.
(192) Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial 
necrosis during reperfusion of ischemic myocardium. Circulation 1998 March 
3;97(8):795-804.
(193) Brandt BL, Kimes BW, Klier FG. Development of a clonal myogenic cell line 
with unusual biochemical properties. J  Cell Physiol 1976 July;88(3):255-75.
(194) Kimes BW, Brandt BL. Properties of a clonal muscle cell line from rat heart. Exp 
Cell Res 1976 March 15;98(2):367-81.
(195) Heads RJ, Yellon DM, Latchman DS. Differential cytoprotection against heat 
stress or hypoxia following expression of specific stress protein genes in 
myogenic cells. J  M ol Cell Cardiol 1995 August;27(8):1669-78.
(196) Bimbaum Y, Ashitkov T, Uretsky BF, Ballinger S, Motamedi M. Reduction of 
infarct size by short-term pretreatment with atorvastatin. Cardiovasc Drugs Ther 
2003 January; 17(1)^25-30.
(197) Bimbaum Y, Ye Y, Rosanio S et al. Prostaglandins mediate the cardioprotective 
effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 2005 
February l;65(2):345-55.
(198) Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its 
fundamental role in mediating cell death during ischaemia and reperfusion. J  Mol 
Cell Cardiol 2003 April;35(4):339-41.
(199) Hausenloy D, Wynne A, Duchen M, Yellon D. Transient mitochondrial 
permeability transition pore opening mediates preconditioning-induced 
protection. Circulation 2004 April 13; 109(14): 1714-7.
(200) Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore in 
myocardial preconditioning. Cardiovasc J S  Afr 2004 July; 15(4 Suppl 1):S5.
(201) Juhaszova M, Zorov DB, Kim SH et al. Glycogen synthase kinase-3beta mediates 
convergence of protection signaling to inhibit die mitochondrial permeability 
transition pore. J  Clin Invest 2004 June; 113(11):1535-49.
(202) Ehrenberg B, Montana V, Wei MD, Wuskell JP, Loew LM. Membrane potential 
can be determined in individual cells from the nemstian distribution of cationic 
dyes. BiophysJ 19SS May;53(5):785-94.
Anthony J. Bullard 182
References
(203) Duchen MR. Mitochondria and Ca(2+)in cell physiology and pathophysiology. 
Cell Calcium 2000 November,28(5-6):339-48.
(204) Monastyrskaya EA, Duchen MR, Andreeva LV, Viegant F, Manukhina EB, 
Malyshev IY. Antiapoptotic effect of heat adaptation in cultured cells. Bull Exp 
Biol Med 2003 February;135(2):123-6.
(205) Duchen MR, Leyssens A, Crompton M. Transient mitochondrial depolarizations 
reflect focal sarcoplasmic reticular calcium release in single rat cardiomyocytes. J  
Cell Biol 1998 August 24; 142(4):975-88.
(206) Leyssens A, Nowicky AV, Patterson L, Crompton M, Duchen MR. The 
relationship between mitochondrial state, ATP hydrolysis, [Mg2+]i and [Ca2+]i 
studied in isolated rat cardiomyocytes. J  Physiol 1996 October 1;496 ( Pt 1):111- 
28.
(207) Moon CH, Jung YS, Kim MH, Paik RM, Lee SH, Baik EJ. Protein kinase C 
inhibitors attenuate protective effect of high glucose against hypoxic injury in 
H9c2 cardiac cells. Jpn J  Physiol 2000 December;50(6):645-9.
(208) Jung YS, Jung YS, Kim MY et al. KR-31466, a benzopyranylindol analog, 
attenuates hypoxic injury through mitochondrial K(ATP) channel and protein 
kinase C activation in heart-derived H9c2 cells. J  Pharmacol Sci 2003 
May;92(l):13-8.
(209) Aki T, Mizukami Y, Oka Y et al. Phosphoinositide 3-kinase accelerates necrotic 
cell death during hypoxia. Biochem J 2001 September l;358(Pt 2):481-7.
(210) Ekhterae D, Lin Z, Lundberg MS, Crow MT, Brosius FC, IH, Nunez G. ARC 
inhibits cytochrome c release from mitochondria and protects against hypoxia- 
induced apoptosis in heart-derived H9c2 cells. Circ Res 1999 December 
9;85(12):e70-e77.
(211) Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against 
ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by 
acute atorvastatin treatment: a potential role for phosphatase and tensin homolog 
deleted on chromosome ten 1J  Am Coll Cardiol 2005 April 19;45(8):1287-91.
(212) van den Eijnde SM, van den Hoff MJ, Reutelingsperger CP et al. Transient 
expression of phosphatidylserine at cell-cell contact areas is required for myotube 
formation. J  Cell Sci 2001 October; 114(Pt 20):3631 -42.
(213) Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life 
regulator in apoptosis and necrosis. Annu Rev Physiol 1998;60:619-42.
(214) Yamaguchi H, Wang HG. The protein kinase PKB/Akt regulates cell survival and 
apoptosis by inhibiting Bax conformational change. Oncogene 2001 November 
22;20(53):7779-86.
Anthony J. Bullard 183
References
(215) Brookes PS, Salinas EP, rley-Usmar K et al. Concentration-dependent effects of 
nitric oxide on mitochondrial permeability transition and cytochrome c release. J  
Biol Chem 2000 July 7;275(27):20474-9.
(216) Dedkova EN, Blatter LA. Modulation of mitochondrial Ca2+ by nitric oxide in 
cultured bovine vascular endothelial cells. Am J  Physiol Cell Physiol 2005 
October;289(4):C836-C845.
(217) Horn TF, Wolf G, Duffy S, Weiss S, Keilhoff G, MacVicar BA. Nitric oxide 
promotes intracellular calcium release from mitochondria in striatal neurons. 
F A SE B J2002 October,16(12):1611-22.
(218) Ichas F, Jouaville LS, Mazat JP. Mitochondria are excitable organelles capable of 
generating and conveying electrical and calcium signals. Cell 1997 June 
27;89(7):1145-53.
(219) Ichas F, Jouaville LS, Sidash SS, Mazat JP, Holmuhamedov EL. Mitochondrial 
calcium spiking: a transduction mechanism based on calcium-induced 
permeability transition involved in cell calcium signalling. FEBS Lett 1994 July 
11 ;348(2)^211-5.
(220) Haworth RA, Hunter DR. The Ca2+-induced membrane transition in 
mitochondria, n. Nature of the Ca2+ trigger site. Arch Biochem Biophys 1979 
July;195(2):460-7.
(221) Gunter TE, Pfeiffer DR. Mechanisms by which mitochondria transport calcium. 
Am J  Physiol 1990 May;258(5 Pt 1):C755-C786.
(222) Silvefberg DS, Wexler D, Blum M et al. The use of subcutaneous erythropoietin 
and intravenous iron for the treatment of the anemia of severe, resistant 
congestive heart failure improves cardiac and renal function and functional 
cardiac class, and markedly reduces hospitalizations. J  Am Coll Cardiol 2000 
June;35(7): 1737-44.
(223) Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia 
in severe, resistant congestive heart failure using subcutaneous erythropoietin and 
intravenous iron: a randomized controlled study. J  Am Coll Cardiol 2001 June 
1;37(7): 1775-80.
(224) Silverberg DS, Wexler D, Blum M et al. The effect of correction of anaemia in 
diabetics and non-diabetics with severe resistant congestive heart failure and 
chronic renal failure by subcutaneous erythropoietin and intravenous iron.
Nephrol Dial Transplant 2003 January; 18(1): 141 -6.
(225) Andjelkovic M, Jakubowicz T, Cron P, Ming XF, Han JW, Hemmings BA. 
Activation and phosphorylation of a pleckstrin homology domain containing 
protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase 
inhibitors. Proc Natl Acad Sci U SA  1996 June 11;93(12):5699-704.
Anthony J. Bullard 184
References
(226) Gao T, Fumari F, Newton AC. PHLPP: a phosphatase that directly 
dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol 
Cell 2005 April l;18(l):13-24.
(227) Gao F, Gao E, Yue TL et al. Nitric oxide mediates the antiapoptotic effect of 
insulin in myocardial ischemia-reperfusion: the roles of PD-kinase, Akt, and 
endothelial nitric oxide synthase phosphorylation. Circulation 2002 March 
26;105(12):1497-502.
(228) Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E. 
Mechanisms of erythropoietin-mediated cardioprotection during ischemia- 
reperfusion injury: role o f protein kinase C and phosphatidylinositol 3-kinase 
signaling. FA SE B J2005 August;19(10):1323-5.
(229) Sulis ML, Parsons R. PTEN: from pathology to biology. Trends Cell Biol 2003 
September; 13(9):478-83.
(230) Sly LM, Rauh MJ, Kalesnikoff J, Buchse T, Krystal G. SHIP, SHIP2, and PTEN 
activities are regulated in vivo by modulation of their protein levels: SHIP is up- 
regulated in macrophages and mast cells by lipopolysaccharide. Exp Hematol 
2003 December,3 1(12):1170-81.
(231) Leslie NR, Downes CP. PTEN function: how normal cells control it and tumour 
cells lose it. Biochem J 2004 August 15;382(Pt 1):1-11.
(232) Baneijee D, Rodriguez M, Nag M, Adamson JW. Exposure of endothelial cells to 
recombinant human erythropoietin induces nitric oxide synthase activity. Kidney 
Int 2000 May;57(5): 1895-904.
(233) Gonzales GF, Chung FA, Miranda S et al. Heart mitochondrial nitric oxide 
synthase is upiegulated in male rats exposed to high altitude (4,340 m). Am J  
Physiol Heart Circ Physiol 2005 June;288(6):H2568-H2573.
(234) Bell RM, Smith CC, Yellon DM. Nitric oxide as a mediator of delayed 
pharmacological (A(l) receptor triggered) preconditioning; is eNOS 
masquerading as iNOS? Cardiovasc Res 2002 February 1;53(2):405-13.
(235) Wang G, Liem DA, Vondriska TM et al. Nitric oxide donors protect murine 
myocardium against infarction via modulation of mitochondrial permeability 
transition. Am J  Physiol Heart Circ Physiol 2005 March;288(3):H1290-H1295.
(236) Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Signalling via the 
reperfusion injury signalling kinase (RISK) pathway links closure of the 
mitochondrial permeability transition pore to cardioprotection. Int J  Biochem Cell 
Biol 2005 October 21.
(237) Giulivi C, Poderoso JJ, Boveris A. Production of nitric oxide by mitochondria. J  
Biol Chem 1998 May 1;273(18):11038-43.
Anthony J. Bullard 185
References
(238) Tatoyan A, Giulivi C. Purification and characterization of a nitric-oxide synthase 
ftom rat liver mitochondria. JB io l Chem 1998 May 1;273(18):11044-8.
(239) Giulivi C. Functional implications of nitric oxide produced by mitochondria in 
mitochondrial metabolism. Biochem J 1998 June 15;332 ( Pt 3):673-9.
(240) Sarkela TM, Berthiaume J, Elfering S, Gybina AA, Giulivi C. The modulation of 
oxygen radical production by nitric oxide in mitochondria. JB io l Chem 2001 
March 9;276(10):6945-9.
(241) Ghafourifar P, Schenk U, Klein SD, Richter C. Mitochondrial nitric-oxide 
synthase stimulation causes cytochrome c release from isolated mitochondria. 
Evidence for intramitochondrial peroxynitrite formation. JB io l Chem 1999 
October 29;274(44):31185-8.
(242) Razavi HM, Hamilton JA, Feng Q. Modulation of apoptosis by nitric oxide: 
implications in myocardial ischemia and heart failure. Pharmacol Ther 2005 
May;106(2):147-62.
(243) Xu B, Dong GH, Liu H, Wang YQ, Wu HW, Jing H. Recombinant human 
erythropoietin pretreatment attenuates myocardial infarct size: a possible 
mechanism involves heat shock Protein 70 and attenuation of nuclear factor- 
kappaB. Ann Clin Lab Sci 2005;35(2):161-8.
(244) Erbayraktar S, Grasso G, Sfacteria A et al. Asialoerythropoietin is a 
nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl 
Acad Sci U SA  2003 May 27;100(ll):6741-6.
(245) Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue 
protective but not erythropoietic. Science 2004 July 9;305(5681):239-42.
(246) McClure BJ, Hercus TR, Cambareri BA et al. Molecular assembly of the ternary 
granulocyte-macrophage colony-stimulating factor receptor complex. Blood 2003 
February 15;101(4):1308-15.
(247) Blake TJ, Jenkins BJ, DfAndrea RJ, Gonda TJ. Functional cross-talk between 
cytokine receptors revealed by activating mutations in the extracellular domain of 
the beta-subunit of the GM-CSF receptor. JLeukoc Biol 2002 
December;72(6): 1246-55.
(248) Jubinsky PT, Krijanovski OI, Nathan DG, Tavemier J, Sieff CA. The beta chain 
of the interleukin-3 receptor functionally associates with the erythropoietin 
receptor. Blood 1997 September 1;90(5):1867-73.
(249) Scott CL, Robb L, Papaevangeliou B, Mansfield R, Nicola NA, Begley CG. 
Reassessment of interactions between hematopoietic receptors using common 
beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence
Anthony J. Bullard 186
References
of functional interactions with receptors for erythropoietin, granulocyte colony- 
stimulating factor, or stem cell factor. Blood 2000 August 15 ;96(4): 1588-90.
(250) Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of 
phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-l-benzopyran-4- 
one (LY294002). JB io l Chem 1994 February 18;269(7):5241-8.
(251) Solenkova NV, Solodushko V, Cohen MV, Downey JM. Endogenous adenosine 
protects the preconditioned heart during the early minutes of reperfusion by 
activating Akt. Am J  Physiol Heart Circ Physiol 2005 September 9.
(252) Di LF, Menabo R, Canton M, Barile M, Bemardi P. Opening of the mitochondrial 
permeability transition pore causes depletion of mitochondrial and cytosolic 
NAD+ and is a causative event in the death of myocytes in postischemic 
reperfusion of the heart. JB io l Chem 2001 January 26;276(4):2571-5.
(253) Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed 
during cardiac ischaemia, but open upon reperfusion. Biochem J 1995 April 1 ;307 
(P t l):93-8.
(254) Mori M, Uchida M, Watanabe T et al. Activation of extracellular signal-regulated 
kinases ERK1 and ERK2 induces Bcl-xL up-regulation via inhibition of caspase 
activities in erythropoietin signaling. J  Cell Physiol 2003 May;195(2):290-7.
(255) Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic 
neuronal protection through modulation of microglia, A ktl, Bad, and caspase- 
mediated pathways. Br J  Pharmacol 2003 March;138(6): 1107-18.
(256) Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 
form the critical elements for cerebral vascular protection by erythropoietin. J  
Cereb Blood Flow Metab 2003 March ;23(3):320-30.
(257) Diaz R, Paolasso EA, Piegas LS et al. Metabolic modulation of acute myocardial 
infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative 
Group. Circulation 1998 November 24;98(21):2227-34.
(258) Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of 
acute myocardial infarction: an overview of randomized placebo-controlled trials. 
Circulation 1997 August 19;96(4):1152-6.
(259) Turel B, Gemici K, Baran I et al. Effects of glucose-insulin-potassium solution 
added to reperfusion treatment in acute myocardial infarction. Anadolu Kardiyol 
Derg 2005 June;5(2):90-4.
(260) Zhang L, Zhang L, Li YH et al. High-dose glucose-insulin-potassium treatment 
reduces myocardial apoptosis in patients with acute myocardial infarction. Eur J  
Clin Invest 2005 March;35(3): 164-70.
Anthony J. Bullard 187
References
(261) Mehta SR, Yusuf S, Diaz R et al. Effect of glucose-insulin-potassium infusion on 
mortality in patients with acute ST-segment elevation myocardial infarction: the 
CREATE-ECLA randomized controlled trial. JAMA 2005 January 26;293(4):437- 
46.
(262) Jonassen AK, Brar BK, Mjos OD, Sack MN, Latchman DS, Yellon DM. Insulin 
administered at reoxygenation exerts a cardioprotective effect in myocytes by a 
possible anti-apoptotic mechanism. J  Mol Cell Cardiol 2000 May;32(5):757-64.
(263) Weiss RH, Yabes AP. Mitogenic inhibition by phoibol esters is associated with 
decreased phosphatidylinositol-3 kinase activation. Am J  Physiol 1996 
February;270(2 Pt 1):C619-C627.
(264) Pierce CN, Larson DF. Inflammatory cytokine inhibition of erythropoiesis in 
patients implanted with a mechanical circulatory assist device. Perfusion 2005 
March;20(2):83-90.
(265) Villa P, Bigini P, Mennini T et al. Erythropoietin selectively attenuates cytokine 
production and inflammation in cerebral ischemia by targeting neuronal 
apoptosis. JE xp Med 2003 September 15; 198(6):971 -5.
Anthony J. Bullard 188
